PREDICATE,SUBJECT_NAME,OBJECT_NAME,Factuality_Score,Cancer_Type,Category
AFFECTS,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,FGFR2 gene|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NDUFB3|TNFAIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Topotecan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ACSL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Body mass index,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metabolites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,anthracene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"oxoguanine glycosylase 1, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Malignant Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Topoisomerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
CAUSES,Methylcholanthrene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
DISRUPTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,C-reactive protein level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Proliferation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Carcinoma of the Large Intestine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,CD44 gene|CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Estrogen Receptor Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MTRR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MTA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DYRK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Velcade,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Hormone replacement therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,lycopene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SMURF1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Metabolic Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,"DNA, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Etodolac,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MST1R gene|MST1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lactation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Well in self,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Human Papillomavirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
DISRUPTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TARBP2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Annexin A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BCL9 gene|BCL9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GATA3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CHEK2 gene|CHEK2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,beta-cryptoxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signal Pathways,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TARBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SELENOP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,polyphenols,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Weight Gain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,pleiotropism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Enhancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prognostic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Monocyte Chemoattractant Protein-1|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Complication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,kahweol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,INPP5J,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,heparanase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fitness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTGS2 gene|PTGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Nitrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GLTSCR2 gene|NOP53,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Polymorphism, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Endocrine therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
PREDISPOSES,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Base Excision Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenesis Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CENPN,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Reproductive History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Menopausal Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,KISS1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ABCB1 gene|ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Regular exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antisense RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,ZNF410,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diabetes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Total cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Nuts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Psychosocial problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Red meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Hypothalamic inhibiting factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,DNM1 gene|DNM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Heterocyclic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Primigravida,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Stromal Cell-Derived Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Taxotere,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,educational intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Receptors, Opioid, delta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Amino Acyl-tRNA Synthetases|TRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,AKR1C3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Radial scar,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,methyl 4-azidophenylacetimidate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Catechol O-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TLR3 gene|TLR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vascular Endothelial Growth Factor Receptor-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,dihydroxyacetone sulfate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estradiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Taxanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,fulvestrant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BSG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Thromboembolic event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,CXCR4 gene|CXCR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"Alpha-MMC protein, Momordica charantia",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Ovarian Serous Adenocarcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,HRH4 gene|HRH4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,6-sulfatoxymelatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Methylnitrosourea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carrier of disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,"Fatty Acids, Omega-6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Not significant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Citrate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Estrogens, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Bilateral salpingectomy with oophorectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Drug resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Wine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endocrine therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Smoking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,sulfuretin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Gene Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,FGF10 gene|FGF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Iodine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Clusterin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cytokine Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PRKACA gene|PRKACA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Eosinophilia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin Resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MAD2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Drugs, Investigational",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Urokinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Neoplasm Metastasis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,gamma-tocotrienol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TERT gene|TERT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EGFR gene|EGFR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Oxidative Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Solvents,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
PREDISPOSES,palm oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tongue feature,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Blueberries,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,ITK gene|ITK,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,inhibitors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Threonine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Medical History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CLOCK gene|CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CA-15-3 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MicroRNAs,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Genomic Stability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Methylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,bevacizumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prior Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Medical Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ATM Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,inner centromere protein|INCENP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIRN132 gene|MIR132,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Xenograft procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ginkgo biloba extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCNB1 gene|CCNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,chemokine receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Germ-Line Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vimentin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adverse reactions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Oxidoreductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Baclofen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ORALIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,alpha-carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Treatment Protocols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DHX9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cigarette Smoking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,stromelysin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Worried,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BARD1 gene|BARD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Raloxifene Hydrochloride,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,ERBB3 gene|ERBB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Somatic mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ANO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Klinefelter's Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"Translation, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,alpha Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Carrier status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Doxorubicin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,distilled alcoholic beverage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Flap Endonuclease-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Whole milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PARITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lymph Node Involvement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Body Weight Changes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,osteopontin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cessation of life,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Ether, Ethyl",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,humoral defense mechanism (sensu Vertebrata),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,gonadotropin inhibitor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Adverse effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,BRCA2 gene|BRCA2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,High fat diet NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,protein kinase C eta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Conflict (Psychology),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYR61,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,anastrozole,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Dietary Modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Childbirth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prostate-Specific Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Previous pregnancies 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Infertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Proanthocyanidins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemotherapy-Oncologic Procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Systemic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Folate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Atypical lobular hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BCHE|SNORA73A|ENOPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Tumor Angiogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tumor Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Norplant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Chemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Menopausal symptom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Matrix Metalloproteinases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,E-Cadherin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,"Herpesvirus 4, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Gene-Environment Interaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Galectin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Hyperinsulinism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Ethylnitrosourea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Axillary Lymph Node Dissection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRCA1 Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Free estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Mammary Tumor Virus, Mouse",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Cytomegalovirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Linoleic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,KAT6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fibroblast Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Breast Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Methylnitrosourea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Smoker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Deficiency of testosterone biosynthesis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
CAUSES,SV40 T Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Hydroxyestrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Dietary Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carcinogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mastectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen excess,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AFFECTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Dactinomycin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Aromatase Inhibitors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Early Diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Vitamin C intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Combined Oral Contraceptives,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TFF1 gene|TFF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast cancer recurrent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Serum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
CAUSES,v-Ha-ras Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Genes, Dominant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dysplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Dehydroepiandrosterone Sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tetradecanoylphorbol Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Nuclear Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PREDICTED,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,methylurea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Fibrocystic Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,ras Oncogene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Fibronectins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Egg Food Product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Tenascin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Cholestyramine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Ovulatory,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,4'-deoxydoxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Imidazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,paracrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Fats, Unsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Early menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Triceps skin fold thickness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasm,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cancer-Predisposing Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pregnancy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Thyroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,CATHEPSIN D|CTSD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fusion procedure,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PNMA3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hormone replacement therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,body mass,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cytotoxic Chemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Gene Amplification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Histopathology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fluoroscopy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Diseases,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Cystic Fibrosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Gonadotropin-Releasing Hormone Analog,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,"Genes, Suppressor",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Fatty Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Alkaline Phosphatase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Cholera Toxin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,Propionate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,alpha-latrotoxin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
COMPLICATES,Acute leukemia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Methoxamine,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,diphenyl,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Relaxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Fucose,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Glycol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Peptide Nucleic Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"Chemotherapy, Adjuvant","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,adjuvant therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,estrophilin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BRCA1 gene|BRCA1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Combination Chemotherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Breast Fibrocystic Change, Proliferative Type",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,G-Actin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Theophylline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cisplatin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Digitoxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Aggressive behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cancer-Predisposing Gene,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Screening mammography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Schistosomiasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Gonadorelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Chemotherapy, Adjuvant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Familial cancer of breast,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,C-Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Polychlorinated Biphenyls,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Dietary fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tamoxifen,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Retinoblastoma Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Brain hemorrhage,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alleles,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mammography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"(meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(II)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Lymphocyte Specific Protein Tyrosine Kinase p56(lck)|LCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Long menstrual cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Viral Oncogene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lymphocyte Specific Protein Tyrosine Kinase p56(lck)|LCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Hereditary Malignant Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tobacco,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Receptors, Nuclear",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,beta catenin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,vitamin analog,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
DISRUPTS,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Beer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hereditary Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Prostaglandins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
PREDISPOSES,stearic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,steroid hormone receptor,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
AUGMENTS,CUL4A gene|CUL4A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Antioxidants,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CAMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Silicones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Glycosylated hemoglobin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ovarian Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,"TACSTD1 protein, human|EPCAM",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Mammary Tumor Virus, Mouse",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Signal Transduction Pathways,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,maspin|SERPINB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AFP gene|AFP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Psychological adjustment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,diagnostic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FHIT gene|FHIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Merozoite Surface Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Micronutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Hexachlorobenzene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,Growth Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,High weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,17-Ketosteroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AUGMENTS,"PTPN6 protein, human|PTPN6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Microsatellite Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GSTT1 gene|GSTT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,impression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mismatch Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Urokinase Plasminogen Activator Receptor|PLAU|PRAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,hydroxytamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Estrogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
DISRUPTS,Venoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pre-Eclampsia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Fatty Acids, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Progestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Somatotropin-Releasing Hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Curative Surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,methylurea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dietary intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Oestrogen deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Thromboembolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dieldrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Butyric Acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,fascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Retinoblastoma Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Polychlorinated Biphenyls,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Sausage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,cofactor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Apoptosis Inhibiting Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Li-Fraumeni Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Phytic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Intrinsic factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GGCT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,anastrozole,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,DNA Sequence,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Nucleotide Sequence
PREDISPOSES,Conjugated Equine Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,EGFR gene|EGFR,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Amines,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,"Etiology, operative procedure, as cause of",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,estrone sulfatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Beer intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,trilostane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Protein Kinase C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Nutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Epithelial Cell Proliferation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Development of the breasts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Transgenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast Feeding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,B-pyridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mastodynia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTM1 gene|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NFKB1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,Vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,AROMATICS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Symptoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLK14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tocopherols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Permeability,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,ATP7B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,GGCT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TSG101 gene|TSG101,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Tryptophan|TYRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Mastitis, associated with childbirth",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,SLC19A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Primary carcinoma of the liver cells,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bone Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cellular Retinol Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Down-Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CYR61,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Peptidyl-Dipeptidase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Immunologic Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Body Fat Distribution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SNAI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Thyroid Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Mammary Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Spontaneous abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Mutation, Missense",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Soybean Oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Abortion, Induced",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Oestrogen increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PPIG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Fatty Acids, Omega-3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adhesions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,11q13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Unspecified Abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DNA Damage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Raloxifene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Tumor Promoters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chronic Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Docosahexaenoic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,maspin|SERPINB5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,protein kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Nuclear Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aneuploidy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Progestogen hormone therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Epidermal growth factor receptor inhibitor,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Kininogenase|KLK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Oligonucleotides, Antisense",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Infiltrating duct carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,BONE MASS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BIRTHPLACE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Skin problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic breast density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Mutation, Nonsense",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,mammary gland development,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,19p13.3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Leucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EMSY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Insulin-Like Growth Factor II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MCM2 gene|MCM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ESTROGEN USE,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Normal growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Environmental Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,genotoxicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,stressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,connexin 26,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DDT (Insecticide),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Invertebrate
PREDISPOSES,Stromal Cell-Derived Factor 1|CXCL12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,STK6 gene|AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin E,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Somatomedins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transcriptional Activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thromboembolic event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Encounter due to Screening for malignant neoplasm of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SPRY2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LAG3 gene|LAG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,protective factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signal Transduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Raloxifene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oxidative Stress,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AUGMENTS,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Transforming Growth Factor beta|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Prenatal Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Diastolic blood pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Short menstrual cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CA9 gene|CA9,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cytotoxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Osteoporosis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Dietary Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AUGMENTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cruciferous Vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Encounter due to genetic counseling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Progestational Hormones, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,isoflavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SLC25A18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Juice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Focal Adhesion Protein-Tyrosine Kinases,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Hemoglobin, Glycosylated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Granulocyte Colony-Stimulating Factor,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Isoleucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metabolic Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fat tissue increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,indole-3-carbinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Abruptio Placentae,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SULT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vegetable intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Human papillomavirus 16,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
PREDISPOSES,MET gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cholesterol levels raised,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Postmenopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Female Breast Carcinoma,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
PREDISPOSES,Lobular hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dietary restriction NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Polycyclic Hydrocarbons,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Li-Fraumeni Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Estrogen receptor positive tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Iron intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Hyperparathyroidism, Primary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,migration stimulating factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Magnetic field,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,Chemicals,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Obesity,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
CAUSES,sulforafan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ERCC2 gene|ERCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Monoclonal Antibody Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
CAUSES,Arachidonic Acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Hyposensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,decaffeinated coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,mammaglobin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,ADAM12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Integrin beta3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,apolipoprotein D|APOD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Motility,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,CDV3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"progesterone, micronized",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,SR-2508,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PBRM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,rho GTP-Binding Proteins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RETN gene|RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Adverse effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,caspase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cancer Promoting Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,HIC1 gene|HIC1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,hemagglutinin I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Menopause, Premature",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Oestrogen therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fusion Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Molecular Fingerprint of Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Impaired cognition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,APOA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Disease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AFFECTS,Combined Modality Therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transcription Repressor/Corepressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,beta-adrenergic receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nicotinamide adenine dinucleotide (NAD),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ETS1 gene|ETS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,S-Phase Fraction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HSF1 gene|HSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biguanides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MLLT11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Drink,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Indigotindisulfonate Sodium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Catechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Garlic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,WISP3 gene|WISP3,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Neoplasm Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Xeroderma pigmentosum, group C",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,LAMR1 gene|RPSA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,osteosarcoma,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TWIST1 gene|TWIST1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,Ultrasonography,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Androgen therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,erlotinib,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Sentinel Lymph Node Mapping,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAD50,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sedentary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BLCAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,14q31,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"RNA, Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"RBL2 protein, human|RBL2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"2,5-dichloro-4-bromophenol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SHFM1 gene|SEM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DUSP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,participation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DNA Repair Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Processed meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Interleukin-6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Breast tenderness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,stress-activated protein kinase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Cardiovascular Diseases,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
AFFECTS,gemcitabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Screening mammography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pumpkin seeds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Phytochemical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Fruit intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Angiogenesis Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Decreased translucency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,atorvastatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Phosphoglycerate dehydrogenase|PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Collagen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Topoisomerase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Nitrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Angiopoietin-2|ANG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Neoplasm progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Mucins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Folate intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Animal Feed,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Body mass index,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Atypical hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Point Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lesion,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hypoxia,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Carcinogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Serine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,lycopene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pathogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SRSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Nuclear Receptor Subfamily 4, Group A, Member 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Angiogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,paclitaxel liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin D intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AXL gene|AXL,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,JTB gene|JTB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Interferon Alpha, Human|IFNA1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,toxicant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,"Insulin, Long-Acting",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Radiotherapy, Adjuvant",Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
DISRUPTS,Taxol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SPDEF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,VEGFA,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,BRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Soy Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,BEX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HIF1A gene|HIF1A,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metabolic syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Transcription, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Atypical antipsychotic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Visual Accommodation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cancer prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hormone Receptor,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Hormone
PREDISPOSES,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Placental Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,METHYLATE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,congener,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Xanthine Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,progesterone analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Single Nucleotide Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Epidermal Growth Factor Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,CASP8 gene|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NCOA3|ANIB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Xenograft Model,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Progestins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Glutathione S-Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BHMT gene|BHMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCL12 gene|CXCL12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic procedure,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,response,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Phytochemical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,RASSF1A,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Thyrotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HDAC9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ESTROGEN USE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclooxygenase 2 Inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumorigenicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ITGA11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Small Nucleolar RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,TOX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Physically active,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Niacinamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Protein p53|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Repair Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,epigallocatechin gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Paravertebral anesthesia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,gene polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Psychotherapy, Multiple",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,TP53 gene|TP53,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Body Weight decreased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypertensive disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant Bone Neoplasm,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Cardiovascular Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,MIRN34A gene|MIR34A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,fisetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,systemic administration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GM2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,progesterone receptor positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MIR655,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,peoniflorin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Phosphatidylethanolamine N-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cholesterol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Lipid
DISRUPTS,SPRY1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Epidermal growth factor receptor inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Depressed mood,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Receptor Activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Epidermal growth factor receptor inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Fibronectins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Lipopolysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secondary malignant neoplasm of lymph node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,F3 gene|F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RSU1 gene|RSU1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Induction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Paget's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,curdione,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,14q24.1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SOAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Response Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LOH11CR2A gene|VWA5A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary fiber intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PTPN12 gene|PTPN12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Extracellular Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Atypical hyperplasia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FOXC1 gene|FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ARNTL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Infiltration,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Neoplasm Metastasis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,PORPHOBILINOGEN SYNTHASE|ALAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Hyperandrogenemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Histone Deacetylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RAB8A gene|RAB8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Physical activity,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Tubulin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,ZYX gene|ZYX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MBTPS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NCOR2 gene|NCOR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ethacrynic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ZNF423,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,6q25.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Exertion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TRIM25,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,MIR520C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Tetradecanoylphorbol Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,C6orf106,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"MAPK14 protein, human|MAPK14",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Functional RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Fibroblast Growth Factor Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
DISRUPTS,UBE3A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Dehydration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
CAUSES,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tumor Cell Invasion,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Transforming Growth Factor beta Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Receptors, Interleukin-1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Forkhead Transcription Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,G0S2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Phosphoric Monoester Hydrolases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Death (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,zoledronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,F Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TFF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Advance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa|RPS6KB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,vasodilator-stimulated phosphoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Curcumin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Neoadjuvant Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,anastrozole,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,PLAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,docetaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transforming Growth Factor beta|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Overweight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Neoantigen,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Immunologic Factor
PREDISPOSES,TNFRSF6B gene|TNFRSF6B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,prevention through information dissemination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metaplastic Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Lymph,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SETD7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,PIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cytotoxic Chemotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,"Fatty Acids, Omega-3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,CYP27A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CA-15-3 Antigen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Immunologic Factor
AFFECTS,tumor growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,P2RY6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,MAGI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,diallyl disulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Performance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dietary Component,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transcript,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Metabolites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,stanniocalcin 2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
DISRUPTS,Paclitaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Genes,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,synaptotagmin I|RELA|SYT1|GORASP1|WNK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EPHB2|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Soluble ErbB-1|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AUGMENTS,CYR61,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Primary Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signal Transduction Pathways,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CAMK2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HOXD10,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Honey,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Polymerase|ERVK-9|ERVK-19|ERVK-11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Synaptophysin|SYP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ADIPOR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ISL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RUNX1 gene|RUNX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,hepatocellular carcinoma protein 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Regulatory Element,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Granulocyte-Macrophage Colony-Stimulating Factor|CSF2|LAMC2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIR gene|MLXIP|MYLIP|MARCH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cytotoxic T-Lymphocyte-Associated Protein 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Malignant neoplasm of breast,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Tocopherols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Anthocyanins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DMXL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Curcumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,POU5F1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Stromal Cell-Derived Factor 1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,OBSCN gene|OBSCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,STAT5A gene|STAT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,myricetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Ethanol,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Ultrasonography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PITX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SUMO1P3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Autophagy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,SOHLH2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Clomiphene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AKT2 gene|AKT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GPR1 gene|GPR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,discoidin domain receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PLAUR gene|PLAUR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,SHH gene|SHH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,NEK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,O-GlcNAc transferase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Phosphoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ACKR3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,MicroRNAs,"cellular diagnosis, breast cancer",0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,"Lung Diseases, Interstitial",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
AFFECTS,Cisplatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Dinoprostone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Transcriptase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BRCA2 gene|BRCA2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Reading,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,depolarization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HRG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MERTK gene|MERTK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin B 12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,Peptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Cyclic AMP-Responsive DNA-Binding Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Thrombosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Variation (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, X-Linked",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FOXA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GGN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SLC4A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"PDGFA protein, human|PDGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Crisis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Calcitriol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,RICTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GACAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,preference,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,"Biological function, NOS",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Twin birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP3A4 gene|CYP3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCL13 gene|CXCL13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PSMB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Carcinoma, Non-Small-Cell Lung",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PRMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Small cell carcinoma of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,gefitinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cruciferous Vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 gene|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Topoisomerase Inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,BDE-99,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radionuclide Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Risedronate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,recessive allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cyclooxygenase 2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,DNAJC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,HORMAD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EREG|ESR1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,N-Cadherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,16q12.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,C3|ERVK-2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Hypothyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prognosis bad,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell Cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,resveratrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADAM17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,sunflower seed oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sun Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TYMS gene|TYMS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cytokeratin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,KDM1A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Transcript,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
DISRUPTS,"sal protein, Drosophila",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RAP1A|RABGEF1|TERF2IP,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Mutate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,piperine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SPC24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Endocrine substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,EGFL6 gene|EGFL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Tubulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MULTISECTION:FINDING:POINT IN TIME:BREAST:NARRATIVE:MRI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NOTCH1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LSINCT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,decaffeinated coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,high-dose chemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibrosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,blood lipid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC00310,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Black tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Premarin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ESR2 gene|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EPHB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EIF4G1,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Inflammation Mediators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,baicalein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,erbB-2 Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,racial differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Histologic type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Raloxifene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"UBD protein, human|UBD",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CDC16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mammary Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ARHGAP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogenic effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Membrane Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,cell invasion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,lysophosphatidic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,MMP9 gene|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Postmenopausal syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Hyperthyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Compete,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,Head circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Succinate Dehydrogenase|SARDH|SDHB|SDS,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cell motility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen hormone therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,"Pleural Effusion, Malignant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Immunologic Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SULF2 gene|SULF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ARF6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Alcoholic Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Progestins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BAX gene|BAX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone replacement therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Uterine Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,health-related beliefs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypoxia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ZD 6126,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"VEGF protein, human|VEGFA",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Mucins,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,Tyrphostins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lactation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Organochlorine pesticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lean body mass,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,genetic aspects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Beta Carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Osteoporosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Daily drinker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thinness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pain relief,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,alpha-carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Amitriptyline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Sulfuric Acid Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Somatomedins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,BNIP3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Reexcision,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Endometriosis, site unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GSTT1 gene|GSTT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,GSTP1 gene|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin Resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,celecoxib,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,PRSS3P2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,VEGF gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Physical activity,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,leptin receptor|LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,sulfotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Progesterone Receptor Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Ibandronate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RGS17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Behavior showing increased motor activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Fever,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anthracyclines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Almond Nut,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Up-Regulation (Physiology),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ERCC5 gene|ERCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Secondary malignant neoplasm of liver,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOXL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RHOA gene|RHOA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LGMN gene|LGMN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Enkephalins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antihypertensive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,PRKD1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Atypia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD55|TCN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Waist circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Antigens, CD5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,tibolone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Diagnostic Neoplasm Staging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pancreatectomy,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,MicroRNAs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,personal experience,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,syndecan 2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Tumor Antigens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Recreation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Angiogenesis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Minipill,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiotensin-Converting Enzyme Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ablation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Detection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Energy Metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Diseases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AFFECTS,Sentinel Lymph Node Biopsy,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,8q24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Angiotensin-Converting Enzyme Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Hydroxyestrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogen Antagonists,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,IGFBP3 gene|IGFBP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RHOC gene|RHOC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Promoter Regions (Genetics),Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,DDT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Berries,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Peptidyl-Dipeptidase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Malignant Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,binge drinking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,17q12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antidepressive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,mammary tumor virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"KLK15 protein, human|KLK15",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,response,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,IL6 gene|IL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Positron-Emission Tomography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,PRLR gene|PRLR|PTP4A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LOC118430 gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,FCER1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Endometrial Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Exploration procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SHC1 gene|SHC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,ELF3 gene|ELF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Fatty Acids, Saturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Stearoyl-CoA Desaturase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Antidepressive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Recombinant Erythropoietin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Prolactin Receptor|PRLR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,capecitabine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Tocotrienols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BMP7 gene|BMP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Complication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Low Dose Radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,hemiplegia; ascending,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HPR gene|HPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MUTYH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Beta-carotene intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pulse vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,claudin 6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Tretinoin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Epirubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,UQCRFS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,pterostilbene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Folic Acid Deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Duffy blood group phenotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Asthma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"NUP214 protein, human|NUP214",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CCNE1 gene|CCNE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sleep disturbances,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,argatroban,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,taxane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,retinoic acid receptor beta 2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Chemical
PREDISPOSES,Osteoporosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CLOCK gene|CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogene Proteins c-akt|AKT1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,HERC4,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,responsibility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,pulmonary complications,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,[X]Unspecified osteoporosis with pathological fracture,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,mRNA Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,RHOA gene|RHOA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,OSU 03012,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fine needle aspiration biopsy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Methylenetetrahydrofolate reductase (NADPH)|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Low glycemic index food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Encounter due to In vitro fertilization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ovarian cancer prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Abdominal obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Endocrine therapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Dimethyl Sulfoxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HGS gene|HGS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,research outcome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,hypercholesterolemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Tomatoes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gross' disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Mucin 1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Metastatic malignant neoplasm to brain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,abnormal glucose tolerance test,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ID1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Interstitial Collagenase|MMP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AFFECTS,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,APOBEC3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PPARG gene|PPARG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LOX gene|LOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Human papilloma virus infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SULT1A1|SULT1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cyclooxygenase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,C-reactive protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TNF gene|TNF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carcinoembryonic Antigen|CEACAM5|CEACAM3|PSG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Breast size,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Underweight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA2 Mutation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RNF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,STN gene|EEF1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Depressive disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Ascorbic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Botanicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Weight fluctuates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carboplatin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Equine laminitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Thyroid dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NMU gene|NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GAL3ST1|SLC35A1|CASZ1|CST12P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diethylhexyl Phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypoxia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lymphedema,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Motion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,breast cancer diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,tibolone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Pharmacotherapy,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,"RNA, circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Seizures,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Bendroflumethiazide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FLII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,aurora kinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ultrasonography,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Peanut butter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Strenuous Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diffuse Scleroderma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Symptoms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Diet,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
DISRUPTS,Metastasis Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Gastrin|GAST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TLR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Oral contraception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypersensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Organochlorine pesticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Reduction mammaplasty,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Nephroblastoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Excision,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pork,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Dietary Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CCND1 gene|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Zn-alpha-2-glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Epithelial hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nuclear Hormone Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,resistin|RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Curcumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vegetables,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Reflexology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,vinorelbine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Willing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KISS1 gene|KISS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Protein Subunits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAP Kinase Kinase Kinase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CHD5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,zoledronic acid,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
DISRUPTS,Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Caffeine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Tomography, Emission-Computed",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TWIST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cyclophosphamide/fluorouracil/methotrexate protocol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Metals, Heavy",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,XRCC6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Migraine Disorders,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Histopathology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PRLR gene|PRLR|PTP4A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Androgen Receptor|AR,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,"Diet, Mediterranean",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fish intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,feral,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,5-Alpha reductase inhibitor,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Follistatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Inflammatory Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TGFB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Engine Exhaust,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dioxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Receptor, Angiotensin, Type 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cyclooxygenase 2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mass Screening,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Microsatellite Repeats,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Sentinel Lymph Node Biopsy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,"Antidepressive Agents, Tricyclic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Chinese cabbage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Oncogene Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Screening mammography,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Environmental Tobacco Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Defense Mechanisms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Expressed Sequence Tags,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Dissection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Red meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Skin necrosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,SOX10,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,XRCC2 gene|XRCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Autoantibodies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Dinoprostone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
DISRUPTS,DNA Repair Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Non-Invasive Lesion,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PREDICTED,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Vitality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,KMT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Blood hormone levels,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,bicalutamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,oleuropein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ALKBH3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Malignant Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cytochrome P-450 CYP1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Progesterone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Lesion,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Polymorphism, Genetic",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,GH1 gene|GH1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Virus Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Epidermal Growth Factor Receptor|EGFR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Angiogenesis Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLC45A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,25-hydroxyvitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,sulfotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA topoisomerase II alpha|TOP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,RHBDD1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Gelatinase B|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIRN150 gene|MIR150,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Discrepancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Needle biopsy procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclin-Dependent Kinase 10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secondary malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Medroxyprogesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,exemestane,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Invasive Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hot flushes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP2D6 gene|CYP2D6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GGT1|GGTLC5P|GGTLC3|GGT2|GGTLC4P,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,cyclin D3|CCND3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Lipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Serotonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,SMAD3 gene|SMAD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Ethanol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IRF4 gene|IRF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Composition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Magnetic Resonance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MAP2K3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP2D6 gene|CYP2D6,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,CXCR4 gene|CXCR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA Repair,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,P-Cadherin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Doxorubicin Hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,QUINTILE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mass of body structure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diagnostic radiologic examination,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Calcium Channel Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Strenuous Exercise,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,receptor activator of NF-kappaB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Exposure to,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,collapsin response mediator protein-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin D Deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GSTT1 gene|GSTT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin A intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Red breast,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
CAUSES,endogenous steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AUGMENTS,"Iron, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Hetastarch,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,White bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Endometrial Hyperplasia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,"1,4-dioxin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lasofoxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,"1,4-dioxin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Noninfiltrating Intraductal Carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,XRCC3 gene|XRCC3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MTA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Human Development,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,G-T mismatch-binding protein|MSH6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CCL1 gene|CCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAT3 gene|STAT3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,retinoic acid receptor beta 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ID2 gene|ID2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cullin 1|CUL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,erbB-2 Receptor|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,IARS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Proteasome inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genetic Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chronic inflammatory disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Interleukins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ORALIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PIK3CA gene|PIK3CA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Trans Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Protein phosphatase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Trans Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Corticosterone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Tryptophan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,K-ras Oncogene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin-8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,DNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
AFFECTS,GTP-Binding Protein alpha Subunits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HOXC6 gene|HOXC6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Body mass index procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Peptide Nucleic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Disease or Syndrome
DISRUPTS,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,DANCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Growth Hormone Receptor|GHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Urokinase|PLAU|PRAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Proto-Oncogene Proteins c-myc|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,survivin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Primary idiopathic dilated cardiomyopathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SNORA7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NanoGel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Positive Lymph Node,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Small Inducible Cytokine A18|CCL18,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
AFFECTS,BRCA2 Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Serum Proteins,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Physiological stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anisotropy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,STAR gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Exons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Genes, ras",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RPE65|UVRAG|TP63|CKAP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MAFG gene|MAFG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TWIST1 gene|TWIST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Self-Examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PARVA gene|PARVA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CBFB gene|CBFB|NFYA|NFYB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Arachidonic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Plant Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LINC00968,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,leukemia,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Gastric Inhibitory Polypeptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SNHG7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tic disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Biopsy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,"RNA, Untranslated",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CYP1B1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AUGMENTS,PLK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GALNT16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease susceptibility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,"CHEK2 protein, human|CHEK2",Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,taxane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Red meat,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Digital mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,LINC00460,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CUL4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,honokiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,DNA Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Epstein-Barr Virus Infections,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TUFT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Insulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Glucocorticoid Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tumor Cell Invasion,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,SCUBE2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AUGMENTS,trastuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"N',N''-diacetylspermine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Aromatase|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,"Receptors, Steroid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,Insulin-Like Growth Factor II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gelatinase A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Medication use,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Vascular Endothelial Growth Factor Receptor-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Electromagnetic Energy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NCAPD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Radiotherapy, Adjuvant",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ginsenoside M1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Metformin hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Spermine Synthase|SMS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Hip circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PCB 180,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIRN34A gene|MIR34A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,silybin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KDM5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Ascorbic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,activated RNA polymerase II transcription cofactor 4|IFRD1|KRT6B|SUB1|PCSK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Methyl-CpG-Binding Protein 2|MECP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prognosis good,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Combined Modality Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,sulforafan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PRNCR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,RHOA gene|RHOA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,everolimus,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Functional assessment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR99A gene|MIR99A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stable weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,27-hydroxycholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,ATP8A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CELF6 gene|CELF6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Menstruation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Mitogen-Activated Protein Kinase 3|MAPK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,CGRRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ZMYND10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DNMT3B gene|DNMT3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,RNA metabolic process,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Chemotherapy Regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dense breasts NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vascular Endothelial Growth Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Low absolute lymphocyte count,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Bilateral Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Paralogous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAK6 gene|PAK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00173 gene|LINC00173,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenic Process,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Phenomenon or Process
AFFECTS,Positron Emission Tomography and Magnetic Resonance Imaging,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,clinical aspects,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,claudin 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypertriglyceridemic Waist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,PDZRN4 gene|PDZRN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MK 2206,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,BRD7 gene|BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KDM1A gene|KDM1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR451A gene|MIR451A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC00993 gene|LINC00993,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,JAG1 gene|JAG1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"Leukemia Virus, Bovine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,TP53 gene|TP53,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Breast-Conserving Surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secondary Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Menopause Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SFRP2 gene|SFRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Exogenous Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Reproductive History,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Histamine H1 Antagonists,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,FNDC5 gene|FNDC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Family history,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CNN1 gene|CNN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,beta catenin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,citronellol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,osteopontin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FOXK1 gene|FOXK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Variation (Genetics),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
PREDISPOSES,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"ATP Binding Cassette Transporter, Sub-Family G, Member 2|ABCG2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,GSTM1 gene|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,sulforafan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNA Motifs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Mirn124a microRNA, human",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,SDHC gene|SDHC,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypersensitivity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Gene Mutant,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,TFCP2 gene|TFCP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,RWDD4 gene|RWDD4,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Discordance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Calcium-Sensing Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hormone Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
DISRUPTS,tissue-factor-pathway inhibitor 2|TFPI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,neoplasm-associated factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tumor Escape,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High Level,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Signs and Symptoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Subjective:Finding:Point in time:^Patient:Narrative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SOX10 gene|SOX10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aggressive behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Muscle Strength,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Other
AUGMENTS,"MET protein, human",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CDYL2 gene|CDYL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Quintile,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FGFR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Matrix Metalloproteinase 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Stiffness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CBLB gene|CBLB|MMAB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mammographic Breast Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ribonucleotide reductase M2|RRM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,TRDMT1 gene|TRDMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Physical Inactivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,brown adipose tissue uncoupling protein,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,daunorubicin liposomal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tumor Suppressor Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bisphenol A,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,TMPO-AS1 gene|TMPO-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
DISRUPTS,huaier,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prune Belly Syndrome,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Human Class I Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Increased risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NUDT21 gene|NUDT21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,concise,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,NEK10 gene|NEK10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GPER1 gene|GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,letrozole,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,YES1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,CCL8 gene|CCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,polygene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RUNX1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Carbohydrate intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Neoplastic Cell Transformation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MCM3AP-AS1 gene|MCM3AP-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,interleukin-10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pathologic Response,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,antiporter,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,ELAVL2 gene|ELAVL2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Neuropilin-1|NRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Finding of body mass index,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fumigant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclin B1|CCNB1,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,RNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
AFFECTS,calycopterin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,arctigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibrin fragment D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,pristimerin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Sedentary lifestyle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,kusunokinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DAPK1 gene|DAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Late Relapse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,risk factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FGFBP1 gene|FGFBP1,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,ZEB1 gene|ZEB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TNF wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Puberty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RIOK1 gene|RIOK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,magnesium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Disease or Syndrome
AFFECTS,ergocalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,naringenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Flavanones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metastatic malignant neoplasm to brain,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"RNA, Messenger",Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,wogonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BCL11A gene|BCL11A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,podofilox,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ERR1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LIMK2 gene|LIMK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antimalarials,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MLF2 gene|MLF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MALAT1 gene|MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor size,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,sunitinib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Hyperthyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AMH gene|AMH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACVR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CKLF gene|CKLF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Screening procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PRKN gene|PRKN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,baicalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
DISRUPTS,simvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Anti-Mullerian Hormone Receptor Type II, Human|AMHR2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Excessive dietary caloric intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Genetic Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNAI1 gene|SNAI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ADIPOR1 gene|ADIPOR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Fibroblast Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,APOBEC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Protein, Organized by Structure",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Angiogenic Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,tamoxifen,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Organophosphate pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HER-2 protein|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hormone Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,dna genetics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"DNM1L protein, human|DNM1L",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,GSTP1P1 gene|GSTP1P1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FANCM gene|FANCM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SNAI2 gene|SNAI2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Sodium-Glucose Transporter 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AUGMENTS,ZFPM2-AS1 gene|ZFPM2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BBOX1 gene|BBOX1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Uptake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,Conventional Treatment,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Chemotherapy, Adjuvant",Carcinoma breast stage I,0.0,Female Breast Cancer,Other
CAUSES,Injection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oils,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,TP53 gene|TP53,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,SERPINE1 gene|SERPINE1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,RASAL2 gene|RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00922 gene|LINC00922,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,c-Mer Tyrosine Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Moderate risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Processed meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,estrogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
PREDISPOSES,HMGB1 gene|HMGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"PDIA3 protein, human|PDIA3",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR30E gene|MIR30E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MTOR gene|MTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score C,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,RSPO3 Gene|RSPO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Present,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,A2M-AS1 gene|A2M-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Progranulins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Thymidylate Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SALL4 gene|SALL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Anthracyclines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KCNQ1OT1 gene|KCNQ1OT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,METTL14 gene|METTL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hypoxia-Inducible Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,cryptotanshinone,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,TUG1 gene|TUG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Neural Networks,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,mortalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Zearalenone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alternative Splicing,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,resistin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PCAT7 gene|PCAT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,lamin B2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,High Level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LINC01271 gene|LINC01271,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Elasticity Imaging Techniques,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,"RNA, Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,hereditary factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PTEN gene|PTEN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE3C gene|UBE3C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"IL2RB protein, human|IL2RB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ZNF670-ZNF695 gene|ZNF670-ZNF695,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Risk Scores,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,OXER1 gene|OXER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FBXO22 gene|FBXO22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Uncertainty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,TINCR gene|TINCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00665 gene|LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Bilateral mastectomy,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,iron,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Tumor Promotion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,UCHL1 gene|UCHL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lactates,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,CHEK2 gene|CHEK2,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,AGAP2-AS1 gene|AGAP2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Psychosocial Intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoadjuvant Chemotherapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Immune Checkpoint Blockade,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SDHC gene|SDHC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MBD2 gene|MBD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Obesity, Abdominal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Leisure physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LINC01271 gene|LINC01271,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,leptin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
CAUSES,Nutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Calcium intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypoxia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Metric (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,FZD2 gene|FZD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,gambogic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Malignant neoplasm of breast,"Breast Cancer, Familial",0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,hydroxyl group,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary Neoplasm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,CPT1A gene|CPT1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,calmodulin-dependent protein kinase III,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SENP3 gene|SENP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,elaidic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CDKN1A protein, human|CDKN1A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ATM gene|ATM,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Heterogeneous-Nuclear Ribonucleoprotein K,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,O(6)-Methylguanine-DNA Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Ovarian failure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYTOR gene|CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Immunologic Surveillance,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,COVID-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Tumor Microenvironment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LRRC3B gene|LRRC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,recreational activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hypoxia-Inducible Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Zinostatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Systemic Inflammatory Response Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,ropivacaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Body mass index procedure,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
AFFECTS,"PLK1 protein, human|PLK1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Prognostic Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FBXO32 gene|FBXO32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ELF5 gene|ELF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ENTPD1 wt Allele|ENTPD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDK15 gene|CDK15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transcription Coactivator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Neoantigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ropivacaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FADS1 gene|FADS1,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,hyaluronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Fetal valproate syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,DPP6 gene|DPP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWIST1 gene|TWIST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Intronic Mutation,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PADI1 gene|PADI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR599 gene|MIR599,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FANCA gene|FANCA,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,LOC100505851,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR638 gene|MIR638,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LOC105371267,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carcinoembryonic Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,receptor operated channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Graphene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hydroxymethylglutaryl-CoA reductase,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Thrombophilia,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,ARHGAP1 gene|ARHGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WNT9B gene|WNT9B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,VGLL1 gene|VGLL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Collagen Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HAGLR gene|HAGLR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,cytotoxicity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,KIF23 gene|KIF23,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Consideration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"herstatin protein, human",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Xenograft procedure,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,CDKN2B-AS1 gene|CDKN2B-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,medication risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Full Term Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,VCAN-AS1 gene|VCAN-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LINC01094 gene|LINC01094,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cerebrovascular accident,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,epithelial to mesenchymal transition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL27 gene|MYDGF|IL27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hepatocyte Nuclear Factor 3-alpha|FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,GLUT-1 protein,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC01315 gene|LINC01315,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adhesions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Coronary Arteriosclerosis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,"Drug Resistance, Neoplasm",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AFFECTS,NEIL2 gene|NEIL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ursolic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,bone morphogenetic protein 4|BMP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ZBTB7A|AKIRIN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,fluorouracil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,LINC00922 gene|LINC00922,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,baicalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Stress,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,HOXC10 gene|HOXC10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,New medications,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Tumor Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Transcript,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"EIF4EL3 protein, human|EIF4E2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"herstatin protein, human",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"RNA, Small Interfering",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Mucin-1 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MICAL2 gene|MICAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,TLR1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Endoplasmic Reticulum Stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,COVID-19,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,EHD1 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"CD69 protein, human|CD69",malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fiber intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HSPA9 gene|HSPA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,New Diagnosis Procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ergocalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,high weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,2-(4-morpholinoanilino)-6-cyclohexylaminopurine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,High residue diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RBM38 gene|RBM38,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"herstatin protein, human",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Lactation established in non-human animal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDC20 gene|CDC20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,granzyme B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Prieto X-linked mental retardation syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NFIL3 gene|NFIL3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,KRT19P3 gene|KRT19P3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PTEN gene|PTEN,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathologic Complete Response,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,"LATS1 protein, human|LATS1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CARD.RISK,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,"Genes, cdc",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,omega-3 fatty acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,liquiritigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Autophagy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Vital activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,oxaliplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ADRB2 gene|ADRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"EZH2 protein, human|EZH2",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Antibody Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,Agonist,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,hydrogen peroxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Obesity, Visceral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Ultrasound scan finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SRP9 gene|SRP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tramadol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HTR1A gene|HTR1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00466 gene|LINC00466,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,OPRM1 gene|OPRM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLK3 gene|KLK3,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,DDT (Insecticide),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Invertebrate
PREDISPOSES,Life Expectancy Less than Five Years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ARHGAP17 gene|ARHGAP17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Duration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,tegaserod maleate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Nutrients,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Food
PREDISPOSES,Sports,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypoxia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Screening mammography,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Migraine Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,physiological aspects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NEDD4L gene|NEDD4L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Chemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIR210HG gene|MIR210HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD31 Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,mRNA Expression,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,G-Protein-Coupled Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TRIP13 gene|TRIP13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Keratin-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cisplatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,RAB8A gene|RAB8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PSAT1 gene|PSAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CCR2 gene|CCR2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,RAB8A gene|RAB8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epithelial ovarian cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SREBF1 gene|SREBF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Score,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metabolism,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Has difficulty doing (qualifier value),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"tropomyosin-related kinase-B, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pediatric Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NCAPD2 gene|NCAPD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hyperactive behavior,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
CAUSES,Players,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Endoplasmic Reticulum Stress,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,purinoceptor P2X4|P2RX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Manipulation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GTSE1 gene|GTSE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Magnetic Field Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypersensitivity,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,"Human B-Lymphocyte Antigen CD20, human|MS4A1|KRT20",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,anhydroicaritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Physical function,Locally advanced breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Self-Examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC01287 gene|LINC01287,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Adipokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Frailty,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,Dietary Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Receptor, PAR-1",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,dietary fiber intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diabetes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ATAD2B gene|ATAD2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Chemotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,FOXD3-AS1 gene|FOXD3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Triglycerides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Post-mastectomy radiotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DDX21 gene|DDX21,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"protein TDP-43, human",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,si-wu-tang,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Comorbidity,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
DISRUPTS,folic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,benzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Hydrogen Sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,2-mercaptoethanesulfonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,gamma-Secretase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PSME2 gene|PSME2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ergocalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Helicobacter pylori,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,SCG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Carcinogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,ZNHIT1 gene|ZNHIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,GUSBP11 gene|GUSBP11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,CUEDC2 gene|CUEDC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNA Recognition Motif,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,TP53,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Florid red complexion (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Orthologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CD47,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,Aurora Kinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,intrinsic factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Claudins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PON1 gene|PON1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Eosinum, eosin, Homeopathic preparation",malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Androgen Binding Protein|SHBG|CCHCR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Sleep,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,catalpol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic Breast Density,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,Peptides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lymphatic Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LINC00520 gene|LINC00520,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"RNA, Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,High grade serous carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,PIK3CA Gene Mutation,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,TRANSCRIPTION FACTOR,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Rich food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,"RNA, Long Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Colorectal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Antibody-Drug Conjugates,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
AFFECTS,ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,BVES gene|BVES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Diet, Paleolithic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cardiac event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
DISRUPTS,Inhibitor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,SLC1A5 gene|SLC1A5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Pharmaceutical Preparations,Carcinoma breast stage IV,0.0,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,BRCA2 gene|BRCA2,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPATA25 gene|SPATA25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Metric (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,pigment epithelium-derived factor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,Intercellular adhesion molecule 1|ICAM1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IGHG1 gene|IGHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Screening procedure,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DDX11-AS1 gene|DDX11-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cerulenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Life Expectancy Less than Five Years,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,FTO gene|FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"Receptors, Progesterone",Advanced breast cancer diagnosis,0.0,Female Breast Cancer,Hormone
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,arsenic trioxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Liposomes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Diagnosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,"RAF Proto-Oncogene Serine/Threonine-Protein Kinase, human|RAF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Provisional,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,metformin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,tiliroside,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Programmed cell death ligand 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transection (procedure),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Drugs, Non-Prescription",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Hypoxia Inducible Factor Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,SMURF1 gene|SMURF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,genistein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,insulin-like growth factor 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Catechols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,GNAO1 gene|GNAO1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCND1 gene|CCND1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,AXL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,FOXO1 gene|FOXO1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,CCN1 gene|CCNA2|CYR61|PPP3CA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metabolic marker,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Transcription Factor AP-2 Beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SIRT1 gene|SIRT1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,DANCR gene|DANCR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Tumor Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,malignant disease,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,IGF2BP1 gene|IGF2BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,"High Mobility Group Protein HMG-I, Human|HMGA1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,beta-arrestin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,AKTIP gene|AKTIP,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Prolactin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,green tea extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Drug resistance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,eriocalyxin B,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,HULC gene|HULC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,USP13 gene|USP13,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,NLRP3 gene|NLRP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PHB2 gene|PHB2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,dietary fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Senility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,toosendanin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,VDR gene|VDR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Amino Sugars,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Meal (occasion for eating),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lactates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,clinical aspects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,eltrombopag,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,TTC17 gene|TTC17,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Atrial Fibrillation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Exogenous hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Amino Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,factor VII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PKMYT1 gene|PKMYT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Specific antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,"DICER1 protein, human|DICER1",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NUMB gene|NUMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obesity,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,COG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ultrasonography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Salpingo-oophorectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor Microenvironment,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Sleep duration:Time:Pt:^Patient:Qn,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ursolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Hydroxy Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"SDHD protein, human|SDHD",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Immune checkpoint inhibitor therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lactates,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,"CTSH protein, human|CTSH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,Immune Checkpoint Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TYMS|PYCARD,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,CDK1 gene|CDK1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epithelial proliferation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fibronectins,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,COPS6 gene|COPS6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Life Expectancy Less than Ten Years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,KIF2C gene|KIF2C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Severe (severity modifier),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIR326 gene|MIR326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"HMGA2 protein, human|HMGA2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RNA-Binding Protein Musashi Homolog 1,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Non-Small Cell Lung Carcinoma,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IPO7 gene|IPO7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ROR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Peripheral Nerve Sheath Neoplasm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"TNF protein, human|TNF",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RNA-Binding Protein Musashi Homolog 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Peptides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Biological Markers,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,PPP1R14B-AS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,doxorubicin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,RNA-Binding Protein Musashi Homolog 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FOXP3 gene|FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,palbociclib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA2 Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Inflammasomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HIPK3 gene|HIPK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,pre-miRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Metabolite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,alpha Catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,YOD1 gene|YOD1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Obesity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,SMYD2 gene|SMYD2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TUSC2 gene|TUSC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPX4 gene|GPX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Circulating Tumor DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,interleukin-6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,AURKA gene|AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"CREB1 protein, human|CREB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cervical Cancer Screening,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Protons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ascorbic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Performance,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,zoledronate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Caspase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,astragaloside IV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,mammaglobin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,TMED2 gene|TMED2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Secondary Neoplasm,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,HASPIN gene|HASPIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Ferritin Light Chain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SNHG14 gene|SNHG14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lymphatic Invasion,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Allele-Specific Oligonucleotide,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,beta catenin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,NR1D1 gene|NR1D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mitosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,risk factors,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,estrogens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,euphorbia factor L1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,ketamine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXO3 gene|FOXO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,andrographolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NEK2 gene|NEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Flavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pharmacologic Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,signaling cascade,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Phosphates,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,PAXX gene|PAXX,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Obesity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Sesquiterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Colorectal Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,PIN1 gene|PIN1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,FMO4 gene|FMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fibroblast Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Vacuum assisted biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR223 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,taxane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inhibitor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,hydroxypropylbetadex (0.58-0.68 MS),Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,"POSTN protein, human|POSTN",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,TWIST1 gene|TWIST1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,chelidonine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Homologous Recombination Repair Gene,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,YBX1 gene|YBX1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Plasma Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FBXO3 gene|FBXO3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Precision Medicine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chlordan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Shift worker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Stress, Psychological",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MTDH gene|MTDH,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,calcifediol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Low Level,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
DISRUPTS,c-src Genes|SRC,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,HSP90 Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Psychotic Disorders,Carcinoma breast stage IV,0.0,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Ubiquitin-Conjugating Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,Equilibrium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TIPARP gene|TIPARP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proliferative vitreoretinopathy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Complementary therapies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RAD51 gene|RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Duration,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GALNT7 gene|GALNT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MELK gene|MELK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leukotriene B4 Receptors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Eicosanoid
AFFECTS,GRB2 gene|GRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LIAS gene|LIAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HER2/Neu Positive,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SNORD16 gene|SNORD16,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,clinical aspects,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,FBXO8 gene|FBXO8,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fertility Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,icariin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Receptor Protein-Tyrosine Kinases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,cadmium chloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Oxidoreductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ECM1 gene|ECM1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNHG1 gene|SNHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Personal status - Adopted,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"ORF74 protein, Human herpesvirus 8",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Tea Extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Ubiquitin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SNORD49B gene|SNORD49B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Healthy Lifestyle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,YAP1 gene|YAP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"herstatin protein, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Clinical Significance,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,HOTAIR gene|HOTAIR,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Secondary Neoplasm,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"ATP8A2 protein, human|ATP8A2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alzheimer's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Pathogenic Variant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
PREDISPOSES,Alzheimer's Disease,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Performance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Obesity,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,UGT2B7 gene|UGT2B7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HIF1A gene|HIF1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,O(6)-Methylguanine-DNA Methyltransferase|MGMT,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,baicalein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Biological Processes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,GCKR gene|GCKR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDP1 gene|PDP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,FSCN1 gene|FSCN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,thiostrepton,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Malignant Neoplasms,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"CDK7 protein, human|CDK7",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NODAL gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6, human|CEACAM6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Progranulins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Uridine Diphosphate Glucose Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Personal Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Oligoribonucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Nitric Oxide Synthase Type II,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TCF7L2 gene|TCF7L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NCOA1 gene|NCOA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MLH1 gene|MLH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Motility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"GMNN protein, human|GMNN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PAK1|PKN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Methotrexate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Adenosine A1 Receptor|ADORA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,Mammary Neoplasms,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,LSP1 gene|LSP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,indole-3-carbinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TNFSF6 gene|FASLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Prevention,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,bortezomib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,NME1 gene|NME1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,Amyloid beta-Protein Precursor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,survivin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Connexins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Compound V,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Pharmaceutical Preparations,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Bacterial Endocarditis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Bacterium
AUGMENTS,activating transcription factor 3|ATF3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immune Cell Activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD47 gene|CD47,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Interleukin-17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,bone morphogenetic protein 6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NTRK2 gene|NTRK2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,PITPNM1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,IGKC gene|IGKC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CIP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AUGMENTS,BST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Estrogen Receptor beta|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Encounter due to genetic counseling,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,ethnic differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BMP2 gene|BMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen receptor positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Catenins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, cdc",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,nitidine chloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"DNA, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,BIRC4 gene|XIAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Contraceptive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,MC4R gene|MC4R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,KIFC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Syndrome,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,PSMB6|YY1|DLL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,cilostazol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,FOXM1 gene|FOXM1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,PAWR gene|PAWR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,UBE2N,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,STMN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IQGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,profilin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KISS1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Neuromedin U|NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mullerian-inhibiting substance receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR98,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CENPA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,isoliquiritigenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Centchroman,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,MIRN21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estradiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ERBB2IP gene|ERBIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RARRES3 gene|RARRES3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Adenocarcinoma of large intestine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,dihydroxyacetone sulfate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Leisure Time,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EPSTI1 gene|EPSTI1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Prodrugs,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,NRIP1 gene|NRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,platelet-derived growth factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,"TIMP1 protein, human|TIMP1",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclophosphamide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Encounter due to genetic counseling,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
PREDISPOSES,Thymidylate Synthase,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,APC gene|APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genes,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast cancer invasive NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Orosomucoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CTCF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TLR4 gene|TLR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Sialoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK1 gene|CHEK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Organic Chemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,XRCC4 gene|XRCC4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Phosphotransferases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,estrone sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Glutamate Carboxypeptidase II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDH1 gene|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,KISS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"HGF protein, human|HGF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,STAT5B gene|STAT5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,transcription cofactor activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Supraventricular arrhythmia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Wiskott-Aldrich Syndrome Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Proto-Oncogene Proteins c-sis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CA-125 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,PFN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sodium Selenite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GRHL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Epigenetic Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Glutamic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,1-Phosphatidylinositol 4-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Receptors, Tumor Necrosis Factor, Type II",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,PELP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SOX11,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,Interleukin 4 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CMA1|SLC16A1|MCAT|MCTS1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,gamma-secretase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carboxypeptidase U,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Atrial Fibrillation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cancer of Rectum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,TNFSF10 gene|TNFSF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epstein-Barr virus antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,TSG101 gene|TSG101,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Neoplasm,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,Epinephrine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Reserpine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Castration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIRN17 gene|MIR17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SHC1 protein, human|SHC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,In complete remission,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aspartic Endopeptidases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Reproduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Up-Regulation (Physiology),Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,chromosome 17q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Milk intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chronic inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fibrosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Caseins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Menstrual cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Reserpine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,SRC gene|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,OLFM4 gene|OLFM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Circadian Rhythms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Virus,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Virus
CAUSES,retinol acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Selenium intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vinyl Chloride,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,N-acetyltransferase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,retinyl methyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA2 gene|BRCA2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Interleukin-13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,inhibitors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Exogenous hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,calcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"RARB protein, human|RARB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LEPR gene|LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Xeroradiography,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AFFECTS,Bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,leptin receptor|LEP,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,Exogenous hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Cyclin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,"CST6 protein, human|CST6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Metabolites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Fatty Acids, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"Puberty, Female",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Vitamin D3 Receptor|VDR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,pyrrolidino-4-iodotamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Transcriptional Activation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,valyl-valyl-valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Infusion procedures,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,20q13.2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Proto-Oncogene Proteins c-akt|AKT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Somatotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Progesterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Fibroblast Growth Factor 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,BONE MASS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,No past history,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Molecular Abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Indoles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Immunotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Involution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cadherins,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Retroviridae,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Enzymes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
PREDISPOSES,EYA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Pill,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,neu Differentiation Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Reproductive History,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,parathyroid hormone-related protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hyaluronan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aromatic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Dietary Fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasm,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,CA1|S100A10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Binding Sites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Proto-Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Urea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Melatonin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Fenretinide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Oncogene, HST|FGF4|HSF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrogen Replacement Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sterility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Benzanthracenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Absolute Alcohol,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AFFECTS,Cytotoxic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Polyunsaturated fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,3-hydroxytamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,PHENYL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Termination of pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,adjuvant therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of bone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Estrone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,hormonal changes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fluorouracil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TAG 12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Term pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alkaline Phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alkaline Phosphatase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Advance,Breast cancer stage II,0.0,Female Breast Cancer,Other
PREDISPOSES,Athletics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EGF gene|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Height / growth measure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ARGINASE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Breast Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Seizures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Induction,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Malignant transformation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Thyroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tissue Polypeptide Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Pharmacotherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of stomach,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Testicular Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mammography,Breast Mucinous Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,Haloperidol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hysterectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Medroxyprogesterone 17-Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Ovariectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,v-H-ras Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Prolactin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hair Dyes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
CAUSES,Neuromedin U|NMU,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
COMPLICATES,"Liver Failure, Acute",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Ovariectomy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Monoterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Hydrocortisone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,melanoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Antagonists,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Neurotropism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Cystic Lesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Contraction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Prostaglandins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Eicosanoid
PREDISPOSES,2-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Hamartoma Syndrome, Multiple",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Aminoglutethimide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antipyrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Levamisole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,transglutaminase 1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hydrocortisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Goserelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Visual impairment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Scanning,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogenic,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Introns,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Flutamide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,CATHEPSIN D|CTSD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dichlorodiphenyl Dichloroethylene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,Acetyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carrier of disorder,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,"(meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(II)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mixture,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Human Chorionic Gonadotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Date of birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Short stature,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin D1|CCND1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,Complex carbohydrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,SERPINB2 gene|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PTK2B gene|PTK2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Phenothiazines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,retinoic acid receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Cyclic AMP Receptor Protein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Maternal history,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Vegetable Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,6-pyruvoyltetrahydropterin synthase|SLC25A3|REG1A|PTPRU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Beans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Insulin-Like Growth-Factor-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Integrins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
COMPLICATES,Pathological fracture,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Nulliparous,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mean blood pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,glypican 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Herpesvirus 4, Human",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AUGMENTS,DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,"Smoking, Passive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lhermitte-Duclos disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,BRCA2 gene|BRCA2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CDKN2A gene|CDKN2A,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,NAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Overnutrition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transcription Factor AP-2 Alpha|FABP4|GTF3A|TFAP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SPO11 gene|SPO11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ultraviolet Rays,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GRB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Premature Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gene Expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Mitogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gene Amplification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,ras Oncogene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Invasive Carcinoma,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Fibroadenoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Receptors, Nuclear",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cytochrome P450 3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,estriol 3-sulfate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CHGA gene|CHGA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Vascular Endothelial Growth Factor Receptor-1|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Disintegrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NMU gene|NMU,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Pre-Eclampsia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ovarian function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,Gross' disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,"Polycyclic Hydrocarbons, Aromatic",Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vitamin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Endostatins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,glutathione S-transferase M1|CHRM1|MRLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation therapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,bone sialoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Adrenal carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Encounter due to prophylactic surgery, unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Scanning,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,psychological stressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Opioid Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,BRCA1 Protein|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,Depo-Provera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Stress, acute",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,3MC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Epoxy Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Methylcholanthrene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Ibuprofen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Beta Carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ESRRA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2 gene|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,specific immunity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Repressor Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Radioimmunotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
PREDISPOSES,TIE gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Thyroid Hormone Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HDAC1 gene|HDAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ATM gene|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,XRCC2 gene|XRCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic procedure,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Kininogenase|KLK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EGFR gene|EGFR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
CAUSES,ZHX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Sporadic Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Oleic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,GTPase-Activating Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Telomerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth-Factor-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Estrogens, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Guanosine Triphosphate Phosphohydrolases,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,TP53 gene|TP53,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Apple,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,parathyroid hormone-related protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Female genital tract problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fatty food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Embolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CHEK2 gene|CHEK2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,Carcinoma of Male Breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"SKIL protein, human|SKIL",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ADAM23,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"retinoic acid binding protein II, cellular",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CANADIAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mass in breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Carcinoma, Lobular","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,Medroxyprogesterone 17-Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA1 Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,Prolactin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mammary Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BIRC5 gene|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Creatinine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mammary Tumorigenesis,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Hepatocyte Growth Factor|HGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,"JARID1B protein, human|KDM5B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Receptiveness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,pregnancy hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Recreation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,peptide I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IGKV2D-40,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Malignant neoplasm of prostate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hexachlorobenzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,HFE gene|HFE,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,Methylcholanthrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Single-Stranded Conformational Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Emotional support,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,WNT7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,Synucleins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Conjugated Equine Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,beta-ionone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Androgen therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,death receptor-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Iodides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Tumor Protein p53 Binding Protein 2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Paroxysmal atrial tachycardia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Estrogenic,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hormone
PREDISPOSES,Hyperglycemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,Thrombospondin 1|THBS1|CRISP2|PRSS55,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Increase in blood pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Convenience food,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
DISRUPTS,AKR1C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,EVL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,"Contraceptives, Oral",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Fibrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CHEST PATHOLOGY,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,CYP1A2 gene|CYP1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transcription Initiation Site,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Aggressive cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,connective tissue growth factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Dopamine Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,WNT7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cyclic Peptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Spray,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,N-Cadherins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AFFECTS,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HSP90 Heat-Shock Proteins|HSP90AA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Dairy Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SLC25A18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Climacteric discomfort,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Microdochectomy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Molecular Chaperones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Trans Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Integrins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"Diabetes, Gestational",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,intestinal bacteria,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Bacterium
PREDISPOSES,Prolactin level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasm Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Tumor Suppressor Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,ADRA1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,IRS1 gene|IRS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Pregnanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PRL increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Molecular Target,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PTH gene|PTH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tocotrienols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Biopsy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,IGF1 gene|IGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,E-Cadherin,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
DISRUPTS,allyl sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AUGMENTS,Tetanus Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Biological Models,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mouse Pancreatic Intraepithelial Neoplasia-1B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,"Estrogens, Catechol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Lymph Node Involvement,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Anti-Inflammatory Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Betaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Platelet-Derived Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,gamma-Glutamyl Hydrolase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Integrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Endocrine Disruptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CD44 gene|CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vitamin B Complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Mutation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BRMS1 gene|BRMS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disclosure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,phospholipid-hydroperoxide glutathione peroxidase,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,alpha-Fetoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SIRT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tea intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TP53 gene|TP53,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,CATHEPSIN D|CTSD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TP53 gene|TP53,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Diethylstilbestrol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Coronary heart disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Serotonin Uptake Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AUGMENTS,Pesticides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Detectors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serine Protease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,prolylarginine|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHEK2 gene|CHEK2,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cortisol level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 Protein|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,NEK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,EGFR gene|EGFR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Thrombospondin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Aldosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
AFFECTS,CCNA2 gene|CCNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Estrogen Receptor beta|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor Cell Invasion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRANSCRIPTION FACTOR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NPY1R gene|NPY1R,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HGS gene|HGS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Ascorbic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,FANCA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Actin bundling protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hypermethylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Oligonucleotides,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Metabolic syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,PGR gene|PGR,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Cyproterone Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Malignant Neoplasms,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Development of the breasts,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,PIN1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,Alpha tocopheryl succinate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Obesity,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,steroid hormone receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Guanosine Triphosphate Phosphohydrolases,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Alar,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ANXA1 gene|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,estradiol-17 beta-glucuronide,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,NF1 gene|NF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptors, Notch",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Organic Anion Transport Polypeptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Nucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Polyomavirus Middle T Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,Thymidine Phosphorylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Study models,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hyperthyroidism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,SLC25A4|CD5|IL1RL1|TRAPPC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CENPH gene|CENPH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,erlotinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,lapatinib,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Carcinogens, Environmental",Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Telomerase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,JAG2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,PARP1|COL11A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD27,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,"Estrogens, Catechol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Vanadium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cancer Treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SPN|DEAF1|PPP1R9B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CLDN2 gene|CLDN2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sex Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Antagonists,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
DISRUPTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TWSG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Enzyme variant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Development of the breasts,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,PIK3R1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CD24,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Levonorgestrel,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
DISRUPTS,Epicatechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Vascular Endothelial Growth Factor C|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,SH3KBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Double Strand Break Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SLC9A3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,LEPR gene|LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Homeostasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Migraine Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Mastication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,2q35,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell physiology,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carcinogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Sphingosine-1-Phosphate Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nicotinic Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiogenesis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,8q24,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,src-Family Kinases|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Microsatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Increased estrogen level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Oxidation-Reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MicroRNAs,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,B3GNT2|B3GNTL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,FRAGMENTS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CD44 gene|CD44,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Elevated insulin-like growth factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,WWP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Calcium, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,High Mobility Group Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Calgranulin B|S100A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRAZILIAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hydroxide Ion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Angiotensin-Converting Enzyme Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Enzyme
AFFECTS,Adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAD51C gene|RAD51C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,6q22.33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,brightness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SPN|DEAF1|PPP1R9B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,FHL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sodium Valproate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TOPBP1 Gene|TOPBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proteins,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RPE65|UVRAG|TP63|CKAP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Somatomedins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,epithelial to mesenchymal transition,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Enhancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Phosphatidylethanolamine Binding Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PTPN11 gene|PTPN11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cadherin 5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,METHYLATE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AUGMENTS,soy protein isolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,SNAI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,patient family history,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,Tamoxifen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AFFECTS,Sirolimus (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,MicroRNAs,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Malignant neoplasm of cervix uteri,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Receptors, Cytoplasmic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MS4A1|BBS9|IGKV7-3|SPANXB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Very high,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Paraffin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAB1B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,PYRUVATE CARBOXYLASE|PC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Annexin A1|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,IL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Integral Membrane Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Arthralgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PIAS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Chemotaxis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Lead compound,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,treatment method,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,betaine-homocysteine methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CYP4Z1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PRICKLE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transfer RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PROTEIN KINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Choline dehydrogenase|CHDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,N-ras Genes|NRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Extravasation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IGF2BP2|IMMP2L|SPPL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABCG2 gene|ABCG2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,furanodiene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Androgen Receptor|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,2q33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Tumor Necrosis Factor Receptor Superfamily, Member 10B",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,IL33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vascular Cell Adhesion Molecule-1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,OTUD1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Neurofibromin 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BRCA1 gene|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Annexin A3|ANXA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,galangin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Processed meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,tubeimoside I,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Sulindac,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PAQR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,G-Protein-Coupled Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RECQL gene|RECQL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Trans-Activation (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pyrimidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SOX17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
DISRUPTS,"DICER1 protein, human|DICER1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,myristoylated alanine-rich C kinase substrate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Ovarian ablation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,IKBKB,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of lymph node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Osteopenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Extracellular Matrix Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RHOBTB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SYF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Enhancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CTSO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dietary cholesterol intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,PK 11195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TAF7L gene|TAF7L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL8RB gene|CXCR2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEUROD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Maternal history,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Diphosphonates,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Solid tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,KDM6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Matrix Metalloproteinase Inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,butylbenzyl phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Prolactin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Recombinant Interferon-gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Myosin Light Chain Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pain relief,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Magnetic field,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Curcumin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,STXBP4 gene|STXBP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Treatment Protocols,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Extracellular Matrix Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,EGF gene|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,cyclopamine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,GTF2H1|SQSTM1|KHDRBS1|NUP62|DCTN4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,sphingosine 1-phosphate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PRDM1 gene|PRDM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Iodine-131,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epigenetic Process,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Morphine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Triazoles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,recombinational repair,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BMP4 gene|BMP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ADAMTS18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,MAS1 gene|MAS1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Housekeeping Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Genes, Developmental",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Birth length,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,beta catenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Genes,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,WNT10B gene|WNT10B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Helminths,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,MIRN200A gene|MIR200A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PVT1 gene|PVT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BRF1 gene|ZFP36L1|BRF1|MST1L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RECQL4 gene|RECQL4,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,RAB11FIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,molecular chaperone GRP78,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of stomach,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Sirolimus (substance),Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Substance
AFFECTS,TCP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibroblast Growth Factor Receptor 2|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Vascular Endothelial Growth Factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,EHMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ZEB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,FGFR1 gene|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,pertuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nelfinavir,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDK6-associated protein p18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Metastasis Suppressor Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,cucurbitacin B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,imbalance,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Hypogonadism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Atenolol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic breast density,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AUGMENTS,STX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Methylene blue,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EIF4G2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,epigallocatechin gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mammary Neoplasms,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,SKP2 gene|SKP2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HIF1A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,exemestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BCYRN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,chrysophanic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,SRPK1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,capecitabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Body Weight decreased,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,SRD5A2 gene|SRD5A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Calcitriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,proto-oncogene protein Spi-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Factors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Neprilysin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,EIF4G1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cardiovascular event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,resistin|RETN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Monoclonal Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cereals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NF-kappa B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor Suppressor Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,Estradiol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,TCF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,UGT2B4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LATS1 gene|LATS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Small Interfering",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,IQUB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SYVN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Sponges, Gauze",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LIMK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Luciferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PCDH17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CD8B1 gene|CD8B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,endogenous steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,POMC gene|POMC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DLG5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Quercetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CDK14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Does stand,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,genetic locus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PMS2 gene|PMS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TSLP gene|TSLP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ITGB2 gene|ITGB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BIBR 1532,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,extracellular signal-regulated kinase 3|MAPK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Extracellular Matrix Proteins,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MFN2 gene|MFN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,brca gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,REST gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PKM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth-Factor Binding Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Membrane Transport Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SPRY4-IT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"PER2 protein, mammalian",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Alkaloids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Eicosanoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
AFFECTS,Vision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADAM12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,LINC01116,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TP53 gene|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,OIP5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,polyphenols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Blue light,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,phenyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Heparitin Sulfate,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
CAUSES,Study models,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor II|CD74|GCNT2|TCN2|VIPR1|TAF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,FAS gene|FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hesperidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,PDK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Garlic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Multiple Myeloma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anesthesia procedures,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Soybeans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclical mastalgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NAT2 gene|NAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Yogurt,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,UGT8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nuclear Factor 45 Protein|ILF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"DNA, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PSMD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,antibody conjugate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,GSTM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sterol Regulatory Element Binding Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,src-Family Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MYC gene|MYC,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chicken Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A7,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,CD24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYTH3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Interleukin-2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,UGT1A1 gene|UGT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,2-chloroethyl ethyl sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Signal Transduction,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Flavonols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Alcoholic Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Depressed mood,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ZFHX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Functional disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Intellectual functioning disability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD247,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Epidermal Growth Factor Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Transfer RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,gene therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,lysophosphatidic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Measles-Mumps-Rubella Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,THBS1 gene|THBS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Loss of Heterozygosity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,WWOX,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Deoxycholic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,polymorphic microsatellite markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
CAUSES,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Malignant neoplasm of endometrium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Menstrual cycle,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,dietary intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Reliance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PSYCHIATRIC HISTORY,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Neoplastic Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fibroblast Growth Factor Receptor 2|FGF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,"RNA, Messenger",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"DNA, Complementary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Histamine H2 Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Hormones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,interleukin-23,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CXCL1 gene|CXCL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Acetaminophen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diphosphonates,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of breast,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
CAUSES,benzanthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GSTM1 gene|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,adjuvant therapy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AFFECTS,Disease Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation therapy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Strenuous Exercise,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,EGR1 gene|EGR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant Neoplasms,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Insulin, Glargine, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,IL13Ralpha2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Ataxia Telangiectasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Analgesics,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Insulin Receptor|INSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immune response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Calcium Channel Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,alcohol effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 gene|BRCA1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Ovarian Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Female Homosexuality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,delta-hexachlorocyclohexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DPF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Personality Traits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Paraoxonase 1|PON1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hydroxyestrones,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,checkpoint kinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HMGB1 gene|HMGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSD11B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Growth Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,DNA Methylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF217 gene|ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Tenascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IRS1 gene|IRS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXC Chemokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Organic solvent product,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Chemical
AFFECTS,Simvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,bevacizumab,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inflammation Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Moderate Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Uniparental Disomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Rubidium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,19p13.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Injection procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Plasminogen Activator Inhibitor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sitting height,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,JNK Mitogen-Activated Protein Kinases|JUN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,E2F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 gene|BRCA1,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
PREDISPOSES,6/4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,capecitabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Heme Oxygenase-1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pregnancy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Metric,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Insulin|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RABGEF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,participation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FLOT2 gene|FLOT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Behavior,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Thromboembolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,response,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,NBN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chronic lymphocytic inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Organic Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,HFE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"APEX1 protein, human|APEX1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RRM2 gene|RRM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chemotherapy-Oncologic Procedure,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Enrich,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nipple discharge NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Symptoms,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Hair Dyes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Histopathology,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Renin-angiotensin system inhibition,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MAP Kinase Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Autoantibody NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Neutropenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Decalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Asthenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Nicotine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sulfonylurea Compounds,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
DISRUPTS,Protein-Serine-Threonine Kinases,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Vitamin D-Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ursolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Physical activity,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,NANOG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breastfeeding performance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TRAN gene|TRA-TGC7-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Overweight,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Estrogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Depressive Symptoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,receptor for advanced glycation endproducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anorexia Nervosa,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,crocetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AKT1 gene|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,delphinidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Common wart,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,apolipoprotein D|APOD,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Inflammation,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LAPTM4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,COPS5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"Breast Feeding, Exclusive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,everolimus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Xenograft Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Radiation-Induced Change,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Stress,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Self-Examination,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast neoplasm screening,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 gene|BRCA1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,Multiple alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Deficient knowledge,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CLCN3 gene|CLCN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ethylmalonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,HTATIP gene|KAT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Taurine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genes,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Menopausal Status,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Angiotensin-Converting Enzyme Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Enzyme
PREDISPOSES,Benzodiazepines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Untranslated Regions,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LINC01585,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MGMT gene|MGMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Natural Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Physical activity,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Ibuprofen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Serine Protease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,Emergency contraception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carbon ion,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Prognostic Factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Chemical Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,vitamin supplement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,coenzyme Q10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,MicroRNAs,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Verbal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Genes,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,PGR gene|PGR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCDC6 gene|CCDC6,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Personal Satisfaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Oligonucleotide Arrays,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Hot water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Methotrexate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Consanguinity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Verbal,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Ions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,BLM gene|BLM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Tamoxifen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,DMBT1 gene|DMBT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Multiple Sclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Positron-Emission Tomography,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Noninfiltrating Intraductal Carcinoma,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Human Chorionic Gonadotropin|CGA|HTC2|CGB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Steroidal Aromatase Inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Steroid
PREDISPOSES,"Obesity, Morbid",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,perfluorooctanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,F2RL1|NR1I2|SLC52A1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Rheumatoid Arthritis,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,NFKB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,letrozole,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,GHRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MATP gene|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BRCA1 gene|BRCA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Animal fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Dietary Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,peroxiredoxin I|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GHSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NBS1 gene|NBN|NLRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrone sulfotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Recombinant Interferon-gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,[V]Follow-up examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breasts asymmetrical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Long chain fatty acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Interleukin-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HSD17B6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Positive Lymph Node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,XRCC5 gene|XRCC5,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Triglycerides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Membrane Glycoproteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Systemic Scleroderma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast composition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,LHX1 gene|LHX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Life Style,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PGRMC1 gene|PGRMC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PIWIL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ANLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ethnic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gynecomastia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NAT2 gene|NAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,WWC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adverse effects,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,pertuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Behcet Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Carrier of disorder,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Egg Food Product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Whole-Brain Radiotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Perceived comfort level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glutamate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anovulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,phenylpyruvate tautomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Ovarian Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,FANCM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Invasive Malignant Neoplasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obesity,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AUGMENTS,CCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Levonorgestrel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Free testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Mimicry,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,1-Phosphatidylinositol 3-Kinase|PI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sclerosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,flavan-3-ol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast cancer invasive NOS,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
CAUSES,MME gene|MME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Galectin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PARK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,alpha Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Excision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endocrine therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,Protein Overexpression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen receptor negative,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BRCA2 Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gall Bladder Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,STAT5A gene|STAT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Calcium Channel Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ionizing radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin-Like Growth Factor I|INS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Bleomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MSH6 gene|MSH6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Suspensions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Coronary Arteriosclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alcoholic Beverages,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Maternal Mortality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Reaction emotional,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Sulfonylurea Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Neoplasm,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,KDM4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cerebrovascular accident,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Undifferentiated carcinoma of ovary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,glutathione S-transferase M1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,brca gene,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MDM4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KPNA2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,cytotoxicity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Positive Finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MFG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,desires,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,bufadienolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tamoxifen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,PGK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carcinoembryonic Antigen|CEACAM5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
DISRUPTS,ZNHIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SEMA3C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Amino Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Little's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,ginsenoside Rk1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Physiological Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
DISRUPTS,Pimozide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ZNF423,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RNA Sequence,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Nucleotide Sequence
AFFECTS,Antidiabetics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HIF1alpha protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Adriamycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,caveolin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ZNHIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SNHG7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SOX8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MIRN106A gene|MIR106A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Myocardial Ischemia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,phthalates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Leucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDC2 gene|CDK1|POLD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Cancer-Predisposing Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,shikonin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,NFE2L3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,lysyllysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,G3BP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CBX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Interleukin-4,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,Monomeric GTP-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PPM1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mitomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Endocrine System Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,cell motility,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,ataxia telangiectasia mutated protein|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,glutathione S-transferase M1|GSTM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,9-deoxy-delta-9-prostaglandin D2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
AFFECTS,Liposomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,activated RNA polymerase II transcription cofactor 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HGS gene|HGS,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,Formaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,Natural Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Phenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,preference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PIK3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LINC00339,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,VIRMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,VIRMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Compete,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Platelet-Derived Growth Factor beta Receptor|PDGFRB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,"3,4-Methylenedioxyamphetamine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Single Nucleotide Polymorphism,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Bariatric Surgery,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Integrin alphaVbeta3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IDO1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,kaempferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nephroblastoma,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Diphenylamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Homologous Gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SERPINI2 gene|SERPINI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,centromere protein F,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Aging-Related Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,anillin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"PTTG1 protein, human|PTTG1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Poly(ADP-ribose) Polymerases|WDTC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FBXL19-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Treatment Protocols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Polychlorinated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TAGLN2 gene|TAGLN2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,gadoterate meglumine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PCB 138,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antipsychotic Agents,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,SLC4A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antioestrogen therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,UDP-Glucuronosyltransferase 1A1|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pigment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mitochondrial Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Formance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHD4 gene|CHD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gambogic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,RPS27 gene|RPS27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,hippo signaling,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,BARD1 gene|BARD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,food product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Functional RNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Albendazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Activator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Interleukin-17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hydrogel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Glioblastoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TTN-AS1 gene|TTN-AS1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"MMP14 protein, human|MMP14",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,small molecule,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Profilins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HAND2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Lipid Peroxides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Pre-op diagnosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SOX2 Transcription Factor|SOX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Letter:Finding:Point in time:{Setting}:Document:{Provider},Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP27A1 gene|CYP27A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ENO1 gene|ENO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BRCA2 Gene Mutation,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,rosemary extract,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Hormone use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,RESF1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Integrin alpha3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PPEF1 gene|PPEF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HDAC5 gene|HDAC5,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Colorectal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CYP7B1 gene|CYP7B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAK2 gene|PAK2|PKN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,socioeconomic differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,epigallocatechin gallate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,FTSJ3 gene|FTSJ3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SFRP1 protein, human|SFRP1",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Alternative Splicing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"CD69 protein, human|CD69",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GACAT3 gene|GACAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Adriamycin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SPRY4-IT1 gene|SPRY4-IT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KLK12 gene|KLK12,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"GOLPH3 protein, human|GOLPH3",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Underlying,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Microsatellite Instability,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,USP43 gene|USP43,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"CEACAM5 protein, human|CEACAM5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TRIP6 gene|TRIP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,mica,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Detection,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ERR1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Immune response,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Immunologic Factor
DISRUPTS,FOXN4 gene|FOXN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Soluble fiber (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,High expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"CD69 protein, human|CD69",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MYCN gene|MYCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transforming Growth Factor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,"Chemotherapy, Adjuvant",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Genome,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATM,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,glypican 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTTG1 gene|PTTG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Adipokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CTCb regimen,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,lumican,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SOAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tissue-factor-pathway inhibitor 2|TFPI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Marital Status,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AUGMENTS,MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gestational Diabetes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CERNA2 gene|CERNA2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,"TP53BP1 protein, human|TP53BP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,interleukin-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ALKBH5 gene|ALKBH5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BET Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Receptor alpha,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Diagnostic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Integrin alpha5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ECE1 gene|ECE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,lovastatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Invasive Carcinoma,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
CAUSES,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenic Process,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Phenomenon or Process
DISRUPTS,GKLF protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PRR14 gene|PRR14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GKLF protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,hexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RNA-Binding Protein Musashi Homolog 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Account number:Identifier:Point in time:^Patient:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,KIF15 gene|KIF15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,D Vitamin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Food
PREDISPOSES,FZR1 wt Allele|CDH1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
PREDISPOSES,LINC00707 gene|LINC00707,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FGFR1 wt Allele|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Abnormal metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,aquaporin 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,COTL1 gene|COTL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GPX3 gene|GPX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Herbicides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,caspase-3|CASP3,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,"SLC16A3 protein, human|SLC16A3",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Pivot,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NME1 gene|NME1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,erastin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Metastatic malignant neoplasm to brain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Anti-Inflammatory Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Tumor Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,TNIP2 gene|TNIP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,acetylglucosamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alternative Splicing,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,purpurin 18,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,hesperetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Geldanamycin Analogue,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,XIST gene|XIST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Flavonols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ado-trastuzumab emtansine|DMPK|IGHD1-7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Dysbiosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Therapeutic Effect,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
PREDISPOSES,Matrix Metalloproteinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Mucin-1 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,OIP5-AS1 gene|OIP5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hyperlipidemia,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Lipid
AFFECTS,Sexual function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnostic radiologic examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CERNA2 gene|CERNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Diphosphonates,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
CAUSES,Viral Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Disease Progression,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CMTM5 gene|CMTM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIR22 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Serum Proteins,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,arbutin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diet high in saturated fats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MSH2 gene|MSH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCNAP1 gene|PCNAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FOSL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LINC00346 gene|LINC00346,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Signaling Protein,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ANGPTL4 gene|ANGPTL4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Negative Regulation of Apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CD8A wt Allele|CD8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,sunitinib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,brazilin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,cyclooxygenase 2|PTGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RAD21 gene|RAD21,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,DYRK2 gene|DYRK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,leptin,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,TT genotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Water consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Vitronectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Product containing glucagon-like peptide 1 receptor agonist (product),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CYP27B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR100HG gene|MIR100HG,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sphingomyelins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Infiltration,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Thyroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Acetylserotonin N-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
CAUSES,Sleeve,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Rheumatoid Arthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MicroRNA 205-5p,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Cyclin-Dependent Kinase Inhibitor p16|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,periodate-oxidized adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Acidosis,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical
AFFECTS,Intercellular adhesion molecule 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KIF15 gene|KIF15,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Erythropoietin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,K-ras Oncogene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast Imaging Reporting and Data System,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diagnosis,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AFFECTS,Circulating Tumor DNA,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,ciclesonide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NRG1 gene|NRG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ryanodine Receptor 3|RYR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PPP2R2B gene|PPP2R2B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FN1 gene|FN1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,patient characteristics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Weight decreased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,amygdalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GPM6B gene|GPM6B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,HHEX gene|HHEX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Copy Number Polymorphism,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
DISRUPTS,SOY ISOFLAVONES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,verteporfin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,High expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Apoptosis Inducing Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BTF3 gene|BTF3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Metastatic malignant neoplasm to brain,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,butein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ST8SIA6-AS1 gene|ST8SIA6-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,si-wu-tang,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,A2M-AS1 gene|A2M-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR22HG gene|MIR22HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Bilateral mastectomy,Unilateral Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,27-hydroxycholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,paclitaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Detection,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,DSCAM-AS1 gene|DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PGK1 gene|PGK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Neuropeptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor size,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
DISRUPTS,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Diphosphonates,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,interleukin-10,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,"WFDC2 protein, human|WFDC2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Proliferation (morphologic abnormality),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,SMAD2 gene|SMAD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IL6ST gene|IL6ST,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,COVID-19,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,TRIM6 gene|TRIM6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"UBASH3A protein, human|UBASH3A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PALB2 gene|PALB2,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,YY1 gene|YY1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LAGE3 gene|LAGE3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00885 gene|LINC00885,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutation,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ZNF385B gene|ZNF385B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pain relief,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Connexin 43|GJA1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,CHFR gene|CHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,pristane,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,ruthenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,tripterine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Trans Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,IL20RA gene|IL20RA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Health behavior,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
PREDISPOSES,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Functional Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Phosphatidylinositide 3-Kinase Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,AQP5 gene|AQP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00511 gene|LINC00511,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
CAUSES,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,OLFML2A gene|OLFML2A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Basis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gene Mutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High Level,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Volatile Organic Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,USP6NL gene|USP6NL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Transcription, Genetic",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HOXB5 gene|HOXB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gamma-glutamyl transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hormone Therapy,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
DISRUPTS,MTUS1 gene|MTUS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SF3B3 gene|SF3B3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"LCN2 protein, human|LCN2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ATP5F1B gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Cancer Prognostic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Discoidin Domain Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Photochemotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoantigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Diuretics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Transcript,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Matrix Metalloproteinases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Pills,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Autoimmune Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,paracrine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Radiation,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ferroptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Candidate Disease Gene,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
AFFECTS,Central Serous Chorioretinopathy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAD51 gene|RAD51,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"HIF1A protein, human|HIF1A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,high density lipoprotein binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,HOXB7 gene|HOXB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathologic Complete Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,paclitaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Tobacco smoking behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Infiltration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PIR gene|PIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDC25C gene|CDC25C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,CLEC2D gene|CLEC2D,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,sirolimus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"MEN1 protein, human|MEN1",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Brominated Diphenyl Ethers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ACSL4 gene|ACSL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Flap Endonuclease-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,IDO1 gene|IDO1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Immune response,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
PREDISPOSES,>40 years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cyclin-Dependent Kinases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,DPP3 gene|DPP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,niclosamide,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,PQBP1 gene|PQBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antihypertensive Agents,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Responsive Disease,Locally advanced breast cancer,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,CEP295 gene|CEP295,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,tissue polypeptide specific antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,PBXIP1 gene|PBXIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pyroptosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Duration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Axillary node METASTASIS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIR655 gene|MIR655,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LOC105371267,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ITGA2B wt Allele|ITGA2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Pathogenic Variant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AUGMENTS,"E2F1 protein, human|E2F1|UBE2L3",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,phthalates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasm,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CATHEPSIN D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Possible,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,IL27 gene|MYDGF|IL27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,AZD4547,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Gene Mutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GANT 61,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MARCHF5 gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,GLI1 gene|GLI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LGALS8-AS1 gene|LGALS8-AS1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Body mass index procedure,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Liposomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Drug resistance,Carcinoma breast stage IV,0.0,Female Breast Cancer,Pharmacologic Substance
CAUSES,HOXD9 gene|HOXD9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Immunologic Adjuvants,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Genome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,POTEH-AS1 gene|POTEH-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAT3 gene|STAT3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,FAM111B gene|FAM111B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Growth Differentiation Factor 15|PAEP,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Decreased translucency,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Performance,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,TSPAN1 gene|TSPAN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,astaxanthin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,Hypoxia-Inducible Factor 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Elevated Expression,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KLF5 gene|KLF5,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,SETDB1 gene|SETDB1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Circular",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"TNFSF10 protein, human|TNFSF10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"WNK1 protein, human|WNK1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ENPP1 gene|ENPP1,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
AFFECTS,METTL14 gene|METTL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NDUFV1 gene|NDUFV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NOLC1 gene|NOLC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Resistance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AMACR wt Allele,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
DISRUPTS,ADRB2 gene|ADRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SEP15 protein, human|SELENOF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HOXC-AS3 gene|HOXC-AS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mutant Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,AA genotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Architectural Distortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,EPB41L4A-AS1 gene|EPB41L4A-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Genomic Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Consideration,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Circulating Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Elevated Expression,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,KCNQ1OT1 gene|KCNQ1OT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,endosulfine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Hormone Receptor,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Hormone
PREDISPOSES,fusion transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Protein Subunits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,COVID-19,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
PREDISPOSES,PPP1R14C gene|PPP1R14C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Ovarian hyperstimulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,brazilian,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast Cancer Therapeutic Procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Healthy Lifestyle,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NFIB gene|NFIB,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Pathogenic Variant,"Breast Cancer, Familial",0.0,Female Breast Cancer,Virus
AUGMENTS,fluvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RAC2 gene|RAC2,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,interleukin-6,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,GSDMB gene|GSDMB,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Immune,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypercholesterolemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,LINC00092 gene|LINC00092,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Sleep Apnea, Obstructive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HMMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Agent,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Organic solvent product,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Chemical
AFFECTS,DDX5 gene|DDX5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmacologic Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,1 time,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,secretory protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol consumption,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"IL17A protein, human|IL17A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LINC00472 gene|LINC00472,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Diffusion Kurtosis Imaging,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCNB2 gene|CCNB2,Stage 0 Breast Cancer AJCC v6 and v7,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Adenocarcinoma in Situ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"Carcinoma, Lobular","Breast Cancer, Familial",0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"CD69 protein, human|CD69","Breast Cancer, Familial",0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,RBMS1 gene|RBMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tea without milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,genetic risk factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Infantile Neuroaxonal Dystrophy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,doxorubicin liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,sigma-2 receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SNHG3 gene|SNHG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HMGB1 gene|HMGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Processes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Phenomenon or Process
AFFECTS,Gene Silencing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,False Positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Multifactorial,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MEDAG gene|MEDAG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Post-mastectomy radiotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,PIK3CA gene|PIK3CA,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,"Antibodies, Bispecific",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,FBXW7 gene|FBXW7,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AUGMENTS,CCL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mitochondrial mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Basis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,MIR191 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GLI4 gene|GLI4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Convenience food intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Cancer Therapeutic Procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PEDS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Monoclonal Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,fluoxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,canagliflozin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,PAFAH1B1 gene|PAFAH1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proto-Oncogene Protein c-kit,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCDC102B gene|CCDC102B,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,RACK1 gene|RACK1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Imbrication (procedure),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,catalpol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"RNA, Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Score,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Transsexual (finding),Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Responsive Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"IL17A protein, human|IL17A",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ZNF276 gene|ZNF276,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anabolism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,TIMM8A gene|TIMM8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Estrus,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FER1L4 gene|FER1L4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Vitamin D Deficiency,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Food
AUGMENTS,UBE2C gene|UBE2C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,diltiazem,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,resveratrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FRG1 gene|FRG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NF2 gene|NF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Observation parameter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Emodin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Clinical Significance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"PIK3CB protein, human|PIK3CB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,METTL14 gene|METTL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,N-acetyltransferase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Selective Estrogen Receptor Down Regulator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,water channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diffusion weighted imaging,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ARL11 gene|ARL11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,MIR217 gene|MIR217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERBB2 Overexpression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FOXN3 gene|FOXN3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ellagic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,"Retinol-Binding Proteins, Cellular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cancer-Related Death,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cell-Free DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Duration,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Risk Scores,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Present,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,1-Phosphatidylinositol 3-Kinase,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,"neoisoliquiritin, (E)-isomer",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Phosphotransferases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Matrix Metalloproteinase 9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,HDAC7 gene|HDAC7,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IGF2BP2 gene|IGF2BP2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,BCL2A1 gene|BCL2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Arrest,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GNAS gene|GNAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,arginylproline|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,hexanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Tripe,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RMI2 gene|RMI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Candidiasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SCAMP3 gene|SCAMP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPC25 gene|SPC25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,KDM4A gene|KDM4A,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Treatment Protocols,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Neuregulin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmaceutical Preparations,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,LBH589,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CBX7 gene|CBX7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PRAF2 gene|PRAF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Histone H3 Lysine 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Low Level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,paclitaxel,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Malignant neoplasm of breast,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Genetic Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ANTXR1 wt Allele|ATR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Genes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,FKBP12-rapamycin associated protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ROS1 wt Allele|ROS1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Mitophagy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,"FABP1 protein, human|FABP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,gamma-aminobutyric acid,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Chemical
CAUSES,Mouse mammary tumor virus infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,chaperone-mediated autophagy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dairy Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen receptor positive,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoadjuvant Therapy,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,KAT7 gene|KAT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Anxiety,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,stanniocalcin 2|STC2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,RNF43 gene|RNF43,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Secondary Neoplasm,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,F-Actin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,CPVL gene|CPVL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vegetarian diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TMEM105 gene|TMEM105,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SIRT7 gene|SIRT7,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RHD gene|RHD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,STAT1 gene|STAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Axillary node METASTASIS,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,HHEX gene|HHEX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Kanglaite Injection,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SIRT7 gene|SIRT7,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,SDC1 gene|SDC1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Long Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Marital Status,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,CARD.RISK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Agent,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,human papillomavirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
PREDISPOSES,kaempferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,dydrogesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Ribonucleoprotein, U1 Small Nuclear",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,USP29 gene|USP29,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Galanin peptides, human (123 aa, ~13 kDa)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NDC80 gene|NDC80,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammatory Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLF2 gene|KLF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Luteolin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"PDCD1 protein, human|PDCD1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Magnetic Resonance Imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,copper,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,VEGFA gene|VEGFA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Negative Surgical Margin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Agonist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NUCB2 gene|NUCB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Mouse mammary tumor virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Oligonucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Betaretrovirus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
AFFECTS,stanniocalcin 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Methylnitrosourea,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,epithelial to mesenchymal transition,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDH12 gene|CDH12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacotherapy,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
CAUSES,Invasive Ductal Breast Carcinoma,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,RNA-Binding Protein Musashi Homolog 2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,16 alpha-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,hydrocortisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ectonucleotide pyrophosphatase phosphodiesterase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,oxybenzone,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Menstrual period late,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pediatric Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,lysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NR2F1-AS1 gene|NR2F1-AS1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,MCM6 gene|MCM6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Psoriasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MAP7D3 gene|MAP7D3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,DEGS1 wt Allele|DEGS1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AFFECTS,polyphyllin D,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SPDEF gene|SPDEF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FAM171A1 gene|FAM171A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,olive oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Poly(ADP-ribose) Polymerase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HNRNPA2B1 gene|HNRNPA2B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EYA4 gene|EYA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Parafibromin|CDC73,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RHOV gene|RHOV,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,LINC01140 gene|LINC01140,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Progression,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,"TNFSF10 protein, human|TNFSF10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoadjuvant Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,TYMSOS gene|TYMSOS,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ligands,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,CD69,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Life Expectancy Less than Five Years,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Decreased Expression,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Phenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,medroxyprogesterone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,SEMA3B-AS1 gene|SEMA3B-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Anti-HER2 Monoclonal Antibody|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,C-reactive protein,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR122 gene|MIR122,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAF1 gene|MAF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Toll-Like Receptor 1, human|TLR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,perfluorooctanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Oncogenes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,CD82 gene|CD82,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,Stage 0 Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Matrix Metalloproteinases,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Ketogenic Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MicroRNA Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PSMD14 gene|PSMD14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00702 gene|LINC00702,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Phytochemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,DNPH1 gene|DNPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IMPA2 gene|IMPA2,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXO3 gene|FBXO3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Survival,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,OLT1177,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Neuroleptic Malignant Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Crohn Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,HMGB3 gene|HMGB3,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Markers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"COPEB protein, human|KLF6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secondary Neoplasm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Cardiorespiratory Fitness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"PIK3CB protein, human|PIK3CB",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Radiation-Sensitizing Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,STMN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Waist Circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,olaparib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Mammographic Breast Density,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,PALMD gene|PALMD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,1+,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NOTCH3 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ferroptosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,CELSR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,WASF3 gene|WASF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Rhythm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thrombospondin 1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Dormancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR203A gene|MIR203A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,lutein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of liver,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Macrophage Activation Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnosis,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Mouse Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,post surgery radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Pathogenic Variant,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Virus
AFFECTS,Cell Death,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Plasma Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ARHGAP6 gene|ARHGAP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ELAVL1 gene|ELAVL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FRY gene|FRY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IDO1 gene|IDO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CLEC11A protein, human|CLEC11A",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Polynucleotide Adenylyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,idebenone,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,"Tenascin, human|TNC|TNNC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Fibrocystic Disease,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,OGG1 gene|OGG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PDZK1 gene|PDZK1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,MTCH2 gene|MTCH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Infiltration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,KLRK1 gene|KLRK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01572 gene|LINC01572,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Dickkopf-Related Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,RAMP2-AS1 gene|RAMP2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TLR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA1 gene|BRCA1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLCO1B1 gene|SLCO1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ezetimibe,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,NR2F2 gene|NR2F2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Nanotubes, Carbon",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Follistatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,AGRN gene|AGRN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NKAIN1 gene|NKAIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,mitochondrial calcium uniporter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ononin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,tanshinone II A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,S14 gene|PSMD8|RPS14|THRSP|LOC107228383,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TCF7L2 gene|TCF7L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,oncostatin M receptor|OSMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anthocyanins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prostaglandins,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Eicosanoid
DISRUPTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Insulin used,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TAL1 gene|TAL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Tumor Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DNMT3B gene|DNMT3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,resveratrol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,RHOC gene|RHOC,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Human plasma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
AFFECTS,glycosylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Estrogen Antagonists,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,CA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Steroid 17-alpha-monooxygenase|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cardiovascular morbidity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IKZF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Interleukin-24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tumor Necrosis Factor Ligand Superfamily Member 6|FASLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Benzoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Estrogen Receptor alpha,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,SMARCA4 gene|SMARCA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Radioisotope scan of lymphatic system,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,RHOA gene|RHOA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Folic acid supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Acrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ESTROGEN USE,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AFFECTS,recombinational repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,KDM5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Menopause, Premature",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,APC2 gene|APC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CETN1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Aging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Metaplastic carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Suicide Gene Therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Combined Modality Therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDX2 gene|CDX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DUSP4 gene|DUSP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FLT1 gene|FLT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Menstrual migraine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Eclampsia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nucleic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,APOBEC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Immunologic Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Whole Cell Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,XBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cancer Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Calcium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cytochrome P-450 CYP1A1|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,High fiber food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Malignant neoplasm of breast,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,MAP3K3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,UDP-Glucuronosyltransferase 1A1|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NANOG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CADMIUM EXPOSURE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,TISSUE TRANSGLUTAMINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TLR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Quinones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Progestins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,VEGF gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,[D]Nausea and vomiting NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,JAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Fatty Acids, Saturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,8q22,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,transcription factor PEA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,TLR4 gene|TLR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Genes, Homeobox",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Deferoxamine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
PREDISPOSES,PCAF gene|KAT2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Specimen from breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIR27B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BIRC5 gene|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,RUNX1|MECOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ANKRD12|ANKRD11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Interleukin-8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RNASE3L gene|DROSHA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,RHOBTB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen excess,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
DISRUPTS,ID1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,cyclooxygenase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Leptin|LEP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MULTISECTION:FINDING:POINT IN TIME:BREAST:NARRATIVE:MRI,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Quantitative Trait Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MRPS30,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Genes, Homeobox",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,BIRC7 gene|BIRC7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Annexin A2|ANXA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ATR gene|ATR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,TSLP gene|TSLP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Endostatins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SH3KBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,S100A9 gene|S100A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nitrite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast Cancer Treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ARF6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Extracellular Signal Regulated Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunoglobulin G,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,TG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CTNNB1 gene|CTNNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antiperspirants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,asparaginylendopeptidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Soy Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,20q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCR3 gene|CXCR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PTPN11 gene|PTPN11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant neoplasm of endometrium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Interleukin 7 Receptor|IL7R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Livebirth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease Outcome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,BMPR1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sulfuric Acid Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,BMPR2 gene|BMPR2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Laminin Receptor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Protein-Serine-Threonine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Environmental Effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Environmental Effect of Humans
PREDISPOSES,ACR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metabolic Rates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CATHEPSIN D|CTSD,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Antibodies, Anti-Idiotypic",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Carotenoids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Fibroadenoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Insulin-Like Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,cDNA Library,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Estrous Cycle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Toxic effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Irregular menstrual cycle NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Pregnancy, Multiple",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TACSTD2 gene|TACSTD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cystic Breast Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,BRCA1 gene|BRCA1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,LAMR1 gene|RPSA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,fulvestrant,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,BCAS1 gene|BCAS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSD17B4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nifedipine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mechanics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Body mass index,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,LRRC32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cysteine Proteinase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Signal Pathways,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,salinomycin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,mutant gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Reconstructive Surgical Procedures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Prostaglandin-Endoperoxide Synthase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Eicosanoid
PREDISPOSES,GALNT14,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,mammary tumor virus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Cadherins,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
CAUSES,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Manganese Superoxide Dismutase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
DISRUPTS,Tretinoin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Medroxyprogesterone,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Hormone
PREDISPOSES,Para 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dessert,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Trihalomethanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ZNF121,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Paraffin,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,Retroviridae,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Cytologic finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GATA3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,hybrid gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCND1 gene|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Etoposide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Collagen,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,activity level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Biological Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Trans-Activators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SHBG gene|SHBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Athletic Training,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Aromatic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Anovulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,alpha-Lactalbumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,FGF3 gene|FGF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Prolactin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Serum Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Photosensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
CAUSES,Female Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Electromagnetic Fields,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Phosphotransferases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,DNA biosynthesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,"TFF1 protein, human|TFF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Hypercalcemia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"serine repeat antigen, Plasmodium",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AUGMENTS,Estrogenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Pharmaceutical Preparations,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Pharmacologic Substance
PREDISPOSES,Animal protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Proto-Oncogene Proteins p21(ras)|HRAS,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogen Antagonists,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,FGF3 gene|FGF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,international differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"Genes, Suppressor",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Hydrocarbons, Aromatic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,onapristone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Paraffin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Monoclonal Antibodies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Debrisoquin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gonadorelin|GNRH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Urea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor Burden,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Dimethyl Sulfoxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BCL-2 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,beta-hexachlorocyclohexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gamma-glutamyl transferase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Interferons,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Bromocriptine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,IGF2 gene|IGF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,methylurea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of bone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Pathogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prognostic Factor,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Advanced cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ascorbic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,"Antigens, Viral",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
DISRUPTS,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
DISRUPTS,AFP gene|AFP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,HRAS gene|HRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Breast cancer invasive NOS,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PIP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Wound Healing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lymph node excision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Genes, Regulator",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High income,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lutein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radionuclide Imaging,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,X-Pro dipeptidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,New finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
PREDISPOSES,Obesity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CATHEPSIN D|CTSD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,tissue-factor-pathway inhibitor 2|PPP5C|TFPI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fever,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,alpha-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,MLH1 gene|MLH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,regular physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transfection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,NBEAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Linoleic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Carcinoma in Situ,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,C2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BUB1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Glucagon|GCG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Fatty Acids, Unsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,MFT 279,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,GATA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ETS Variant Gene 6 Protein|ETV6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,folligen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Genes, Regulator",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,sodium-iodide symporter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Indomethacin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Increased body mass index,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Integrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Insulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Decapeptyl,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Radium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interstitial Collagenase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HIV Infections,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Allelic Imbalance,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,response to hormone stimulus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,glycosylation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Polyamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell Communication,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Electromagnetic Energy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Chronic Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Protein Overexpression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CDC25A gene|CDC25A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,checkpoint kinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Passive smoker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypokinesia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Isotopes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Sterol Regulatory Element Binding Protein 1c,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Psychometrics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,I Kappa B-Alpha,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Triethylenemelamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,fluorodeoxyglucose positron emission tomography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lymphoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NFKBIA gene|NFKBIA,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fibroblast Growth Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Chromosome abnormality,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Kininogenase|KLK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CLARITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ral Guanine Nucleotide Exchange Factor|RALGDS,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Transcription Coactivator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Retroviral Vector,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Serine Protease,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Enzyme
PREDISPOSES,Saturated fat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"N,N-dimethyl-4-anisidine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA1 gene|BRCA1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,skills,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EMSY,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Family history of breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Amino Acid Substitution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Reproductive Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ERCC4 gene|ERCC4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Venous Thrombosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,VEGF gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Quantitative Trait Loci,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Prempro,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PGR gene|PGR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,maspin|SERPINB5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Dehydroepiandrosterone Sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Micronutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ID-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Polypeptides,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Soy bean product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cancer-Predisposing Gene,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,Angiogenic Switch,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ID1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cryptococcus,Cancer en cuirasse,0.0,Female Breast Cancer,Other
AFFECTS,Infertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,EEF1B2P2|BHLHE22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Decreased density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CD82 gene|CD82,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Kinase C Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,NQO1 gene|NQO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,apomucin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NELFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Neoplasm Metastasis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
CAUSES,repair enzyme,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Enzyme
AFFECTS,Orthologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CASP1 gene|CASP1,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,TNFRSF1B gene|TNFRSF1B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Granulocyte Colony-Stimulating Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tamoxifen,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,cyclooxygenase 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL8 gene|CXCL8,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Steroidal Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Fibroblast Growth Factor 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,MFG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Catechol O-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hyperprolactinemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aromatase Inhibitors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
CAUSES,CAV1 gene|CAV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Tamoxifen,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Estradiol,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
CAUSES,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,lariciresinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Single Nucleotide Polymorphism,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Raloxifene,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,Anovulatory,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sore to touch,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gegenhalten,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CLCA2 gene|CLCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Xanthine Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,pleiotrophin|PTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,epigallocatechin gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,beta catenin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,WISP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Glutathione S-Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Endopeptidases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,anti-apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Environmental stimuli,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Asparagine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HPSE gene|HPSE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cytochrome P450 3A4|CYP3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,polyphenols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Breast Cyst,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Retinoblastoma Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Mannose Binding Lectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Stanolone,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ghrelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Ovarian Cysts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adaptor Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen Receptor alpha|EREG|ESR1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fertility Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Thrombospondins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Catecholamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Oxytocinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Apolipoprotein E|APOE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Isoflavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Encounter due to puberty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CXCL12 gene|CXCL12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PLAT gene|PLAT,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TSPYL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SIPA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PPAR gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Vitamin E,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,Walking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABCC11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CXCL12 gene|CXCL12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Primary Prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SHFM1 gene|SEM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Thrombolytic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,14q24.1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MTNR1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"PSMD10 protein, human|PSMD10",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MTNR1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Receptors, Progesterone|PGR",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,Titanium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gastric Adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,mTOR Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Clonal Expansion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Acetyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADH1B gene|ADH1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SULT1A1|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Potato,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast tenderness,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,TNFSF11 gene|TNFSF11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Transfection,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Autoimmune thyroiditis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,OPN1LW|CRCP|RAB11FIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,K-ras Oncogene|KRAS,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Carcinogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,gene polymorphism,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,PREDICTED,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Interleukin-15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NEK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cigarette smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Sulfatases|ARSH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,estrogen receptor gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Single Nucleotide Polymorphism,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,TRANCE protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,KL gene|KL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCDC88A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogen Receptors|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Agent,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,"Fatty Acids, Omega-6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,SP1 gene|SP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,G-Protein-Coupled Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Diabetes Mellitus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Somatomedins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Hypermethylation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phototherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Granulocyte Colony-Stimulating Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,IL8 gene|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,UTS2R|SLC14A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ANP32B gene|ANP32B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Compete,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Magnesium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Calgranulin A|S100A8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cytochrome P450,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ERR1 protein|ESRRA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ETV4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Bone Morphogenetic Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PTH protein, human|PTH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Minisatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Anabolic steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,PPAR gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NOTCH4 gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,S100A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Growth retardation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Niacin intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SIX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Arrestins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BACH1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,chromosome decondensation factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,PHB2|SIL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Advance,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MAPK14 gene|MAPK14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Protein Isoforms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,SLX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Tetradecanoylphorbol Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,amsonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Alcoholic Liver Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,AKT1 gene|AKT1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Catechol O-Methyltransferase|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MRE11,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AUGMENTS,protein-tyrosine kinase c-src|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,vasodilator-stimulated phosphoprotein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,hesperetin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,BRIP1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AUGMENTS,ING5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Angioendotheliomatosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Phosphatidylethanolamine Binding Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Aromatase Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
PREDISPOSES,Pharmaceutical Preparations,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AFFECTS,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BCL6 gene|BCL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Paclitaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,RPRD1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,XPO5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Therapeutic procedure,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Natural menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MYC gene|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,sphingosine kinase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,KLF9 gene|KLF9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,NKD1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Hyperbaric Oxygenation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,USP21 gene|USP21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hexachlorobenzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,CRHBP gene|CRHBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Myeloid Leukemia, Chronic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,benzyl isothiocyanate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oxides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ABCB10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SMAD3 gene|SMAD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"20-hydroxy-5,8,11,14-eicosatetraenoic acid",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,shikonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KLF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,fucoidan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PROTEIN KINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,letrozole,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Cyclin E,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,"Lupus Erythematosus, Systemic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Steroids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,BRCA1 gene|BRCA1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Lipogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant meningitis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,NBAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Promoter Regions (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SULF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,arctigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,xanthohumol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Interstitial Collagenase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,BVES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,POU5F1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MSI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ANXA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,curcumol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,iron ion homeostasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Oxygen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Transferrin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Phosphotransferases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,pomegranate juice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LRRC3B gene|LRRC3B,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,MET gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,YAP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ITGB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,discoidin domain receptor 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,protein tyrosine phosphatase 1B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Heat Shock Protein 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Complement 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,HVCN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IGKV6D-21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cell invasion,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tenascin|TNC,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Heightened perception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,C1GALT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Bone remodeling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,caveolin 1|CA5A|CAV2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Functional RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Malignant tumor of colon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PGR gene|PGR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Serotonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,ANG gene|ANG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CALCA gene|CALCA,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lactate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Agent,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Diabetes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
DISRUPTS,bakuchiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Dyslipidemias,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,TFF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,pregnane X receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasm Metastasis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,OGG1 gene|OGG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MT2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Endocrine therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,isoalantolactone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LEF1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HIST2H2AC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epithelial antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AUGMENTS,"BCAR1 protein, human|BCAR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fluoxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,sinomenine hydrochloride,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Interleukin-17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TARDBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin B6 intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,Fibroblast Growth Factor Receptors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AUGMENTS,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,exemestane,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Adenocarcinoma of esophagus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ADAM33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Homologous Recombination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,RNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,hepatocellular carcinoma protein 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,VTCN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RELN gene|RELN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Urine protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FCRL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Interleukin-1 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Antibodies, Anti-Idiotypic",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,intervention program,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PTEN gene|PTEN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SHARPIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,methyl 4-azidophenylacetimidate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Total estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,PGR gene|PGR,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Polycomb,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,S1PR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SP7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCL20 gene|CCL20,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ITK gene|ITK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNU4-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,meleagrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Brown rice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CD29 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Forkhead Transcription Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Transcriptase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Receptors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,salinomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ANKLE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,skills,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AUGMENTS,sigma-1 receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MAPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Orthologous Gene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
CAUSES,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TGFBR1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,NBS1 gene|NBN|NLRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Apoptosis Inhibiting Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,sphingosine kinase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ischemia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,S100A4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Cervix carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Stem cell transplant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,progesterone receptor negative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,Soybean preparation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
DISRUPTS,CDC42 gene|CDC42,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Multiple malignancy,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,SENP2 gene|SENP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SUCLA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Neoplasm,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,CDCA7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,diallyl disulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Relaxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GEN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,4-chlorophenyl methyl sulfide,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
CAUSES,H2AFX gene|H2AFX,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,CDH1 gene|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Difficulty sleeping,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PRI-2191,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Collagen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,CXCR4 gene|CXCR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Toremifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MSH6 gene|MSH6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCND2 gene|CCND2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GLS gene|GLS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Dietary Component,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin-1 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Isoprostanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TXNIP gene|TXNIP,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
DISRUPTS,WWC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,phenidone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,MALAT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,fibulin-3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Chitosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MAPK8 gene|MAPK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"PER2 protein, mammalian",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,"RNA, Satellite",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,LGALSL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,aloperine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CD80 gene|CD80,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Protein Precursors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hydrogels,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Adverse effects,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Test Result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cancer cachexia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Fibrosis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Membrane receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Glycine Hydroxymethyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Luteolin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,TLN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,erbB-2 Receptor|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Gelatinase B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,disease stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,midkine|MDK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,pregnane X receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cigarette Smoking,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,BITTER MELON,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BCAR3 gene|BCAR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,crystalloid,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,genetic locus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHI3L2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,3MC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AR gene|AR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,FGFR2 gene|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TMEM25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLK10 gene|KLK10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CD247,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Oncogene Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MLL gene|KMT2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDH1 gene|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Antineoplastic Agents,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,TP53 gene|TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclin D1|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Axillary Lymph Node Involvement,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,"TNF protein, human|TNF",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Mutation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CATHEPSIN D|CTSD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Skim milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,Epidermal Growth Factor Receptor|EGFR,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biologically Active Substance
AFFECTS,Dissection,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Symptoms,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Atypical lobular hyperplasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Hexachlorobenzene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,personal responsibility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,beta-hexachlorocyclohexane,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Growth,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,receptor expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Generalized obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RHCE|FIP1L1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Ischemic stroke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Malignant disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,Tamoxifen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,CD27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SALL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,cathepsin K|CTSK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,paxillin|PXN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Metformin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CTHRC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CTHRC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Hydroxyl Radical,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,DDT (Insecticide),Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Invertebrate
PREDISPOSES,Medication use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Depo-Provera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Composition,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Ductal Breast Hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,prednisolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,5-hydroxymethyl-2'-deoxyuridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diabetic Retinopathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Depressive disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,SYK gene|SYK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,DHFR gene|DHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2|NEU1|NEURL1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,IGF1 gene|IGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Aspirin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Dairy Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Maternal status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PAX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vascular Endothelial Growth Factor Receptor-1|FLT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Paclitaxel,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,OR10J3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IRS2 gene|IRS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fine needle aspiration biopsy,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ERBB2 gene|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic regimen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Allelic Imbalance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Soy Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,2-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Early Diagnosis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Lobular Neoplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ultrasonography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,small molecule,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Noscapine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,S100A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,response,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,SLCO1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD40 gene|CD40,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Acquired Immunodeficiency Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Systemic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KISS1 gene|KISS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,osteopontin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Zeranol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ZNF365,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Leg length,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Worried,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Calgranulin B|S100A9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,CCNE1 gene|CCNE1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,Progesterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,MIRN27A gene|MIR27A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,B3GNT2|B3GNTL1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,coping resources,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DDX5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aberrant DNA Methylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,aldehyde dehydrogenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"ribosomal protein S6 kinase, 70kD, polypeptide 2|RPS6KB2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,S100A9 gene|S100A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ORAI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Creatinine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Speech reception threshold,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Interleukin-17,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,osteopontin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,SOD2 gene|SOD2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,Metaplastic Breast Carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Testosterone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AUGMENTS,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Berberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Squamous cell carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,AG 14361,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Functional disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Amenorrhea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Biological function, NOS",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Fluoxetine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SMARCE1 gene|SMARCE1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PTEN gene|PTEN,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTT1 protein|SLC25A4|CD5|IL1RL1|TRAPPC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GSTT1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Oral form estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Microinvasive carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,beta Sitosterol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Pharmaceutical Preparations,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,Estradiol acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell fusion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KDM3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,May-Hegglin anomaly,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Invasive Malignant Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MMP9 gene|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,trastuzumab,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Pharmacologic Substance
CAUSES,crocin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PGR gene|PGR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Rare Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,PGRMC1 gene|PGRMC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,meningioma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Deferoxamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Rifabutin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Diabetes Mellitus, Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,XIST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glucocorticoids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,RNASEL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,oncostatin M|OSM,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Not significant,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carcinogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,MIRN223 gene|MIR223,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TERT gene|TERT,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prophylactic immunotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,TP53 gene|TP53,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,RNA I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Fertility problem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HTATIP2 gene|HTATIP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL10 gene|IL10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cyclooxygenase 2|XK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,S-Adenosylmethionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hyperparathyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,household cleaner,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Behavior,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,LUM gene|LUM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Extravasation of lymph,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CAV1 gene|CAV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PRKDC gene|PRKDC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ethanol Metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABCB1 gene|ABCB1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,BAX gene|BAX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,acadesine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIRN21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclooxygenase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NR4A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alcohol interaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Insulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Angiography, Digital Subtraction",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Malaise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDK2AP1 gene|CDK2AP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD28 gene|CD28,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease Outcome,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Primary tumor size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Genes,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,S100A9 gene|S100A9,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,breast cancer prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,SPSB1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,TNFRSF1B gene|TNFRSF1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Inflammatory Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aromatase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Cytochrome P450,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fertilization in Vitro,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ligands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cookie and/or cracker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Heregulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Kininogenase|KLK4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"TERT protein, human|TERT",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Conjugated Equine Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Uterine hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,steroid sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
AFFECTS,Clinical Protocols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Beef,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RNA Interference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Saponins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,glutathione S-transferase M1|CHRM1|MRLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Plasminogen Activator Inhibitor 1|SERPINE1|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Saponins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Maximum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,versican|VCAN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Regional Disease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Unreported,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Total cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,Chlorogenic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,SGCB|APOBEC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AANAT gene|AANAT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,4-hydroxy-2-nonenal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Contraceptives, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD2 gene|CD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PROCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SELPLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic breast density,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,TIAM1 gene|TIAM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Examination of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Detection,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CDKN1C gene|CDKN1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,8-oxo-7-hydrodeoxyguanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carboplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chemoprevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DAND5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Cosmic Radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,loss; bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,lobaplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Peptide Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,zoledronic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
DISRUPTS,DMBT1 gene|DMBT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,arginylarginine|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Female Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,ABCG2 gene|ABCG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adaptation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Toll-like receptor 9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoplasm,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Atypical lobular hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AR gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Not significant,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,Hemoglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Propranolol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cosmetic surgery,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Paget's Disease,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Disease or Syndrome
CAUSES,NF-kappa B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,MIRN107 gene|MIR107,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
AFFECTS,Thioctic Acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Mammaplasty,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fat graft,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Regulatory Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"ESR1 protein, human|ESR1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Initiative - finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,tumor growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Calcium Channel Blockers,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Adverse effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,autoimmune thyroid disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Injectables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Proto-Oncogenes|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Local Anesthetics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thymine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Puberty,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,Tumor Markers,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Absorptiometry, Photon",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Osteocalcin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Alendronate,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,KDM4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TINCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KRT19 gene|KRT19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,DDT EXPOSURE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radiation therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Benzanthracenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Vimentin|VIM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Latent Virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Malignant neoplasm of breast,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,phospholipase C beta2|NEUROD1|TUBB4B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,EVI1 gene|RUNX1|MECOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATG9A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MUTYH,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Periodontal Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,K-ras Oncogene|KRAS,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Morphine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC00339,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MKNK1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,nicotinamide phosphoribosyltransferase|NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Induction,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,VEGFA,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Little's Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,HOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fluphenazine Hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen receptor negative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Naloxone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Glucosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FOXP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FOXP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SNORA7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Magnesium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CASC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fatty acid glycerol esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Infiltration,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Small Inducible Cytokine A18|CCL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,beta catenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,LINC01857,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tissue Model,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Schizophrenia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Antisense RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CASC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,glycogen synthase kinase 3 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NR0B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,schisandrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Antigens, Fos-Related|FOS",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Treatment Protocols,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,RFP2 gene|TRIM13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Green Fluorescent Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FSIP1 gene|FSIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,racial differences,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,COPB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Binding Sites,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,tropomyosin-4|TPM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KDM1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Steroid 17-alpha-monooxygenase|CYP17A1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Estrogen receptor positive,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,saikosaponin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,RHPN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chronic inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,LINC00460,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,UBE2D2 gene|UBE2D2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RASSF1A|RASSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TGFB1 gene|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CYP24A1 gene|CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SATB1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ENOLASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ACSF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Red Meat Consumption,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,E2F1 gene|E2F1|UBE2L3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Estrogens, Conjugated (USP)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,NCK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Matrix Metalloproteinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ENO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CUL5 gene|CUL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BODY HEIGHT:LENGTH:POINT IN TIME:^PATIENT:QUANTITATIVE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Apocrine adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,FOSL1 gene|FOSL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,mastitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Ribosomal RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PCB 153,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,STIM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,NBEAL1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AUGMENTS,PCB 153,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,acetylacetone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,betulinic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADCY4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AZIN2|GADL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PCB 118,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,11-beta-Hydroxysteroid Dehydrogenase Type 2|HSD11B2|RNU1-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Implantation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,caspase-8|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Electromagnetic Energy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,PALB2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,Polycystic Ovary Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Neuropathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GTPase-Activating Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,C11orf74|C17orf49,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,ATP8A2 gene|ATP8A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Aromatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AFFECTS,regulatory loop,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Enrich (product),Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,CGRRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,estrogens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,GTPase-Activating Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Tumor-Associated Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,PPAR gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PRDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Thrombospondin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,MIR223 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Hepatolenticular Degeneration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Nuclear Receptor Coactivator 3|NCOA3|ANIB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MAP2K4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LHX1 gene|LHX1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,blood test result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MIR195 gene|MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,quinoline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Deoxyuridine,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,High Confidence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,UGT2B7 gene|UGT2B7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,LINC02657 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ZEB1-AS1 gene|ZEB1-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,thrombin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,prasterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Substance with phenol structure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,thymoquinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cyclin D1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,"TFF1 protein, human|TFF1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SETD3 gene|SETD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diagnostic Imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,GADD45A gene|GADD45A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LSR gene|LSR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,27-hydroxycholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Accumulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Radiopharmaceuticals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Prognosis bad,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,DNA Minor Groove Binding Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Sex Hormone-Binding Globulin,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,GSTT1 gene|GSTT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,mullerian-inhibiting hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,NOP2 gene|NOP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,E2F3 gene|E2F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gamma-linolenic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Adriamycin,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,PLSCR1 gene|PLSCR1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,glutathione S-transferase pi|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Primigravida,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
DISRUPTS,MIR454 gene|MIR454,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Binge Drinking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Basaloid squamous cell carcinoma,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,apolipoprotein D|APOD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IGFBP7|SFPQ,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Small Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TXNIP gene|TXNIP,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,platinum,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,"EIF2C2 protein, human|AGO2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,pioglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,gonadorelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A14 gene|S100A14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,LINC00261 gene|LINC00261,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Methyl-CpG-Binding Protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CTHRC1 gene|CTHRC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,rhein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"POU5F1 protein, human|POU5F1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR622 gene|MIR622,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TFEB gene|TFEB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Profilin 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Aromatase,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Enzyme
AFFECTS,Hypersensitivity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,RB1CC1 gene|RB1CC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mitotic Activity,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,LMNB1,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
CAUSES,ESM1 wt Allele,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Cereal intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,aggressive cancer,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LOXL4 gene|LOXL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Extensive Necrosis,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TMPO wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"RNA, Messenger",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,MIR145 gene|MIR145,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HOPX gene|HOPX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,risk factors,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,CD163,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neurosurgical Procedures,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,LMNB1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,3-methylquercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TMED3 gene|TMED3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPC1 gene|GPC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Transcript,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Industrial fungicide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Biological Factors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Negative,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TAC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alleles,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
AFFECTS,Negative Regulation of S Phase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SALL4 gene|SALL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Immunoregulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,IL31 gene|IL31,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,fos-related antigen 1|FOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SAMD4A gene|SAMD4A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,WWOX wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Treatment modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SMAD7 gene|SMAD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Residual Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Low Density Lipoprotein Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Illness (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,UGT1A1 gene|UGT1A1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SKA3 gene|SKA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Glucocorticoid Receptor,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Nucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,HOMER1 gene|HOMER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Blood Proteins,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Hyperphagia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypomethylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,cytokine,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Biologically Active Substance
AFFECTS,Synthetic glucocorticoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,fructose,Carcinoma breast stage IV,0.0,Female Breast Cancer,Carbohydrate
PREDISPOSES,CYFIP1 gene|CYFIP1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,HER2-negative breast cancer,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"GPER protein, human|GPER1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Family history,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Deubiquitinating Enzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Family history,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,"CRYAB protein, human|CRYAB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"YAP1 protein, human|YAP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,DSCC1 gene|DSCC1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Benzo(a)pyrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin-Dependent Kinase Inhibitor Proteins,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ATXN8OS gene|ATXN8OS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,CHPF gene|CHPF,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,palbociclib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AFFECTS,epithelial to mesenchymal transition,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Aurora Kinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC12A8 gene|SLC12A8,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transferrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Deodorants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,thioguanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Copy Number Polymorphism,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
PREDISPOSES,"Receptor, Transforming Growth Factor-beta Type I|TGFBR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GOLPH3L gene|GOLPH3L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cystathionine beta-Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Color doppler ultrasound,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,KIF15 gene|KIF15,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,osthol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,KIF3B gene|KIF3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,DNA Methyltransferase Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Agent,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,mitogen-activated protein kinase kinase kinase 11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KIF3B gene|KIF3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Cathepsin L,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,Squalene monooxygenase,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,osthol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AFFECTS,Hormone Receptor Positive Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,"ABCG2 protein, human|ABCG2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Genes,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,PARP inhibitor therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ITM2A gene|ITM2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,thymoquinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TOX3 gene|TOX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR22 gene|MIR22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,estradiol,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,saffron extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,beta-2 Microglobulin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,small size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SHISA3 gene|SHISA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSEC gene|GSEC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Smoking,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,ST7-AS1 gene|ST7-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alleles,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,KIAA1109 gene|KIAA1109,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,Aquaporin 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,ACTL8 gene|ACTL8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Stimulation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,2 times,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,interleukin-10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Botanical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"RNA, Small Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,LGMN gene|LGMN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,research results,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SLAMF7 gene|SLAMF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Childbirth,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,calcium ion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fatty-acid synthase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
PREDISPOSES,UGT1A7 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Modest-Temperature Hyperthermia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,SRSF1 gene|SRSF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PVR gene|PVR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,E-Box Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FBXO5 gene|FBXO5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SRSF1 gene|SRSF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,CEP55 gene|CEP55,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Artificially Sweetened Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mood:-:Point in time:^Patient:-,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Crotoxin,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Chemical
AFFECTS,jolkinolide B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antigen Processing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,DPP4 gene|DPP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Portal Hypertension,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIR526B gene|MIR526B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,Heparin Binding Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,EN1 gene|EN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Smoke Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IFI30 gene|IFI30,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EGR1 gene|EGR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DPP10 gene|DPP10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Glycosphingolipids,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Lipid
CAUSES,pyridine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,cyclin B2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Xenograft procedure,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,ANLN gene|ANLN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC01089 gene|LINC01089,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Copy Number Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SMUG1 gene|SMUG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RNA modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ataxia telangiectasia mutated protein|ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Stilbenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,NOL10 gene|NOL10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,TMEM238L gene|TMEM238L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Drug Combinations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,IMPACT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR155 gene|MIR155,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Monocyte Chemoattractant Protein-1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Intravenous therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TCOF1 gene|TCOF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,TBX15 gene|TBX15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNAs,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,disorder control (procedure),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,H1-5 gene|HIST1H1B,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Oils,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Breast Density,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Coronary Arteriosclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tRNA modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRCA1 Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Normal weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR4521 gene|MIR4521,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Periodontitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,lead,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,Polyunsaturated fatty acid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Response to treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Parity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,hyaluronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,LIG1 gene|LIG1|LRIG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ARHGAP9 gene|ARHGAP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,mortalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RPS6KA3 gene|RPS6KA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Matrix Metalloproteinase 11,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hypersensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tanshinol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,RTL8C gene|RTL8C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,JAM2 gene|JAM2|JAM3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,progesterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,SYVN1 gene|SYVN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Constitutive skin pigmentation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Genetic Profile,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,MALAT1 gene|MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FAM189A2 gene|FAM189A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,sinomenine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Lipoxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VIRMA gene|VIRMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TSHZ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MRPS30-DT gene|MRPS30-DT,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Taxol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,HOXC-AS3 gene|HOXC-AS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LPAR6 gene|LPAR6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Very Important,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,Anti-Bacterial Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Injections, Intraperitoneal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Receptors, KIR2DL4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EIF6 gene|EIF6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Rhythm,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,ANKDD1A gene|ANKDD1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MEOX2 gene|MEOX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR660 gene|MIR660,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,UHRF1 gene|UHRF1,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,mRNA Precursor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CDC42,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,PDE5A wt Allele|PDE5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pregnancy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"IL22 protein, human|IL22",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Homologous Recombination Deficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,inermin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,STAMBPL1 gene|STAMBPL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LINC00472 gene|LINC00472,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Therapeutic procedure,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,GZMK gene|GZMK,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,CDK16 gene|CDK16,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Sulfatases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"RNA, Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Indicators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,Protein p53|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,diallyl trisulfide,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Malignant Neoplasms,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AUGMENTS,ATP6AP2 gene|ATP6AP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LMNB1 gene|LMNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of bone,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Neoplastic Process
AUGMENTS,MARK2 gene|MARK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RBIS gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,corynoline,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Ovarian Stimulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,urokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mouse mammary tumor virus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,History of previous events,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
DISRUPTS,Micelles,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,cytochrome b561,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,File Being Validated,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,C17orf49 gene|C17orf49,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,docetaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,eribulin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,MYC gene|MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,RUNX2 gene|RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNHG14 gene|SNHG14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,intracellular protein transport,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,WNT2 gene|WNT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,fulvestrant,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,"Food, Preserved",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Malignant Neoplasms,"Breast Cancer, Familial",0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Elevated Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KIF11 gene|KIF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Lactic acid dehydrogenase isoenzyme 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,ANLN gene|ANLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,COL11A1 gene|COL11A1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Melanocyte stimulating hormone,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Hormone
PREDISPOSES,ACTA2-AS1 gene|ACTA2-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"IRS1 protein, human|IRS1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Tumor Necrosis Factor Signaling Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IMPA1 gene|IMPA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC01194 gene|LINC01194,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,4 times,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,perfluorooctane sulfonic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Sulfonic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Disease,Refractory Breast Carcinoma,0.0,Other,Disease or Syndrome
AFFECTS,EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,New medications,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,MRPS7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ascorbic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,sirolimus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Matrix Metalloproteinase 9|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Generalized obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IMPA1 gene|IMPA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider},Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Membrane Transport Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,E2F6 gene|E2F6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,homocysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TP53 gene|TP53,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACBD3 gene|ACBD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GAS6-AS1 gene|GAS6-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SERPINA12 gene|SERPINA12,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,SEMA3B-AS1 gene|SEMA3B-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Calcinosis universalis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SLC3A2 gene|SLC3A2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,GLI1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,carbidopa,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,RYK gene|RYK,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,heparanase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Matrix Metalloproteinase 2|MMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,FRY gene|FRY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MUC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"ERCC5 protein, human|ERCC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MYCL gene|MYCL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL14 gene|CXCL14,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,AURKB gene|AURKB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lipopolysaccharides,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,lidocaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HSPB2 gene|HSPB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Early Diagnosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,RECQL4 gene|RECQL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EXO1 gene|EXO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Ligands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mevalonate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunogenic Cell Death,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Pathogenic Variant,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Virus
AFFECTS,Metabolite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,glutathione S-transferase pi|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LINC00473 gene|LINC00473,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,FOXA1 gene|FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,glutathione,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BARRIER,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Antiplatelet Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Basis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,USP37 gene|USP37,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,PPARA gene|PPARA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,boswellic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Biological Markers,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,dihydrotanshinone I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SOX8 gene|SOX8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Low-Dose Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,health knowledge,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC00536 gene|LINC00536,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,panobinostat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CBX3 gene|CBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Anti-Inflammatory Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Interventional procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SOAT2 gene|SOAT2,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,FRMD3 gene|FRMD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ENOLASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,perfluorooctanoate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,thiamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IMPACT gene,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,SDC1 gene|SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Circulating MicroRNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,TINCR gene|TINCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,birth control pill use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MIR497HG gene|MIR497HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Differential Diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Responsive Disease,Carcinoma breast stage IV,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,LAPTM5 gene|LAPTM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CLDN6 gene|CLDN6,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,TAF15 gene|TAF15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RHOV gene|RHOV,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Transforming Growth Factor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,sauchinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Targeted Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,GABRD gene|GABRD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MVP wt Allele|RPSA|LRP1|PTPRA|MVP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CBFB|NFYA|NFYB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SIRT7 gene|SIRT7,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,caspase-3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Disease/diagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Energy Balance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,MYBL2 gene|MYBL2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Improved,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NOTCH1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,COMMD3 gene|COMMD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leisure behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NPY1R gene|NPY1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,cyclic guanosine monophosphate-adenosine monophosphate,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,Sugar-Sweetened Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
CAUSES,Cobalt dichloride,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,Hexokinase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"herstatin protein, human",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Adaptor Proteins, Signal Transducing",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,PLPP4 gene|PLPP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TIPARP gene|TIPARP,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Metabolic Profile,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Hexokinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,GJA1 gene|GJA1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathogenic Variant,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Virus
CAUSES,Phytochemicals,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
CAUSES,Pyrenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,C1QL4 gene|C1QL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Food Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Noninfiltrating Intraductal Carcinoma,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AFFECTS,fruit extracts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Heat Shock Protein 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Sulfhydryl Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,IDO2 gene|IDO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Players,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,NDC80 gene|NDC80,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,reproductive hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,ADAR gene|ADAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Liposomes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,GPT2 gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Long Interspersed Nucleotide Element-1,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,PTCSC3 gene|PTCSC3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,histone deacetylase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SCRIB gene|SCRIB,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Infiltration,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Tumor Microenvironment of Metastasis Density,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Immune,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,IRF7 gene|IRF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HDAC1 gene|HDAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ferritin Light Chain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypothalamic inhibiting factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,MED1 gene|MED1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Triple Negative Breast Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MAPK1 gene|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinogenesis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,xiaoyaosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gravidity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cytochrome b561,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obesity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Suppressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Multiple tumors,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
CAUSES,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Thrombotic Microangiopathies,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Alkaloids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,ZNF831 gene|ZNF831,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MC1R gene|MC1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,estrogens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
DISRUPTS,pristane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Non-alcoholic Fatty Liver Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Ginsenosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ethanol,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,40-49,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,interleukin-6|IL6,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,"estrogens, conjugated (USP)",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,MIR429 gene|MIR429,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Interleukin-16, human",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,polyphyllin II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"ATF2 protein, human|ATF2",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,FTO gene|FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,mahanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,trastuzumab deruxtecan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,doxorubicin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,KLF5 gene|KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Perimenopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,FZR1 wt Allele|CDH1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
AFFECTS,Screening for malignant neoplasm of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FAM83D gene|FAM83D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RACK1 gene|RACK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CXCL8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,A1BG-AS1 gene|A1BG-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ANO6 gene|ANO6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AFF4 gene|AFF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PROS1 gene|PROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,testosterone,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,Hemoglobin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,butylbenzyl phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lesch-Nyhan Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,CAVIN1 gene|CAVIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"Receptors, Opioid, kappa",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,AMACR wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TDRKH-AS1 gene|TDRKH-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"IMP3 protein, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"MFGE8 protein, human|MFGE8",Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Organic solvent product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Endometriosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TTPAL gene|TTPAL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FOXK1 gene|FOXK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR205 gene|MIR205,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Non-alcoholic Fatty Liver Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Implants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biomedical or Dental Material
PREDISPOSES,ESR1,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
AFFECTS,FTO gene|FTO,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,GNAO1 gene|GNAO1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Tobacco,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FOXQ1 gene|FOXQ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tea,Breast cancer stage II,0.0,Female Breast Cancer,Other
AUGMENTS,PARK7 gene|PARK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PPARGC1B gene|PPARGC1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TPM2 gene|TPM2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Pivot,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,RSRC2 gene|RSRC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,erbB-2 Receptor|ERBB2,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
COMPLICATES,Sarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"CD69 protein, human|CD69",Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Estrogen Receptor alpha,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Score,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Other
PREDISPOSES,SIK2 gene|SIK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carney Complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"interleukin-1, beta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,magnesium cation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplastic Cell Transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,pimozide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Movement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR205 gene|MIR205,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Androgen Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SLC7A11 gene|SLC7A11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Expression,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,MT-RNR1 gene|RNR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RAB5A gene|RAB5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CAT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Patient Derived Xenograft,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CCDC150 gene|CCDC150,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Male-to-female transsexual (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Autoantibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MXRA5 gene|MXRA5,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,claudin 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NF2 gene|NF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,humanin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,translation factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,WWOX gene|WWOX,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EP300 gene|EP300,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leucine-Rich Repeat Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,scopolamine,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
COMPLICATES,EYA2 gene|EYA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PKMYT1 gene|PKMYT1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,ME1 gene|ME1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CACNG4 gene|CACNG4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Upstaging,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,obeticholic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Neoadjuvant Therapy,bilateral breast cancer,0.0,Female Breast Cancer,Other
AUGMENTS,CCL20 gene|CCL20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MBD2 gene|MBD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"IL1A protein, human|IL1A",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,IL22 gene|IL22,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Therapy,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,taurine,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Multiple Sclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Targeted Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Bee Venoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Human Class I Antigens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AFFECTS,DNA Replication,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CCNB1 gene|CCNB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Urolithin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Protective Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,pyruvate dehydrogenase kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tissue texture abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Basal Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC38A5 gene|SLC38A5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FGF11 gene|FGF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,phosphatidylinositols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,4-aminohippuric acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ZBTB10 gene|ZBTB10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Combination Chemotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Folliculin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nitric Oxide Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,20q13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GRB7 gene|GRB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CCL18 gene|CCL18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,TBX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TIMM50,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Stromelysin 1|MMP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EPHA10 gene|EPHA10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cancer-Predisposing Gene,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,MAP3K1 gene|MAP3K1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Estrogens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Integrin alpha4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,intraoperative radiotherapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Menopause,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
DISRUPTS,BRMS1L,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CYP1A1 gene|CYP1A1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AUGMENTS,"WBSCR22 protein, human|BUD23",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,11q13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Renal Cell Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,cyclin A1|CCNA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Oxygen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tangeretin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Enhancer Elements (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Glutamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Heregulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIRN143 gene|MIR143,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RAD51C gene|RAD51C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,AATF gene|AATF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,beta catenin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,STF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Selective serotonin re-uptake inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AUGMENTS,SLC39A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,8-Oxoguanine DNA Glycosylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Annexin A1|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Organized pneumonia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Methotrexate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IFNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor Suppressor Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin-18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Receptors, Opioid, delta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,IL18 gene|IL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Androgen Receptor|AR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Pads,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Hypoxia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Autophagy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Genuineness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BAG3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Carcinoma, Ductal, Breast",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNAI1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cytotoxicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,NOP14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Rectal hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NRIP1 gene|NRIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Activins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Microtubule-Associated Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Phosphoglycerate dehydrogenase|PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,WRAP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Epidermal Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,STC1 gene|STC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Environmental Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SNAI1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,TRIM62,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Wound Healing,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,ERBB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,osteoblast cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Congestive heart failure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,octylphenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ir Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ADGRF5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Salts,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,FH: Father NOS,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,carnosol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Insulin-Like Growth Factor Receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,ADRA2A gene|ADRA2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"1,4-dioxin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,icariin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gene Expression Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR200A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"ST13 protein, human|ST13",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,PIK3R1|PIK3R2|ARHGEF7|CBFA2T2|PPP1R13B|PPP1R12C,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Physical activity decreased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FABP5 gene|FABP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Follicle Stimulating Hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PRLR gene|PRLR|PTP4A3,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTA1 gene|GSTA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,retinyl methyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,High Vegetable Diet,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Levodopa,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,receptor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Gin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin-Like Growth Factor I,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
AFFECTS,Clomiphene,bilateral breast cancer,0.0,Female Breast Cancer,Other
CAUSES,Viral Tumor Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Diphosphonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,glycosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Brachytherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Nifedipine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cytokine,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Central Nervous System Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Estrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ukrain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin D1|LMOD1|BBS9,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Human papillomavirus 16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Malignant mixed salivary gland tumor,Cancer en cuirasse,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Human Platelet Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,reproductive hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,TARBP2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Agent,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,MAPKAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CTTN gene|CTTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Atypical proliferation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tumor Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Edema,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Voluntary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Sulfones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Polyunsaturated Fatty Acids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,CD44 gene|CD44,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Herpesviridae,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Microsatellite Repeats,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Fatty Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Z-alpha-chlorochalcone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PRLR gene|PRLR|PTP4A3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LALBA gene|LALBA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,R-38486,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclophosphamide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,"TFF1 protein, human|TFF1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Carotenoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MENSTRUAL STATUS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Common Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Menopausal Status,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,Mechlorethamine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Goiter,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Epidermal Growth Factor Receptor|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,OK-432,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tall stature,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Caloric Restriction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Esters,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Hodgkin Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Atrophic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Excessive self-esteem,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Confident,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Dinoprost,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,cDNA Library,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,FGF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibrosing adenosis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,Epoprostenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RBBP1L1 Protein|ARID4B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,FGF4 gene|FGF4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Pregnancy review,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Zuclomiphene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,EMD 16795,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Silicones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Malignant Carcinoid Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ergocornine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Cisplatin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,2-Acetylaminofluorene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hypolipidemia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Lipid
CAUSES,Retinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Hormone manipulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Transgenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Microsatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adipositas,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Drink,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogen Replacements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Neoplasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,ATM gene|ATM,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Noninfiltrating Intraductal Carcinoma,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,TP73|ARHGAP24,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,thermography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Calcium Glucarate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Psychological Impact,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,p65|RELA|SYT1|GORASP1|WNK1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Dietary Fats,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,PPARBP gene|MED1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Insulin-Like Growth Factor I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,whey protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TP53 gene|TP53,bilateral breast cancer,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Osteoclastic resorption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,SYK gene|SYK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Microsatellite Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,2-chloroethyl ethyl sulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Jogging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TFF1 gene|TFF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Postmenopausal Hormone Replacement Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Pregnenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,casein kinase II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Overweight,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Tumor Angiogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,matrix metalloproteinase 26,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,8-hydroxy-2'-deoxyguanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,glutathione S-transferase pi|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Germ-Line Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Integrin alphaV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,alpha-Fetoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BIN1 gene|BIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BIRC5 gene|BIRC5,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Encounter due to Unspecified general medical examination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Neoplasm,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,ERBB2|NEU1|NEURL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SLC39A6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Diet,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Parkinson Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Menopausal hot flushes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CD82 gene|CD82,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Tumor Suppressor Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Amphiregulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TNFSF10 gene|TNFSF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Transforming Growth Factor alpha|TGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Tumor Suppressor Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,estrone sulfatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Bone Resorption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Phytoestrogens,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AUGMENTS,SNCG gene|SNCG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Fatty Acids, Monounsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,H-ras Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Carcinoembryonic Antigen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AUGMENTS,REL gene|REL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Selenium,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Ethylnitrosourea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,"N,N-dimethyl-4-anisidine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tamoxifen,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
CAUSES,"BCAR1 protein, human|BCAR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,AKT3 gene|AKT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Surgical biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Technetium Tc 99m Sestamibi,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Hexestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Opioid Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,stanniocalcin 2|STC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Early menarche,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AUGMENTS,8-hydroxyguanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Fatty Acids, Omega-6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Receptor, Melatonin, MT1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Antidepressive Agents, Tricyclic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,LIG4 gene|LIG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SNCG gene|SNCG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mitotic Activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tamoxifen,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,Alpha heavy chain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"1,2-dibromo-3-chloropropane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,BRCA1 Protein|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Slow acetylator status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ibandronate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"NOS2A protein, human|NOS2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carcinoma in Situ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,PTEN gene|PTEN,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Glutathione S-Transferase|SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Embolism, Tumor",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Therapeutic regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Myocardial Infarction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmaceutical Preparations,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,ATP12A|HK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogenic effect,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AUGMENTS,FGF3 gene|FGF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,P-Cadherin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Prenatal Exposure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,BAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Eicosapentaenoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Cytokinesis of the fertilized ovum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,adjuvant therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Phosphorylcholine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Dydrogesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Calgranulin B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,SPOCK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RUNX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obstruction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,8q24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Genes,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
DISRUPTS,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cold temperature,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,helicase|HFM1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Epithelial Cell Proliferation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fanconi's Anemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Atypia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Monocyte Chemoattractant Protein-1|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,TNF,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,RANTES|CCL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Recombinant Interleukin-8|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Angiotensin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,E-Cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Apigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Palmitic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"STK6 protein, human|AURKA",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,AROMATICS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,N-6 fatty acid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,tanshinone II A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of prostate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Puberty, Precocious",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chronic Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Estrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Oxidoreductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TNFSF6 gene|FASLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Delayed menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ERBB3 gene|ERBB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Testosterone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,PPAR gamma|PPARG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MERTK gene|MERTK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ASAP1|MYCBPAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glycol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PARP1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Oncogenes,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,polyphenon E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Activins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"RNA, Small Interfering",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Plants, Edible",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Analgesics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Disintegrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,prohibitin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Phosphatidylinositols,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Conjugated Equine Estrogens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,leucylproline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Antihormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Connexins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,podocalyxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HIVEP2 gene|HIVEP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Platelet-Derived Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Non-esterified cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,ERbetacx,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"Receptors, Cell Surface",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GSDME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Norgestrel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,reproductive hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,IFNG gene|IFNG,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Amphiregulin|AREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,bone morphogenetic protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epidermal Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Body mass index,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Specific antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AUGMENTS,CHEK2 gene|CHEK2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
CAUSES,RAD50,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CA-125 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Gene Expression,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,EGLN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Glutathione S-Transferase|SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CD24,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,STK11 gene|STK11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,anti-apoptosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogen Receptors,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Communication,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ERBB2 gene|ERBB2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,CTCFL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LIN28A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Compound Q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Simvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Human Chorionic Gonadotropin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HMMR gene|HMMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD70,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,OTP gene|OTP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Janus kinase 2|JAK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Histologic type,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Protein Expression,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP1B1 gene|CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,nuclear receptor coactivator 1|SRC,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Convenience food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,Liposomes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,KDM8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Cations, Divalent",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HMMR gene|HMMR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Disulfiram,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,IDO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Molecular Fingerprint of Tumor,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
PREDISPOSES,healthful behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"2,5-dichloro-4-bromophenol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cullin Proteins,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Carbon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,BRMS1 gene|BRMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PLXNB1 gene|PLXNB1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"SMO protein, human|SMO",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Lemon extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,invariant chain|CD74,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,survivin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Cell-cell adhesion molecule,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Introns,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FAN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Apocrine adenocarcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MYB gene|MYB,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Aluminum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,RBBP7,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,quinoxaline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Germ-Line Mutation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,YBX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,isoflavonoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Spontaneous abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Receptors, Nuclear",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PLG gene|PLG,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,FASTK Gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,CYP2S1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A11 gene|S100A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fenretinide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDC25A gene|CDC25A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AUSTRALIAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,UTS2R|SLC14A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RAD51,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,NRDC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,S100A1|S100B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemoprevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Field crops,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Core needle biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NOV,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,TP53BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,ATM gene|ATM,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacologic Substance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Mammary Neoplasms,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,NCOA7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ALCAM gene|ALCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SPDEF gene|SPDEF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCR4 gene|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptors, Steroid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
DISRUPTS,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SERPINE1 gene|SERPINE1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Cancer Promoting Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Metabolic Marker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CXCL10 gene|CXCL10,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,CBX7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,caveolin 1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,MMP9 gene|MMP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"TIMP2 protein, human|TIMP2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BEX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Growth,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SOX18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MAP Kinase Gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CD44 gene|CD44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,intraoperative radiotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Gallic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,ATP2B2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAD51B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lipids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Lipid
DISRUPTS,FBXW7 gene|FBXW7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,diindolylmethane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,S Phase Arrest,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ASAP1|MYCBPAP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,hypercholesterolemia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Lipid
AUGMENTS,Functional RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,COX7A2L gene|COX7A2L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Gelsolin|GSN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,F3 gene|F3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Primary Neoplasm,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,aurora kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCL22 gene|CCL22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vascular Endothelial Growth Factor C|VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Primary carcinoma of the liver cells,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CRY1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CIP2A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Berberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Vimentin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,IL2-inducible T-cell kinase|ITK|SLC22A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,KIF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ATG4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chloroquine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TMEM88,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Tumor Suppressor Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
CAUSES,Proto-Oncogene Proteins c-myc|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cysteine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FGF1 gene|FGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SFRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PFN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alport's syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,ERCC1 gene|ERCC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Diphosphonates,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,Overweight,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PARK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Malignant neoplasm of prostate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,molybdenum disulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,OIP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHEST PATHOLOGY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,oleocanthal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neuromedin U|NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CASP9 gene|CASP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Angiopoietin-2|ANGPT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DEAE-Dextran,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Disaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LEPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,docetaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Reproductive History,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,dieckol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Lovastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic Touch,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Smoking Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Phenformin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CCL13 gene|CCL13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Taxanes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,teleocalcin,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,ligustilide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Biogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,C-terminal binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TNFAIP8L3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,LGR5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immune response,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,Malignant neoplasm of urinary bladder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Polyaromatic hydrocarbon,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,matrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Protein phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CCR7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Glucuronosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,interleukin-17E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Proto-Oncogene Proteins c-akt|AKT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAGEA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Genes, Regulator",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Inactivation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Somatostatin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC9A3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Docosahexaenoic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,CDX2 gene|CDX2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,RCCD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIRN34A gene|MIR34A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,NBAT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Neuropilin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inflammation,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"kallikrein 5, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inflammation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endothelin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast cancer invasive NOS,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Ethanol,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Fatty Acids, Omega-3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,NSUN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Primary carcinoma of the liver cells,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Lysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cadherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MTA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Membrane Transport Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Trichloroethylene,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
COMPLICATES,topical application,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"KLK5 protein, human|KLK5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Non-alcoholic fatty liver,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Age at menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sleep behavior finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ESR2 gene|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NOD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCL4 gene|CCL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Oligonucleotides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,receptor,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Antiepileptic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,GSTM3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SIRT7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Neoplasm,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Progesterone level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Aptamer,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,FABP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,E2F7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,zinc-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Proliferation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hydroxyestrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KRT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Isoprostanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Coffee intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Choline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,WWOX,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,PPM1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transcriptional Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,GATA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,everolimus,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,decorin|DCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epidermal Growth Factor Receptor|EGFR,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Dessert,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PHF5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ITGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,thymoquinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cucurbitacin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Thyroid Hormone Receptor Alpha-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,dronedarone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,FOXC1 gene|FOXC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Menarche,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,kaempferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Encounter due to prophylactic surgery, unspecified",Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
CAUSES,zileuton,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,APC,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,Stanolone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Loops,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,polycylic aromatic hydrocarbons-DNA adduct,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,XRCC1 gene|XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Fibronectins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,"Neoplastic Syndromes, Hereditary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,APOE gene|APOE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Ceramides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ATP phosphohydrolase|DNAH8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Metabolic syndrome,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
AFFECTS,Angiogenesis,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Spectroscopy, Nuclear Magnetic Resonance",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radiofrequency ablation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ANAPC15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDC2 gene|CDK1|POLD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EZH2 gene|EZH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,lapatinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Apolipoprotein A-I|APOA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,UGT1A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Integrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CHES1 gene|FOXN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,S100A8 gene|S100A8,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Emodin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Raloxifene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Neoplasm progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fasting,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TOB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fatty fish,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,caveolin 1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,RAD51C gene|RAD51C,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Anti-Anxiety Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Polyunsaturated Fatty Acids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,P-Glycoprotein,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hormone replacement therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
PREDISPOSES,Recreation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Endopeptidases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,BRCA1 gene|BRCA1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Osteoporosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogen Replacement Therapy,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,LACRT gene|LACRT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Phenelzine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Oral Contraceptives, Low-Dose",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nortriptyline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Overweight,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Diet,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Overoptimism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nonpuerperal mastitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Health promotion behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"IGFBP2 protein, human|IGFBP2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Excision,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,somatotropin-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Behavioral change,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Smoking,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Alkaline Phosphatase,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,RFC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Health-related behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Androgen Receptor|AR,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,phenylalanyl-glycyl-valyl-statyl-alanyl-phenylalanine methyl ester,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Aromatase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,Gonadotropins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutation,bilateral breast cancer,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CCND1 gene|CCND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,bexarotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Serum Albumin,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Body Substance
AFFECTS,Diastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antineoplastic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diabetes type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ataxia Telangiectasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TMEM131L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MMP14 gene|MMP14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,16q12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Macrophage Colony-Stimulating Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell Cycle Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Goserelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Air Pollution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Biotinidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,UBE2S,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Carcinoma, Ductal, Breast",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Primary Lesion,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mastectomy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Vincristine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Punctate calcium deposition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hodgkin Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Dietary Supplements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Endotoxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,IRS1 gene|IRS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,STN gene|EEF1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Excessive weight gain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Drinking pattern,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prunes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Thyroid Hormones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Cosmetic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Drug Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AFFECTS,CCL5 gene|CCL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Autoimmune hypothyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nuclear Receptor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcoholic Beverages,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,VASOMOTOR SYMPTOM,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,epigallocatechin gallate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,agonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tipifarnib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Activins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MUC4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Personal Satisfaction,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,PALB2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,lapatinib,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Interleukin-8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Steroidal Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,trichostatin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLK5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Family history of breast cancer,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Rare Diseases,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,deceased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Telomere Maintenance Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cyclin-dependent kinase 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,conjugation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,overdiagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Sirolimus (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,NR5A2|P2RX5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diabetes Mellitus,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,KRT20|C17orf97,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NR3C1 gene|NR3C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptors, Progesterone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,zeaxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BRCA3 gene|BRCA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,heparanase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CD40 Ligand|CD40LG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,interleukin-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Calgranulin A|S100A8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Physical therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Red Meat Consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Muscular Dystrophy, Facioscapulohumeral",bilateral breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,Instability,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diabetes Mellitus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CSH2 gene|CSH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Actin bundling protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IL8 gene|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KIF2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Apoptosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,MTHFR gene|MTHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AKR1C4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ABCC10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCDC91,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ribonucleotide reductase M2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,MT1A|MT1B|MT1E|MT1F|MT1G|MT1H|MT1JP|MT1M|MT1L|MT1X|MTNR1A|ALG1|MT1IP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cadmium Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Mutation,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,psychological distress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PALB2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AUGMENTS,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Insulin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Alcohol products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammography abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Copper,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,germin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Smoking,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Pharmaceutical Preparations,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AUGMENTS,Hyaluronan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,diindolylmethane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disorder of pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Sleeplessness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RRM2 gene|RRM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Sirolimus (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,Soluble ErbB-1|EGFR,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Silence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gene Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PELP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fertility care,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MMP11 gene|MMP11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mammographic microcalcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MIRN93 gene|MIR93|MIR9-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Urokinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Protein p53|TP53,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Tumor Suppressor Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Rye flour,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Clusterin|CLU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gonadal Steroid Hormones,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
AFFECTS,Diffusion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Co-morbid conditions,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,regular physical activity,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,C-KIT Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MICE gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Mitotic/Spindle Checkpoint,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol consumption,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,claudin 6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,NEK2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Somatotropin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CHD5 gene|CHD5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Glutamate-Cysteine Ligase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PERP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EGF gene|EGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mammaplasty,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Mammographic breast density,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Autoimmunity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sunlight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PARD6A|PWAR6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cardanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,None|SLC16A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinoma in situ of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Corn Oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Zinc,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,UCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"CHEK1 protein, human|CHEK1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Non-Viral Vector,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,aglepristone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,White bread,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disability NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ERCC2 gene|ERCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
DISRUPTS,"Calcium, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radiation,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fluorodeoxyglucose F18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Interleukin-18,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,chemokine receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CCND1 Gene Amplification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Integrin alphaV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PROX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Dioxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cisplatin/cyclophosphamide/etoposide protocol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PINX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,BST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,aldehyde dehydrogenase 1|ALDH1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Membrane Transport Proteins,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Tryptophan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Baresthesia,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Taurine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast arterial calcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FBXW7 gene|FBXW7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,palmitoleic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,LPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Amphiregulin|AREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PROTEIN KINASE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,C14orf166 gene|RTRAF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,EGFR Protein Overexpression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RPS6KA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FBXO31 gene|FBXO31,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FABP4 gene|FABP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Peroxisome Proliferator-Activated Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GATA3 gene|GATA3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Reexcision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Encounter due to breast augmentation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Vimentin|VIM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MAPK12 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,tacrolimus binding protein 4|FKBP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,COPS5,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,ZNF350,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Air Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Hyperostosis, Diffuse Idiopathic Skeletal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD151,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Fenretinide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signal Transduction Pathways,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Cancer Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Ellagic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,FGFR1 gene|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Immunomodulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,HADHA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,N-acetyltransferase 1|EREG|ESR1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,Antiplatelet therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,BRCA2 gene|BRCA2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,TIMELESS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Annexin A2|ANXA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Work stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cancer Promoting Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RHBDD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Heparan Sulfate Proteoglycan|HSPG2|SDC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,LAMTOR5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MALAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PGD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"MAPK14 protein, human|MAPK14",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Estrogen Receptor Status,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Liver Cirrhosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Brain Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oranges,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Fatty Acids, Saturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Edema,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,SESTAMIBI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Aspirin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Onions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Lamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Androstenedione,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body mass index,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,LINC00518,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DDT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Overweight,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,ID2 gene|ID2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,thrombospondin 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Histone Deacetylase Inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,AQP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ranolazine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,mannuronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,exemestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Repeat Surgery,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,PIP5K1C,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,KRT19 gene|KRT19,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ectopic Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOCS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,AQP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MFAP5 gene|MFAP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CCL20 gene|CCL20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ENPP2|SMG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vitamin D3 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,PDLIM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SDC1 gene|SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gamma-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Supportive care,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,CD44 gene|CD44,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RBMS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,VIPR1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,triptolide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,targeting,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
CAUSES,Skin Lymphangiosarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Coronary heart disease,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Metformin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Phosphorus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Rosacea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PUF60,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MAFG gene|MAFG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,oncostatin M|OSM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dexamethasone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Phthalimides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HDAC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,VIM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CISH,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,ADAMTS1 gene|ADAMTS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Honey bee venom,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Antigens,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,C-Phycocyanin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant Neoplasms,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,ATP-Binding Cassette Transporters|ATP8A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antisense RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,SNHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Metals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,mRNA Expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Anaplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SDC1 gene|SDC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GLI3 gene|GLI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tissue-Specific Gene Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Egg Food Product,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
PREDISPOSES,Hyperglycemia,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Valproic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,MDM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Proto-Oncogene Proteins c-jun|JUN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MDM2 gene|MDM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,E-Cadherin|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pollutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Medication use,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Chinese herbal medicine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TIMM13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"PER2 protein, mammalian",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Cyclin-Dependent Kinase Inhibitor 2A|CDK4,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,silybin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PCB 138,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP2C8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIRN192 gene|MIR192,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Extracellular Matrix Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Phenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TRIM44,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Quinoxalines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PXDNL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vitamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,TUFT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,transcription factor PML,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Silence,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Premenopause,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,PTP4A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDK12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinosarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Tumor stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Monocyte Chemoattractant Protein-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,JPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Transcription Repressor/Corepressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,UBE2V1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,RUNX2 gene|RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,APRIN gene|PDS5B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Chalcone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BMX gene|BMX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mitogen-Activated Protein Kinase 3|MAPK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,everolimus,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Alternative Splicing,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,ethylene oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FAM53A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Microbicides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GABRA3 gene|GABRA3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,paclitaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,HULC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Trans Fatty Acids,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Chemical
AFFECTS,TGFB1 gene|TGFB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,silence,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Promoter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"nuclear receptor subfamily 1, group H, member 2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR30A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nance-Horan syndrome,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,intrauterine disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,mercury,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AUGMENTS,CLDN11 gene|CLDN11,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,MicroRNAs,"Breast Cancer, Familial",0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,RHPN1-AS1 gene|RHPN1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA2 gene|BRCA2,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,ibrutinib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,Ubiquitin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Copy Number Polymorphism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,"Antibodies, Blocking",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TT genotype,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,opium alkaloids and derivative combination cough suppressants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tamoxifen,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Pharmacologic Substance
AFFECTS,letrozole,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Mutation,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SIRT4 gene|SIRT4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,MIR221 gene|MIR221,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Invasive carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,LINC00963 gene|LINC00963,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,29+,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Polyunsaturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Patient Derived Xenograft,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,"TGFB1 protein, human|TGFB1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MIR221 gene|MIR221,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BHLHE40-AS1 gene|BHLHE40-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLX4IP gene|SLX4IP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,olaparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Contrast enhanced spectral mammography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
CAUSES,SFN,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,MTOR gene|MTOR,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,SOX21-AS1 gene|SOX21-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Detection,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,STAT1 gene|STAT1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,Transcriptome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Macrolides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Gonadal Steroid Hormones,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,Rheumatoid Arthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunohistochemistry,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,"CISH protein, human|CISH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NOP2 gene|NOP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SNHG3 gene|SNHG3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,MDC1 gene|MDC1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXP1 gene|FOXP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE2M gene|UBE2M,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD44,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Iodides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MLKL gene|MLKL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,prolactin,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,subharmonic imaging,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,OSW 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,STAT3 gene|STAT3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,HER2-positive carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Second line treatment,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Hemangiosarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,HEXIM1 gene|HEXIM1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hormone Receptor Positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,"Genes, Modifier",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proliferation (morphologic abnormality),Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Suppressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC00160 gene|LINC00160,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,methanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FOSB,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,KLHL22 gene|KLHL22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Postmenopausal state,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cytotoxic Chemotherapy,HER2-negative breast cancer,0.0,Female Breast Cancer,Hazardous or Poisonous Substance
DISRUPTS,HSP90 Heat-Shock Proteins|HSP90AA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,risk factors,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Cadherins,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Pathogenic,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Virus
PREDISPOSES,information seeking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,RB1CC1 gene|RB1CC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RUNX3 gene|RUNX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Magnetic resonance imaging of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CXCR2 gene|CXCR2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SIRT6 gene|SIRT6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ion Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Eukaryotic Initiation Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Flavanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epigallocatechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SIRT1 gene|SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,apigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AGR2,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vitamin D3 24-Hydroxylase|CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,BHLHE40 gene|BHLHE40,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epicatechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"KRT10 protein, human|KRT10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,UBE2D2 gene|UBE2D2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CST3 gene|CST3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,P-Cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PRS gene|PRS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Easy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,C8A gene|C8A,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Radionuclide Imaging,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CTBP1-AS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,silence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cancer-Predisposing Gene,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEAT1 gene|NEAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Caffeinated coffee,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,steroid glycoside,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Steroid
PREDISPOSES,5-methyltetrahydrofolate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypertrophy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SNAI3 gene|SNAI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,lapatinib,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,rucaparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,FZD7 gene|FZD7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Kynurenine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,ZFPM2-AS1 gene|ZFPM2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Visual Accommodation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,mTOR Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
COMPLICATES,CTHRC1 gene|CTHRC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Crown-Like Structures of the Breast,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,UBR1 gene|UBR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NMU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,xanthomicrol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Crown-Like Structures of the Breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"HLA Class I Histocompatibility Antigen, Alpha Chain G",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,"Receptors, Adrenergic, beta-1|ADRB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,angiotensin converting enzyme 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
DISRUPTS,"YAP1 protein, human|YAP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,polyphenols,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Lipids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Lipid
DISRUPTS,GPER1 gene|GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,rasagiline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,JMJD6 gene|JMJD6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Regulatory Sequences, Nucleic Acid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PPP2R2B gene|PPP2R2B,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Neutrons,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,HHEX gene|HHEX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ERRFI1 gene|ERRFI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Alcohol,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,"CD9 protein, human|CD9",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ZFAS1 gene|ZFAS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"CREB1 protein, human|CREB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,mannose receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RCC2 gene|RCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,HER2-targeting Agent,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Anti-Angiogenesis Effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Volatile Organic Compounds,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Chemical
AFFECTS,gemcitabine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
COMPLICATES,Obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pulmonary Metastasectomy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,ATM,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Other
AFFECTS,Neoplasms by Site,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Systemic Therapy,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
DISRUPTS,MST1 gene|MST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol dehydrogenase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TRIM6 gene|TRIM6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tissue Inhibitor of Metalloproteinase-3|TIMP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,honokiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HNF1A-AS1 gene|HNF1A-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Low BMI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,human MUC1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ethanol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,GZMK gene|GZMK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,pembrolizumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,COL10A1 gene|COL10A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CHAF1A wt Allele|KAT2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,IFNG gene|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Nicotinate-nucleotide pyrophosphorylase (carboxylating),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,lipid mediator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,High birth weight,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mean score,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,VPS35 gene|VPS35,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,water channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TNFRSF11A gene|TNFRSF11A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01977 gene|LINC01977,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,vinorelbine,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
CAUSES,Cytochrome P450|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DEGS1 wt Allele|DEGS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Atypical hyperplasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Second line treatment,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,WNT7B gene|WNT7B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
CAUSES,Reactive Nitrogen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Programmed cell death ligand 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,CYTOR gene|CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vitamin supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,MIR506 wt Allele,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NF-kappa B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,MTERF3 gene|MTERF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,bisphenol A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,lutein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,estrogen receptor-positive breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,voacamine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,GLUCOSE-6-PHOSPHATASE,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Carbohydrate
CAUSES,atmospheric pollution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Sphingolipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,directive therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Pathologic Neovascularization,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"3,3'-diindolylmethane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PFKFB4 gene|PFKFB4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Interferon-alpha,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Biological Response Modifiers,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Metastatic malignant neoplasm to brain,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Angiogenesis Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,FABP4 gene|FABP4,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Imbalance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Chlorpyrifos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Treatment Protocols,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Agent,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Long Intergenic Non-Protein Coding RNA,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TRPV6 gene|TRPV6,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MMP11 gene|MMP11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Interstitial Collagenase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,AMD1 gene|AMD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,E2F1 Transcription Factor|E2F1|UBE2L3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Proton Pump Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,3F8 antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,Increased prolactin level,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,PET/CT scan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,UBA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DEAD Box Helicase p68|DDX5|KHDRBS1|POLD3|GATAD2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Food, Organic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,rutecarpine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Epstein-Barr virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,bruceine D,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Breast Cancer Therapeutic Procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,TBX15 gene|TBX15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Kynurenine 3-monooxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ovary; insufficiency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PIM1 gene|PIM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone Therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Hormone
AFFECTS,AIFM2 gene|AIFM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZBTB7A|AKIRIN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,MCM3AP-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RPPH1 gene|RPPH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"protein tyrosine phosphatase, non-receptor type 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,estrogen use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Metronomic Chemotherapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,PALB2 gene|PALB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Adriamycin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,epithelial to mesenchymal transition,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Adverse Event Emergency Room Visit,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,SNHG3 gene|SNHG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TUBA4A gene|TUBA4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WDR43 gene|WDR43,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,AMIGO2 gene|AMIGO2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,SNHG1 gene|SNHG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Intronic Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammaplasty,Stage 0 Breast Carcinoma,0.0,Female Breast Cancer,Other
CAUSES,"Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit 1, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,glucose high,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,aspirin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Elevation procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,GATA3 gene|GATA3,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,TMEM130 gene|TMEM130,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,oleyloxyethylphosphorylcholine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Plasma Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RASSF1 gene|RASSF1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,BNIP3 gene|BNIP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Overdiagnosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,erbB-2 Receptor|ERBB2,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Other
AFFECTS,fibroblast activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Elevated Expression,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,COMT gene|COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"leptin receptor, human|LEPR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PTPN2 gene|PTPN2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,FGFR4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,FERMT2 gene|FERMT2,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptor Tyrosine-Protein Kinase ErbB-4, human|ERBB4",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,atezolizumab,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,Aromatase Inhibitors,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Hormone
AFFECTS,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Parity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,limonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SHMT2 gene|SHMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EIF3B gene|EIF3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIR21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Suspensions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Ultrasound Tomography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Parallel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,mRNA editing,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Transcription Coactivator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lymphatic Invasion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Precision Medicine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MicroRNAs,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,IRAK1 gene|IRAK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TSPAN8 gene|TSPAN8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genetic Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ergocalciferol,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
COMPLICATES,Lymphedema,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nicotinate-nucleotide pyrophosphorylase (carboxylating),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Confirmation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,cytokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,ALDH2 gene|ALDH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,interleukin-21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NTN4 gene|NTN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,CCL18 gene|CCL18,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,TLN1 gene|TLN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Cell-Free DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Low health literacy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TIMM8A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Free triiodothyronine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HAUS5 gene|HAUS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,LINC01315 gene|LINC01315,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Targeted Therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,DLGAP1-AS2 gene|DLGAP1-AS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chromosomal translocation,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SOX10 gene|SOX10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,lipid mediator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,terminal differentiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UBE2T gene|UBE2T,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Male fertility,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Intraoperative Radiation Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Uptake,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,GHET1 gene|GHET1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PGM5P3-AS1 gene|PGM5P3-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,exenatide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cancer care,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Hereditary Breast and Ovarian Cancer Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Mortality, Premature",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ZNF582-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"Receptor, PAR-1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EBF1 gene|EBF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Recurrent infections,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CENPW gene|CENPW,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GP5 gene|GP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CYP2W1 gene|CYP2W1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Matrix Metalloproteinases,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CDK6 gene|CDK6,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,MFNG gene|MFNG,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Amino Acids, Branched-Chain",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fast Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,asparaginylendopeptidase,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,MCM10 gene|MCM10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SFN protein, human|SFN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CD44,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,tao hong si wu decoction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KDM4A gene|KDM4A,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Asbestos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FOXF2 gene|FOXF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CENPW gene|CENPW,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,somatostatin receptor 1|SSTR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GJA1 gene|GJA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Long Untranslated",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,MELK gene|MELK,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,TIMM8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CASP9 gene|CASP9,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Blood group AB,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Cooking Practices,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mean score,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Phytochemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,PFKFB3 gene|PFKFB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Chemicals,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Chemical
COMPLICATES,Acquired Immunodeficiency Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Acute infectious disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,SLC6A14 gene|SLC6A14,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RPS6KB1 gene|RPS6KB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SULT1A1 gene|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dysbiosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alkaloids,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,medication use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Chemokine CXCL12,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Oral intake,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,AMACR wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,calreticulin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CUEDC2 gene|CUEDC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,NU 7441,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Prognostic Factors,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,Purinoceptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,sorafenib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,trichloroethylene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,estrogens,Advanced breast cancer diagnosis,0.0,Female Breast Cancer,Hormone
AFFECTS,"LATS1 protein, human|LATS1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KIF11 gene|KIF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,nesiritide|NPPB,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,IRS2 gene|IRS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Expression,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEK2 gene|CHEK2,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lymph-vascular invasion,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NR1H3 gene|NR1H3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,isoleucylvaline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"HMGB3 protein, human|HMGB3",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MTNR1B gene|MTNR1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Morbidity - disease rate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"DNA Breaks, Double-Stranded",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Observation - diagnostic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Histone Demethylases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,maintenance of pluripotency,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Female Breast Carcinoma,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
AFFECTS,Tumor Microenvironment,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,MIR382 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hepatocyte Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,SAFB2 gene|SAFB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,trichostatin A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,MicroRNA 367-3p,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Flash,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Substance P Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,Autophagy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,sauchinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vascular Endothelial Growth Factors|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,PARP9 gene|PARP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sentinel node (disorder),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"interleukin-1, beta",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Prolactin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cancer/Testis Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,DDX3X gene|DDX3X,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
DISRUPTS,parecoxib sodium,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,PTPN13 gene|PTPN13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vigorous physical activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biomodulin T,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,KAT7 gene|KAT7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vigorous physical activity,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Ocular Cicatricial Pemphigoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"RNA, Circular",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,IMPACT gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IGF2BP1 gene|IGF2BP1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,Chalcone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Degenerative polyarthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PRMT2 gene|PRMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PCAT19 gene|PCAT19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genes,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,SFXN1 gene|SFXN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,glycyrrhetinic acid,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Chemical
AFFECTS,TWIST1 gene|TWIST1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Psychosocial procedure,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,SFXN2 gene|SFXN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proliferation (morphologic abnormality),HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,hydrochloride,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Reproductive tract infection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Apolipoprotein A-I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neoadjuvant Systemic Therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SOX9 gene|SOX9,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Anthropometric Measures:-:Point in time:^Patient:-,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ETV7 gene|ETV7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"FRAP1 protein, human|MTOR",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,New Target Lesion Identification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,sirolimus,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,SMIM10L2A gene|SMIM10L2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Premenstrual Tension,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,"CDK7 protein, human|CDK7",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC02568 gene|LINC02568,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,morusin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Invasive carcinoma of breast,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
DISRUPTS,quinacrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,polyphenols,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Challenge:Type:Point in time:^Patient:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Emodin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,KCNQ1OT1 gene|KCNQ1OT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Angiotensin II receptor antagonist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,propofol,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,ERBB2 gene|ERBB2,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cardiac dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SNHG11 gene|SNHG11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Mental disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,SLC7A11 gene|SLC7A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tn antigen,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Immunologic Factor
AFFECTS,TIPARP gene|TIPARP,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,pirarubicin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,"TNK2 protein, human|TNK2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,Lymph Node Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,glycosylation,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,beta-Glucans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,rebastinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Indicators,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,MIR182 gene|MIR182,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,receptor for advanced glycation endproducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ATP2C1 gene|ATP2C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,malignant disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,zoledronate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Hypofractionated radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,berberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FOXA1 gene|FOXA1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Synapsin I,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,interleukin-8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,postmenopausal syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,thymidine kinase 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SIGLEC15 gene|SIGLEC15,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,formononetin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,MIDEAS gene|ELMSAN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Amino Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,OTUB1 gene|OTUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,leptin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,High Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Dried fruit intake,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
CAUSES,VEGFA gene|VEGFA,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,LAYN gene|LAYN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PIK3CB gene|PIK3CB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Raw vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,RHOT1 gene|RHOT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inflammatory Response,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,STAT3 gene|STAT3,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,polyphyllin II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SB 203580,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,hydnocarpin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,UHRF1 gene|UHRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAXX gene|PAXX,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Decreasing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,venetoclax,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,doxorubicin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Consideration,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ANXA9 gene|ANXA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SF3B1 gene|SF3B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chest asymmetry,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Positive Regulation of Oxidative Stress Process,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CERS4 gene|CERS4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"MMP11 protein, human|MMP11",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"MAP3K8 protein, human|MAP3K8",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Androgens,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
CAUSES,takinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Squalene monooxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,RIN2 gene|RIN2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,G protein-coupled receptor kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Proteome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABCB1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,"Diet, Western",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,INSM1 gene|INSM1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"PTGS2 protein, human|PTGS2",Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,AZGP1 gene|AZGP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,directive therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CIB1 gene|CIB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Carney Complex,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,NCBP1 gene|NCBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NEU1 gene|NEU1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,factor XIII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ELAVL2 gene|ELAVL2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Breast-Conserving Surgery,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,momordicoside K,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Soybeans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,APOBEC3A gene|APOBEC3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ROS1 gene|ROS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORD49B gene|SNORD49B,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,ezrin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Details of education,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MYC gene|MYC,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SIPA1 gene|SIPA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"ORF74 protein, Human herpesvirus 8",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RBM24 gene|RBM24,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXO3 gene|FOXO3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,NT5DC2 gene|NT5DC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CERNA2 gene|CERNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PTPRG-AS1 gene|PTPRG-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Androgen Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmaceutical Preparations,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SF3A2 gene|SF3A2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,SLC7A11 gene|SLC7A11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDK1 gene|PDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Reproductive History,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Lipidome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,BAIAP2L1 gene|BAIAP2L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cell Cycle Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Endocrine System Diseases,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,Viscosity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hormone Receptor,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Hormone
DISRUPTS,NUDT1 gene|NUDT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CONOTRUNCAL ANOMALY FACE SYNDROME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Corticotropin-Releasing Hormone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,receptor for advanced glycation endproducts,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Intravascular Metastasis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,MAPK8 gene|MAPK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PDZK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,tibolone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CXCL12 gene|CXCL12,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,ATF3 gene|ATF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Soy Milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TRPM7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neuregulin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BCL-2 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TRAF4 gene|TRAF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast cancer metastatic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Estrogen Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Chronic inflammation,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,EPHA10 gene|EPHA10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,STAT3 gene|STAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GSTO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"FRAP1 protein, human|MTOR",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CYP2B6 protein, human|CYP2B6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LECT2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
DISRUPTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Transferase Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA repair protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,p-hydroxycinnamaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,maspin|SERPINB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,arginylarginine|ABL2|RERE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Biosensors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NCOA1 gene|NCOA1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
CAUSES,SRC gene|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of lung,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,ARF6,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,arsenite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,catalpol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TRANCE protein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,pigment epithelium-derived factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,AMOT gene|AMOT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Health behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,3' Untranslated Regions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Estrogen Receptor beta|EREG|ESR1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CYP2C19 gene|CYP2C19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NFKB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GIT1 gene|GIT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Angiotensin II Type 1 Receptor Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogens,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hormone
DISRUPTS,LIN28A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,25-hydroxyvitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Diet good,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,mdm2 protein|MDM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,BMP4|BMP4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Signal Pathways,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,deferiprone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Medroxyprogesterone 17-Acetate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Detection,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Carcinogens, Environmental",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,Genistein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,3/4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FOXP2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Smoking,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,WWTR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast Microcalcification,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Tungsten,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Botanicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HNRPM gene|HNRNPM,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,RAB22A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,PARP1 gene|PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,docetaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,BIRC7 gene|BIRC7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BCL2L11 gene|BCL2L11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Squamous cell carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Heme,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,fraxetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Seafood,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,Animal fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Molecular Chaperones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,lard,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MicroRNAs,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Genes, Suppressor",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Intercellular adhesion molecule 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Colorectal Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,S100 Proteins|S100A1|S100B,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BRCA3 gene|BRCA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,S100A8 gene|S100A8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pteridines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Finding of antibody titer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,Hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Evolution,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PCSK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Reserpine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Interleukin-6,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,MIRN10B gene|MIR10B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,CTSL gene|CTSL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant Neoplasms,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,ERBB4 gene|ERBB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Positive Test Result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Selective Estrogen Receptor Modulators,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Serum Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Genome,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Detection,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nitric Oxide,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Aromatase Inhibitors,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,Study models,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Prostate-Specific Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,FABP7|MAS1L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Retinoblastoma Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,leukemia inhibitory factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phytochemical,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Lactoylglutathione Lyase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BRCA2 gene|BRCA2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
DISRUPTS,Flap Endonuclease-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Gastrointestinal Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,TNFSF11 gene|TNFSF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,E-Cadherin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,thymalfasin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Progestogen only oral contraceptive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vegetables,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Technetium Tc 99m Sestamibi,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Potato,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Deletion Mutation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Integrin beta3|EEF1B2P2|BHLHE22,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,NLRP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gynecomastia,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Fluorouracil,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mammary Neoplasms,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Chemopreventive Agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,Arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Blind Vision,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,family background,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antispasmodics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Chromosome 11 Short Arm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Caffeine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Hydralazine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Skin problem,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,N-Acetylneuraminic Acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,cell motility,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Intraductal Hyperplasia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Fibroadenoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Malignant Neoplasms,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Milk Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Ductal Carcinoma,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Buserelin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ASK Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Carcinoma,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
CAUSES,benzanthracene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CHEST PATHOLOGY,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Thiotepa,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Milk, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibronectins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CEACAM5 gene|CEACAM5,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,HPR gene|HPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mitoxantrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Polyomavirus Middle T Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AFFECTS,trastuzumab,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,Peanut Agglutinin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,PREMARIN USE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"VEGF protein, human|VEGFA",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Androsterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,limonene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,erbB-2 Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Histologic type,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Angiostatins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,sex hormone-binding globulin receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Leucine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Indicators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
CAUSES,Tumor Suppressor Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PBP gene|DOCK3|PEBP1|PKD1|MED1|PPBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,rac-PK beta|AKT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Immunoconjugates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NME2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Glycoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,National origin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Candidate Disease Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Antigens,Breast cancer stage II,0.0,Female Breast Cancer,Immunologic Factor
AFFECTS,Fetal Growth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,tumor growth,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,alpha-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Protease Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
AUGMENTS,formestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Equine laminitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Protease Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Cell Cycle Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CD4 gene|CD4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,CA-15-3 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,HSPB8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Growth Factor Receptors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Androgens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Endometrial Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Telomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,perlecan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Amphiregulin|AREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cyclin D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Study models,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Vascular Endothelial Growth Factor Receptor-2|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,riboflavin-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Progesterone increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Interleukin-18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Brain Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Micronutrients,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Detection,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,c-myc Proto-Oncogenes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Therapy responder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiogenesis Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Epithelial-Stromal Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Immunization,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Hydrocarbons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NF-kappa B,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Punctate inner choroidopathy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,resveratrol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,17q23,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Preventive Services - Orthodontics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,sphingosine kinase-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Endopeptidases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Environmental Pollutants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EPSTI1 gene|EPSTI1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Brain hemorrhage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Molecular Pathology,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Thrombus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,response,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,AKT2 gene|AKT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Transgenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Protein Kinase C|PRRT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Serpins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Endocrine therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Uterine activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Transcript,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,fulvestrant,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"CBFB protein, human|CBFB|NFYA|NFYB",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MSN gene|MSN,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Human Chorionic Gonadotropin|CGA|HTC2|CGB5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Colony-Stimulating Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,VEGF gene|VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,BARD1 gene|BARD1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Renal tubular disorder,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Dinucleotide Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Isothiocyanates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,GADD45A gene|GADD45A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TSG101 gene|TSG101,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fanconi's Anemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,progesterone analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,Mouse mammary tumor virus infection,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Abnormal digestive tract function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LRRC15,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Angiotensinogen|AGT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
COMPLICATES,Poland Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,STK11 gene|STK11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BIN1 gene|BIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,4-nonylphenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,P-Selectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CLSPN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Doxazosin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LZTS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dopamine Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AFFECTS,IL6ST gene|IL6ST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cell Adhesion Molecules,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Fibrinogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,adduct,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tomography,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Clusterin|CLU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hereditary Malignant Neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CASP8 gene|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Acne,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Wine intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Coumestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Lymphoid neoplasm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Pulmonary toxicity,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,"Xeroderma pigmentosum, group C",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IGFBP1 gene|IGFBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Membrane receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carcinogenicity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,APOE gene|APOE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pulmonary Embolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,5'-AMP-activated protein kinase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Transforming Growth Factor beta Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,E2F4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mucinous Neoplasm,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Paroxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,syndecan 1 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Recombinant Transforming Growth Factor-Beta 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,PSMA5|AP5Z1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,RHOC gene|RHOC,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Body mass index,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,CXCR4 Receptors|CXCR4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Farnesyl Transferase Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Antihypertensive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Ethylene Oxide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,catenin p120(ctn) protein|CTNND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PTN gene|PTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SCTR gene|SCTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Complex Extracts,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Biopsy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Repetitive Region,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NBS1 gene|NBN|NLRP2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IL6R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Stromal Cell-Derived Factor 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SULT1A1|SLC45A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ethylene Oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BEX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,steroid hormone receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,semapimod,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Excretory function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,polyphenols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Hamartoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Serum Folate Level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
DISRUPTS,of 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,Nucleotide Excision Repair,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Plasmin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bone morphogenetic protein 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mammaplasty,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,PES1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Transgenes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,INPPL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dyslipidemias,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,PROTEIN KINASE|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,KL gene|KL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,nucleic acid inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KLLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PIWIL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,chemokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Estrogens,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
PREDISPOSES,CYP3A5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,adjuvant therapy,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
CAUSES,Breast cancer metastatic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Medical care, unspecified",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AUGMENTS,Proto-Oncogene Proteins c-akt,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWIST2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,estrogen receptor gamma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADIPOQ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ZNF703,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Progestins,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,PELP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MAPK8 gene|MAPK8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FGFR2 gene|FGFR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Phosphotransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,P-Glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,sarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Annexin A6|ANXA6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,thymidine kinase 1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Chromosome 10 Short Arm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Protein phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,CD44 gene|CD44,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,CD24,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,butylbenzyl phthalate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Transcription Factor 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MAPK12 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Plasminogen Activator Inhibitor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A2 gene|S100A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,antiangiogenesis therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Monocyte Chemoattractant Protein-1|CCL2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SIX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Heat Shock Protein 27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Dipyridamole,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Transforming Growth Factor Beta 2|NEUROD1|TUBB4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,PARD6A|PWAR6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,TUBB4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,plumbagin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,SIX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,6-bromo-2-naphthyl sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"FRAP1 protein, human|MTOR",Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,beta catenin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,KLF9 gene|KLF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin-Dependent Kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,FOXO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TNFRSF10B gene|TNFRSF10B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,corrigendum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Beta-glucuronidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CLDND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Germ-Line Mutation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dietary Supplements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,plumbagin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SNHG12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Fibroblast Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
CAUSES,Ion Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Metabolic syndrome,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AFFECTS,Evolution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Ceruloplasmin|CP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Promoter Regions (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,interleukin-22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SOX17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pyruvate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cholesterol levels raised,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Lipid
PREDISPOSES,MC1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,Protein C Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Dichlorodiphenyldichloroethane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nicotinamide adenine dinucleotide (NAD),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,NR4A1 gene|NR4A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dexamethasone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TWIST1 gene|TWIST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NUCB2 gene|NUCB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Risk Reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,MSI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Diethylstilbestrol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,IL33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CXCL9 gene|CXCL9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TRPV4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Berries,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Margarine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,GPR116 gene|ADGRF5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Docosahexaenoic Acids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
DISRUPTS,Protein phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Colorectal Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,GIT1 gene|GIT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA Adducts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,chemoprotection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Radiation therapy,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RGS2 gene|RGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ABCB6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NUP155,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,atorvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,kinase inhibitor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Adenomatous Polyposis Coli,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Reactive Oxygen Species,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Glioma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasm progression,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,UBE3A,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,CLDN2 gene|CLDN2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,NUMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,liraglutide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BRMS1 gene|BRMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acute myocardial infarction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mammography finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,radiosensitization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CYP2B6 gene|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,membrane-type 1 matrix metalloproteinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Thiamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PLAT gene|PLAT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptor Status,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TARDBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PIWIL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MMP,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Hyperinsulinism,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,KLF17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SHARPIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DACT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,APBA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Benzoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,CYC1 gene|CYC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Late pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,jatrophone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"ABCG2 protein, human|ABCG2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Thiazolidinediones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CISH,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,PPM1D,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,tumor growth,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,calmodulin-dependent protein kinase II|CAMK2G,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,calmodulin-dependent protein kinase II|CAMK2G,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Oncogenes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,Fibrosing adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BCYRN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FGF2 gene|FGF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KRAS gene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL1 gene|CXCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Amino Acids, Branched-Chain",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ALDH1A3 gene|ALDH1A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prostaglandin-Endoperoxide Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
PREDISPOSES,nucleolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Arachidonic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Vitamin D Analog,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anaphylaxis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ARRDC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MST1R gene|MST1R,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,SENP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BCL2 gene|BCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,grasp,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Endogenous Retroviruses,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
PREDISPOSES,CCR7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,PRLR gene|PRLR|PTP4A3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"ESR1 protein, human|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lasso,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIK3R1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,uptake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Proto-Oncogene Proteins c-jun|JUN,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Collagen Type IV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Recombinant Interferon-gamma|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GGN gene|GGN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADH1C|ADH5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CLOCK gene|CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PARP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ATF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Taxol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Receptors, LH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Liposomes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tobacco use,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,BCAS3 gene|BCAS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,N NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sentinel Lymph Node Biopsy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,wogonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MCM10 gene|MCM10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Glutamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Embryonic Development,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,pentabromodiphenyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aromatase,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Enzyme
AFFECTS,OIP5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Linoleic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,TRANSCRIPTION FACTOR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dietary Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NF-kappa B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Rest,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ARNT2 gene|ARNT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Black tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,lysophosphatidic acid,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,PTK6 gene|PTK6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,response,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,ESR1 gene|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Nuclease Sensitive Element Binding Protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,norethindrone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IQGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNAs,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Oxytocin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Galactosamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A9 gene|S100A9,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIRN205 gene|MIR205,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Homeo Box Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Viral Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Early Diagnosis,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,SNW1 Gene|SNW1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Carcinogens, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,RBX1 gene|RBX1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Apoptosis,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,CEACAM5 gene|CEACAM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Chromosome 15 Short Arm,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Superoxides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIP,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Immunoglobulin Fc Fragments,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Cytostatic Agents,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,vigilin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PTPN13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,FADS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fish Oils,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Vascular Endothelial Growth Factor Receptor-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Atypical hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Heat-Shock Proteins 70|HSPA4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,stromelysin 3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Carrier of disorder,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
AFFECTS,FMO5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Endostatins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Loss of Heterozygosity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Optimistic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adrenergic Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Ions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Mammary Carcinoma, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Serine Proteinase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Tumor Necrosis Factor Ligand Superfamily Member 6|FAS,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Atypical proliferation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,SULT1A1|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,C-Peptide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Lecithin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BONE MASS,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CAMP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Freund's Adjuvant,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,PTGS2 gene|PTGS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Low Birth Weights,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,letrozole,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,Rh Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Total cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SSM,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"Contraceptives, Oral",bilateral breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,Contraceptive methods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Multivitamin preparation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR519D,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Puberty stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ERCC5 gene|ERCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Butter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Non-infiltrating lobular carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Heat-Shock Proteins 70|HSPA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Vegetable Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Speaking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Weakly positive,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,adjuvant therapy,Breast cancer stage II,0.0,Female Breast Cancer,Other
PREDISPOSES,Growth Factor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Breast Fibrocystic Change, Proliferative Type",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Transcription, Genetic",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,poor health,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,nimesulide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Eicosapentaenoic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Flavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Magnetic Resonance Imaging,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Adrenal Cortex Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Short Tandem Repeat Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Long chain fatty acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
PREDISPOSES,ADRB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Magnetic Resonance Spectroscopy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Biopsy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Specific antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,GPR30 gene|GPER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ill-at-ease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Detection,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,pterostilbene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PKP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ethanol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Contralateral breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,GDI2 gene|GDI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cadherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Osteogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Klinefelter's Syndrome,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
AUGMENTS,Acetaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ezrin|EZR,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,LIG4 gene|LIG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Silence,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Hypertension induced by pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,APOB gene|APOB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Asleep,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obesity,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Interleukin-17,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,LPCAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Neoplasm progression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CALML3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ODAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MRE11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RPS6KB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Macrophage Chemotactic Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cytokine,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Biologically Active Substance
PREDISPOSES,Vitamin B12 intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,butein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,heparanase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,estrone sulfate,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,atovaquone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CYP24A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemokine (C-X-C Motif) Ligand 1|CXCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estradiol,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
DISRUPTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Computed Tomographic Colonography,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,VASOMOTOR SYMPTOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,osteopontin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,cadherin 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Steroid hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,aldehyde dehydrogenase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Connexin 43,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fruit intake,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
DISRUPTS,Interleukin-12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,biological_process,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,ADAM29,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TYRP1 gene|TYRP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estradiol + norethindrone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GAL3ST1|SLC35A1|CASZ1|CST12P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogen Receptor alpha,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HORMONE REPLACEMENT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Chemotherapy-Oncologic Procedure,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,EMSY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Atypical hyperplasia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Dinoprost,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Chemotherapy, Adjuvant",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Insulin Resistance,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Cytokeratin 18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,Residual Cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Interstitial Collagenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nickel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Breast Feeding,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
CAUSES,BCCIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHI3L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Antigens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Immunologic Factor
AFFECTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Chemical Viewed Functionally
AFFECTS,Somatostatin analog|SST,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Interferon Type II|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Mixed Function Oxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IL1RN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin D1|CCND1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Breast Fibrocystic Change, Proliferative Type",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,S100A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,sake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Protein Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MDM4 gene|MDM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cadmium,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Inorganic Chemical
PREDISPOSES,Xq25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,XRCC5 gene|XRCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,transduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Infectious Mononucleosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Oils,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EGFL7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PROM1,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,DCSTAMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,gefitinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GLIS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,trastuzumab,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,AXILLARY LYMPH NODE METASTASIS,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
PREDISPOSES,Sleep Apnea Syndromes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,regional differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,perfluorooctane sulfonate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Isoenzymes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Riboflavin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HP gene|HP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Breast cancer invasive NOS,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AFFECTS,Second Primary Cancers,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Alcoholic Beverages,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Infant feeding method NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Weight Gain,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,DMD|BEST1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Localized Malignant Neoplasm,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AFFECTS,Wine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Physical function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,Metaplasia,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Aldehydes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Biopsy,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Estradiol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,snail transcription factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,phenethyl isothiocyanate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Black tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Performance,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,oridonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,claudin 1 protein,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Alleles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,volatile substances,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Substance
PREDISPOSES,Poultry Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mammography,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Diabetes, Gestational",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cognitive Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,high-dose chemotherapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Oxytocin Receptor|OXTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,S100A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Does hit,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Fine needle aspiration biopsy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Large Neutral Amino Acid-Transporter 1|SLC7A5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Iodine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Monomeric GTP-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,APEX1 gene|APEX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Primary disease,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
AUGMENTS,pigment epithelium-derived factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Phyllodes Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Diphosphonates,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,SOSTDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"EZH2 protein, human|EZH2",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Blood Coagulation Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Catechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Night sweats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Seeks information,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Neoplastic Process
DISRUPTS,Flavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adverse event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,hydroxytyrosol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,REXO1|ZFP42,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,FOLR1 gene|FOLR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Night Nurse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IL8RB gene|CXCR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NEK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Female,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Inflammation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Body Weight decreased,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Aminolevulinic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Cerebrovascular accident,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Powerlessness, low",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diffusion Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Hypoglycemic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,"Echocardiography, Three-Dimensional",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pregnancy,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,Atypical lobular hyperplasia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Endothelin Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHEK2 gene|CHEK2,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Polymerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic breast density,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,ESTROGEN+PROGESTERONE RECEPTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,Lasofoxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hormones,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
AFFECTS,Mammography,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Alkylating Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Prevention,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,breast implant procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biomedical or Dental Material
PREDISPOSES,Analgesics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adenosine Triphosphate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Anti-Anxiety Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,Mitoxantrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNA,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,PVT1 gene|PVT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Solid tumor,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,protopanaxadiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CDCA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SDCBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTPN1 gene|PTPN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,no positive axillary nodes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gout,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sugar candy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Tyrosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Acetaminophen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TRIM33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC50A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FUT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LINC01638,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PIMREG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Interleukin-17,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,strictinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,phenyl ether,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Plasma glucose result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
PREDISPOSES,advanced disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Atypical proliferation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SLC50A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ezrin|EZR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,beta catenin|CTNNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Coal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RNF115,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,S100B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SP1 gene|SP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,activated RNA polymerase II transcription cofactor 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Progesterone Receptor Status,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,HCP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,nitric oxide receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RUSC1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anticholesteremic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,TSC1 gene|TSC1|CCL26,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Materials,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Substance
CAUSES,Pharmaceutical Preparations,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"CHEK2 protein, human|CHEK2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Juvenile carcinoma of the breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Disease recurrence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,TFF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,HOTAIR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Collagen Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCB 180,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gold,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNA Excision Repair Protein ERCC-5|ERCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,XBP1 gene|XBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Burden,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Energy Balance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor Immunity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,ERBB2 gene|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,HIF1alpha protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HAX1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,LARP4 gene|LARP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, circular",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,angiotensin II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,cedrelone,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Flavones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Catechol O-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Phototherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SMAD4 gene|SMAD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant Neoplasms,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
AFFECTS,Neoadjuvant Therapy,Breast cancer stage III,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,LOXL1-AS1 gene|LOXL1-AS1,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,"2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,punicalagin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PAK4 gene|PAK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAM83H-AS1 gene|FAM83H-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,folic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Late menarche,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,STARD8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Cream,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Protein Isoforms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,chalcomoracin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"PTGS2 protein, human|PTGS2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Phosphoglycerate dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genome,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Hexokinase 2|HK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,insulin detemir,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"PKN1 protein, human|PKN1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ELF5 gene|ELF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Mutant Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,apolipoprotein D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Prophylactic treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TRANSCRIPTION FACTOR,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Fibromyalgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KISS1R gene|KISS1R,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,compromise,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Sentinel node (disorder),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"Sleep Apnea, Obstructive",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chlorpyrifos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CCL5,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,CTCb regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Phosphoric Monoester Hydrolases,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,aluminum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SLCO6A1|GSTK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insoluble fiber (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,Carbon Ion Radiotherapy,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,H19 gene|H19|HILS1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,risk factors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Prolactin Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,BCL11A gene|BCL11A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,PPFIA1 gene|PPFIA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Polybrominated Biphenyls,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PPFIA1 gene|PPFIA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PARP1 gene|PARP1,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,SOX9 gene|SOX9,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Primary care provider:Identifier:Point in time:Provider:Nominal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,limited use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Polycystic Ovary Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,RNF111 gene|RNF111,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,steroid receptor coactivator AIB1|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,betaine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,risk factors,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,Multiparametric Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,new information,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Pharmacotherapy,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,Lyophilized powder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Blood Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,S-adenosylmethionine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Malignant Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Polypeptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MNX1-AS1 gene|MNX1-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,removal technique,Stage IV Inflammatory Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,N-Myc Downstream Regulated Protein 1|NDRG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Dicarboxylic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,glycerin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ENC1 gene|ENC1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,acetylcysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NORAD gene|NORAD,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Mammary Tumorigenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Markers,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,CXCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Genes,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CA10 gene|CA10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NME1 gene|NME1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,MIR326 gene|MIR326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Interferons,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,"Scoliosis, unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PART1 gene|PART1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,erbB-2 Receptor|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,MIR451A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,YTHDF3 gene|YTHDF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacotherapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,leptin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,S100A14 gene|S100A14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Biopolymers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TMPRSS13 gene|TMPRSS13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,nervous system disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TRIO gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSD17B4 gene|HSD17B4,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoma of Male Breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Luteolin,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,"CCND2 protein, human|CCND2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Piperlongumine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,thidiazuron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,methylate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoplasms by Site,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Behaviorial Habits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,UBR1 gene|UBR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCR5 gene|CCR5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptor Tyrosine-Protein Kinase ErbB-4, human|ERBB4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CAVIN3 gene|CAVIN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,epithelial to mesenchymal transition,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,mitoxantrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"TFF1 protein, human|TFF1",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Neoplasm Metastasis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Neoplastic Process
DISRUPTS,Polysaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,estrogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
AUGMENTS,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Transforming Growth Factor beta,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Biologically Active Substance
COMPLICATES,contralateral breast cancer,Right-Sided Breast Neoplasms,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Systemic Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,PRMT5 gene|PRMT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNA replication checkpoint,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fermented Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,NF2 gene|NF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PLEKHA7 gene|PLEKHA7,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Ultraviolet B radiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,B3GNT2|B3GNTL1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,STRN3 gene|STRN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Transcription factor genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ZMYND8 gene|ZMYND8,Refractory Breast Carcinoma,0.0,Other,Gene or Genome
AUGMENTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SOX6 gene|SOX6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RSPO2 gene|RSPO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PEBP1 gene|PEBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Thymidylate Synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Screening mammography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
PREDISPOSES,RARRES2 gene|RARRES2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,EIF4A1 gene|EIF4A1,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,CA13 gene|CA13,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Mouse Model,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Adverse event,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,FOXK1 gene|FOXK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NUP43 gene|NUP43,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MYCN gene|MYCN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,tamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,sanguinarine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HNRNPK gene|HNRNPK,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,ERRFI1 gene|ERRFI1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,STUB1 gene|STUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,S100A7 gene|S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Clinical Significance,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Breast size,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Elevated C-reactive protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Triple Negative Breast Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BTNL9 gene|BTNL9,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,CDC25C gene|CDC25C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Profilin 2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,HMGB1 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Performance,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Other
DISRUPTS,PDCD4 gene|PDCD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,dendrophenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MDM2 gene|MDM2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hydrogel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,"Receptors, Opioid, kappa",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ZNF132 gene|ZNF132,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Pathogenic Variant,"Breast Cancer, Familial",0.0,Female Breast Cancer,Virus
PREDISPOSES,Physical stress,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NRBP2 gene|NRBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCAT1 gene|PCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disease,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Disease or Syndrome
AFFECTS,metoclopramide,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Borg Category-Ratio 10 Perceived Exertion Score 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,TPT1-AS1 gene|TPT1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KIAA1755 gene|KIAA1755,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00467 gene|LINC00467,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormone Therapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
CAUSES,Homeobox Protein ARX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,tripterine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,NORAD gene|NORAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HAGLR gene|HAGLR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proto-Oncogene Proteins c-sis|PDGFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Checkpoints,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inhibitor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Reaching,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,nucleoside diphosphate kinase A|NME1,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,Antibodies,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Cytochrome P-450 CYP1A1|CYP19A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LINC00894 gene|LINC00894,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR373 gene|MIR373,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Monoclonal Antibodies,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,BABAM2-AS1 gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,"Migration, Cell",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,melatonin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,docetaxel,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,CXCL13 gene|CXCL13,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cigarette smoke (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
CAUSES,Oncogene Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,nucleolin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,"Benzimidazole derivatives, antinematodal",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,OVOL1 gene|OVOL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factor beta,Carcinoma breast stage IV,0.0,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Matrix Metalloproteinase 3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Moderate risk,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,PTPN11 gene|PTPN11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,DPP9 gene|DPP9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,STAU2 gene|STAU2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,peroxiredoxin I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,OMA1 gene|OMA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IL17RB gene|IL17RB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Extraction,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Protein-Lysine 6-Oxidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hypermethylation,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RABIF gene|RABIF,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,calreticulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,piperine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cultured Milk Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,NEIL2 gene|NEIL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Hesperidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,AKR1C1 gene|AKR1C1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01094 gene|LINC01094,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Copy Number Polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Matrix,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,cannabinoid receptor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
CAUSES,CASQ2 gene|CASQ2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Pharmaceutical Preparations,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,LRP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Platinum Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Very rare,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Raw Foods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TUBA1C gene|TUBA1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,LINC02381 gene|LINC02381,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LGALS3BP,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SH3BGRL gene|SH3BGRL,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,RGMA gene|RGMA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SARS-CoV-2 P.1 variant,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,SEMA6D gene|SEMA6D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,HSPA5 gene|HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mucin-1 Antigen,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Immunologic Factor
PREDISPOSES,BARD1 gene|BARD1,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,NDRG2 gene|NDRG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXP3 gene|FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell secretion,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Inhibitor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,oleuropein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HSPA5 gene|HSPA5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Pharmacotherapy,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,erbB-2 Receptor|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Histological type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BACH1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,monooxyethylene trimethylolpropane tristearate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LPAR6 gene|LPAR6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,interferon type II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PELI1 gene|PELI1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,KPNA2 gene|KPNA2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZMIZ2 gene|ZMIZ2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,UBA6-AS1 gene|UBA6-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,calcitriol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nutritional status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MALAT1 gene|MALAT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,tanshinone,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
DISRUPTS,anhydroicaritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,interleukin-10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 6|IGFBP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Agonist,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,kinase targeted therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cancer-Predisposing Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ANKDD1A gene|ANKDD1A,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,Inhibitor,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,BNIP3 gene|BNIP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Candidate Disease Gene,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,HCAR1 gene|HCAR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MED1 gene|MED1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Environmental Estrogen,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
CAUSES,PROX1 gene|PROX1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,Histone deacetylase inhibitor,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Other
AUGMENTS,perilipin 2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,estradiol high,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Stat3 protein,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Immune Checkpoint Inhibitors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,ZFR gene|ZFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DNMT1 gene|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RUNX2 gene|RUNX2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Signal Transduction,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,dinaciclib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HSPBP1 gene|HSPBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MAP Kinase Kinase 5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mouse Model,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,MSH2 gene|MSH2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,First relationship,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CDK1 gene|CDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,tumor suppressor activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Acute Promyelocytic Leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,B3GNT5 gene|B3GNT5,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Incomplete penetrance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,pioglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,quercetin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,Tumor Suppressor Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LINC00662 gene|LINC00662,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,KIF4A gene|KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Inflammation Mediators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Hypothalamic inhibiting factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,aucubin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Citrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cyclin D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC01234 gene|LINC01234,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Copy Number Polymorphism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Therapeutic immunosuppression,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,polyethylene glycols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Ryanodine Receptor 2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,RAD51D gene|RAD51D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ALYREF gene|ALYREF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Measurement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,perfluorononanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"POSTN protein, human|POSTN",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RAD51B gene|RAD51B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PNO1 gene|PNO1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Oncogenes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,PIK3R1 gene|PIK3R1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,OTUD6A gene|OTUD6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CXCL14 gene|CXCL14,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,CDKN2A gene|CDKN2A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Immunoregulation,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Complement System Proteins,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Negative,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Large Neutral Amino Acid-Transporter 1|SLC7A5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,plumbagin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Serum autoantibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
AUGMENTS,LINC00520 gene|LINC00520,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,TPD52L2 gene|TPD52L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Glucosephosphate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ATP6AP1 gene|ATP6AP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR1294 gene|MIR1294,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Psychosocial Intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SLC31A1 gene|SLC31A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RNase P,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,TGFB2-AS1 gene|TGFB2-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,inhibitor-of-apoptosis protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MYCL gene|MYCL,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,erbB-2 Receptor|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hypoxia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,DIO3OS gene|DIO3OS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,centromere protein F,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,N4BP3 gene|N4BP3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOD2 gene|SOD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF667-AS1 gene|ZNF667-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Free Energy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inhibitor,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,Parafibromin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RECQL5 gene|RECQL5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RBCK1 gene|RBCK1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Fatty Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,MIR506 gene|MIR506,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZSWIM1 gene|ZSWIM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vascular Endothelial Growth Factors|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AUGMENTS,MIR21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PALB2 gene|PALB2,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genes,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,MCF2L-AS1 gene|MCF2L-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Low Dose Radiation Therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"pregna-4,17-diene-3,16-dione, (17Z)-isomer",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Osteoporosis,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
CAUSES,Histone deacetylase inhibitor|HDAC9,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,NR1H3 gene|NR1H3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Inflammation,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Aryl Hydrocarbon Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ALDH2 gene|ALDH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cytotoxic T-lymphocyte antigen 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Genes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCSK1 gene|PCSK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Drug Repositioning,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Pharmacologic Substance
AFFECTS,YBX1 gene|YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Plasmids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LINC00536 gene|LINC00536,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HNF1A gene|HNF1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,CALML5 gene|CALML5,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOY ISOFLAVONES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Vimentin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RBCK1 gene|RBCK1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,MYO6 gene|MYO6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Metric (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
PREDISPOSES,Clusterin,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Hydroxymethylglutaryl-CoA reductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TLE5 gene|AES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Light Exercise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Drinker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CREB1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,bufalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Alanine Aminotransferase 1, human",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,cytidylyl-3'-5'-guanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Snacks,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HAR1A gene|HAR1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TMED3 gene|TMED3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Anaplastic carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,NUMB gene|NUMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,internal risk factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Fasting blood sugar result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,CENPL gene|CENPL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BRCA2 gene|BRCA2,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,First line treatment,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Long Intergenic Non-Protein Coding RNA,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,glabridin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Toothache,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PCAT19 gene|PCAT19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Food antioxidant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,oleanolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Increased risk,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,EIF4A3 gene|EIF4A3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Antibody-Drug Conjugates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,SOD1 gene|SOD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"ANGPT1 protein, human|ANGPT1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Resistance Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,caveolin 1,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
CAUSES,CYP1B1 gene|CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Global Longitudinal Strain,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoadjuvant Chemotherapy,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Degenerative polyarthritis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Coherent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Matrix Metalloproteinase 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,GPR141 gene|GPR141,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HFM1 gene|HFM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,tamoxifen,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
AFFECTS,LGALS3 gene|LGALS3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Chemotherapy,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,Physiologic calcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZSCAN18 gene|ZSCAN18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NNAT gene|NNAT,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Radioimmunotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Patient age,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,CREBZF gene|CREBZF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,OTUD1 gene|OTUD1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,HMMR gene|HMMR,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Natural Products,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,dihydroartemisinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RNA Sequence,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Nucleotide Sequence
AFFECTS,Luteolin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Severe (severity modifier),Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,BCKDK gene|BCKDK,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Noninfiltrating Intraductal Carcinoma,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Anesthetics, Inhalation",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Tumor Antigens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
DISRUPTS,disulfiram,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Caffeic Acid Phenethyl Ester,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Immune Tolerance,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Menstrual status:Type:Point in time:^Patient:Nominal:Stated,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MicroRNAs,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Neoadjuvant Chemotherapy,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,INSM1 gene|INSM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FUNDC2 gene|FUNDC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Parafibromin|CDC73,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ubiquitin-protein ligase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,euphorbia factor L1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Mammary Neoplasms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,NOX4 gene|NOX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Stereotactic Body Radiation Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,NT5E gene|NT5E,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,FOXQ1 gene|FOXQ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2 Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLRB1 gene|KLRB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Micelles,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
CAUSES,MAPK1 gene|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,platinum,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,CD160,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Polygenic Traits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transfer RNA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,e protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Basis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,graphdiyne,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Collagen Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,DNAJA1 gene|DNAJA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SMAD4 gene|SMAD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Obesity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Biological Response Modifiers,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Hippo Signaling Pathway,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,beta sitosterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LRRC37A2 gene|LRRC37A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FZD8 gene|FZD8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF148,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Possible,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Other
DISRUPTS,quercetin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Tumor Microenvironment,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,VASP gene|VASP,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Responsive Disease,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Clinical Significance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nail-Patella Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,CREB3L1 gene|CREB3L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DHP107,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PSME3 gene|PSME3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MDH2 gene|MDH2,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,FZR1 wt Allele|CDH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PFKP gene|PFKP,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,RNF185 gene|RNF185,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Microenvironment,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,interleukin-1 alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RNA I,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Cheese intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Genes,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oncogene Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,PARD3 gene|PARD3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP4 gene|USP4,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,STING1 gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Origin of Life,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tyrosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,mitogen-activated protein kinase p38,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SLC38A3 gene|SLC38A3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,METTL7A gene|METTL7A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TNF protein, human|TNF",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ASAH2 gene|ASAH2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DCTD gene|DCTD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malate dehydrogenase (decarboxylating),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,AICARDI-GOUTIERES SYNDROME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,dasatinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,DNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
AFFECTS,Immunogenic Cell Death,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Carboplatin/Etoposide/Melphalan Regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Genes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ST14 gene|ST14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RENBP gene|RENBP,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cigarette smoke (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,NAT10 gene|NAT10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pubertal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hypoxia,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,SNORD16 gene|SNORD16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ARID1A gene|ARID1A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,NUDCD1 gene|NUDCD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PKD2 gene|PKD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,phosphatidylethanolamines,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Body composition measure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplastic Cell Transformation,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
AUGMENTS,ZMIZ1 gene|ZMIZ1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Emotional hypersensitivity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Withanolides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,HER2-positive carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,KDM1A gene|KDM1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Triterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,nervous system disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,PRMT6 gene|PRMT6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,YY1 gene|YY1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIRN181A gene|MIR181A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Huntington Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,cyanidin 3-O-glucoside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Rare Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,equol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,OGG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypoxia-Inducible Factor 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Ultrasonography,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,DYRK2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Mitomycin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Leukotrienes,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Eicosanoid
AUGMENTS,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,miltefosine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Heparitin Sulfate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 gene|BRCA1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Ovulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Neoplasm Metastasis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,PSD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gamma synuclein|SNCG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCAAT-Enhancer-Binding Protein-beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,camalexin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ESR1 gene|ESR1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,CUL3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Streams,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TOX3,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,FLT1 gene|FLT1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Annexin A2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,ORAI3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,fluvastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,KDM6B,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,"CRK protein, human|CRK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Progestational Hormones, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,CCR5 gene|CCR5,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,HOXD10 gene|HOXD10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRPV6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,bexarotene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RAC-Alpha Serine/Threonine Kinase|AKT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,dihydroceramide desaturase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CIP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Creatinine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Stearates,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KLF8 gene|KLF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Supplementation,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,methylcobalamin-coenzyme M methyltransferase|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Ubiquitin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Protein Family,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Chemical Viewed Functionally
AFFECTS,Angiotensin II Type 1 Receptor Blockers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MYC Family Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RBBP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Beverages,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HSP90 Heat-Shock Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fat graft,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,mitogen-activated protein kinase p38|CRK|MAPK14|MAPK1|AIMP2|GRAP2|AHSA1|POLDIP2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Ki antigen|PSME3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Hormone Receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Benzimidazoles,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IRAK4 gene|IRAK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Heart Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,lysophosphatidylethanolamine,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Does hit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,cDNA Library,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Flavonoids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,osteoblast cadherin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,HOXD@,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,TFF3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Lovastatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EPHB2|MAPK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GTF2H1|SQSTM1|KHDRBS1|NUP62|DCTN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AXILLARY LYMPH NODE METASTASIS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,APOA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,genistin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GRPR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TRIM62,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,tau Proteins|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"NAT1 protein, human|NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,tipifarnib,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,low protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,C-KIT Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Autophagy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,LRIG1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,erlotinib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dimethyl sulfone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"TRIP10 protein, human|TRIP10",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SRD5A2 gene|SRD5A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Acetate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Tumor Markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,XRCC2 gene|XRCC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Thrombospondin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCNA2 gene|CCNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,icaritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MDC1 gene|MDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gene polymorphism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biopsy finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TWIST1 gene|TWIST1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"NOS3 protein, human|NOS3",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GFRA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,dehydroepiandrosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,formononetin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,8q22,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Effective communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Phospholipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Ataxia Telangiectasia,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,Common Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,DNA,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Stress,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,peptide hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,retinyl methyl ether,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,PROTEIN KINASE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Negative Finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aneuploidy,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,"technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Ethinyl Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DNA Sequence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Nucleotide Sequence
DISRUPTS,"SOD2 protein, human|SOD2",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,E-Selectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Neoplasm Metastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Exogenous hormones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,"Fruit, Citrus",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ETV4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LMO7 gene|LMO7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Antigens,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Immunologic Factor
AUGMENTS,Plasminogen Activator Inhibitor 1|SERPINE1|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,peptide hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Glutaminase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cheese,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Androgenic precursors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TP53 gene|TP53,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,HOXA1 gene|HOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,dihydroxy-vitamin D3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Food
CAUSES,Virus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
CAUSES,spasmolytic polypeptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Aminoglutethimide,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Monoclonal Antibodies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,3-hydroxytamoxifen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Relate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Histological finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Steroid Use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Steroid
PREDISPOSES,Low-Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ESTROGEN USE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Prednisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Caffeine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic Abortion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"Fatty Acids, Nonesterified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Augmentation mammoplasty,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Malignant neoplasm of breast,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AFFECTS,MICE gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Smoking History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sialyltransferases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CATHEPSIN D|CTSD,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Monoclonal Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Genes, vpr",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genome, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,mucinous carcinoma-associated antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Polymerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Dietary Fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Insulin Receptor|INSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Non-smoker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mixed Function Oxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PCAF gene|KAT2B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,CCND1 gene|CCND1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Fluphenazine Hydrochloride,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SHBG gene|SHBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Lymphoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NODULAR DENSITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinoembryonic Antigen,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Immunologic Factor
AFFECTS,Ionizing radiation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Serine Protease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
CAUSES,SH Protease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Enzyme
CAUSES,Breast cancer recurrent,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,3-hydroxytamoxifen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
CAUSES,Study models,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,Glucagon,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Insulin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Secondary malignant neoplasm of liver,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Autologous bone marrow transplant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,cytokine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,Histocompatibility Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
AFFECTS,PGR gene|PGR,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,Epidermal Growth Factor|EGF,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,beta-Chemokines,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,PIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vascular Endothelial Growth Factor C,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Microsatellite Instability,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,Genes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,DNA Polymerase I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,ZNF217 gene|ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Laminin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,riboflavin-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Raw vegetable,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carcinoma in Situ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Transferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CDKN2A|CDKN2D|F9|REG1A|IL23A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EIF3S6 gene|EIF3E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Inositol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SAFB gene|SAFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Angiogenesis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,Primary Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
DISRUPTS,Inositol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Differential Diagnosis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Tumor Markers,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,PRMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aneuploidy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Mitogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hyperlipidemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
DISRUPTS,Bilirubin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,cyclin E2|CCNE2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SPARC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ID-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Germ-Line Mutation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Globo-H,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MYC gene|MYC,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Metformin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,"TACC1 protein, human|TACC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Hydrocarbons, Halogenated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Genetic syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Hormones,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AUGMENTS,Platinum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EGb 761,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,celecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nulliparity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,B-pyridine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Pathologic Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AUGMENTS,ELF3 gene|ELF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Meal pattern NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diastasis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PLAUR gene|PLAUR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fumarate Hydratase|FH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Vidal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Thyrotropin-Releasing Hormone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,E-Cadherin|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AXIN2 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CCL2 gene|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fluoxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bone sialoprotein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Thiazolidinediones,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EZH2 gene|EZH2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
DISRUPTS,antireticular cytotoxic serum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,ERA-923,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,CD151,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,restriction enzyme,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Tretinoin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Multiparity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Tankyrase|TNKS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SEPT9 gene|SEPT9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Beans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Steroids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Steroid
PREDISPOSES,betaIG-H3 protein|TGFBI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,integrin-linked kinase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Tea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PTHLH gene|PTHLH,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,T gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,zeaxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Vitamin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
CAUSES,Gonadal Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Smoking,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,CD109,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ERBB2|NEU1|NEURL1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,IRS2 gene|IRS2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,SRC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Small RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Heterocyclic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PSIP1 gene|PSIP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Aromatic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TBX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CA9 gene|CA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Integrin alpha6beta1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Angiopoietin-2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,LMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Antidepressive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,IGF2 gene|IGF2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,SCTR gene|SCTR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fetus size,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogens,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Hormone
AFFECTS,"Shc1 protein, mouse|SHC1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ERbetacx,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,multicatalytic endopeptidase complex,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Abnormal result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Environmental Estrogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Selective Estrogen Receptor Modulators,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PP5 protein-serine-threonine phosphatase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Lesion,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,IGFBP3 gene|IGFBP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Vascular Endothelial Growth Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,N-3 fatty acid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,cell invasion,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
CAUSES,TRANCE protein|TNFSF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"Genes, Homeobox|LBX1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WISP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,WWP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NDRG1 gene|NDRG1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Combination Drug Therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Eating habit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,alanylalanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MUC5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secondary malignant neoplasm of bone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,genetic element,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"DICER1 protein, human|DICER1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cyclophosphamide,Breast cancer stage II,0.0,Female Breast Cancer,Other
PREDISPOSES,"Nuclear Receptor Subfamily 4, Group A, Member 1",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Xanthine Dehydrogenase|XDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,NOTCH1 gene,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Bloody nipple discharge,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cell Adhesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,CCL18 gene|CCL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,trans-resveratrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,phospholipase C beta2|NEUROD1|TUBB4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PTK2B gene|PTK2B,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,ABCB1 gene|ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cytochrome P-450 CYP2D6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signal Transduction Pathways,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Prolactin Receptor|PRLR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CCL2 gene|CCL2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Receptor Protein-Tyrosine Kinases,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RGS Proteins|PITX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TNFSF11 gene|TNFSF11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PRS gene|PRS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cyclin D1|CCND1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,ADIPOR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Bone remodeling,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,ADRA1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypoxia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,"Receptors, Progesterone|EREG|ESR1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Pharmacotherapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,osteopontin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,cell fate determination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,N-Cadherins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,LSP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Stromal hyperplasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Gene Expression Alteration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cessation of life,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UNC45A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Human Papilloma Virus Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,JTB gene|JTB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CISH,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,Protein Overexpression,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Systemic disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Candidate Disease Gene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,artesunate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Adrenergic beta-Antagonists,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AUGMENTS,Selectins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Paraffin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Extravasation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Alkaline phosphatase isoenzyme,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Enzyme
AFFECTS,heparanase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Hormone Receptor Test,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,"Calcium, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Interleukin Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,denbinobin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AXL gene|AXL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FAT4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,prophylactics use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CD100 antigen|SEMA4D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,TIAM1 gene|TIAM1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,HDAC9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Tumor Suppressor Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,ERBB2 gene|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stiff-Person Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Ethanol,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,COPS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KDM1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cigarette Smoking,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,CBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,metabolic abnormality assessment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Metabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,UHRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Ethacrynic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,asparaginylendopeptidase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Transcript,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,UHRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sweet's Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,heparanase|HPSE,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Prions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PTPN12 gene|PTPN12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Antigens, CD25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,PLK1 gene|PLK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NUCB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Fibroblast Growth Factor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Keratin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,PER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Intercellular adhesion molecule 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,5'-AMP-activated protein kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Metals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Polyethylene Glycols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,flavanone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,WT1 gene|WT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Acetaldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Physiologic Responses,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,SMYD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIRN96 gene|MIR96,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Dimethylformamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PVT1 gene|PVT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Systemic poison,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,Stereotactic radiotherapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Receptors, Progesterone|PGR",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,CD47 gene|CD47,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,mitogen-activated protein kinase 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TGFBR2 gene|TGFBR2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Reactive Oxygen Species,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"ESR2 protein, human|ESR2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,lard,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiotensins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CPEB4 gene|CPEB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,triplet codon-amino acid adaptor activity,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Nicotine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,osthol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,ginkgetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HOXD13,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,diallyl trisulfide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,citrate lyase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmacotherapy,Breast cancer stage III,0.0009990009990009,Female Breast Cancer,Other
DISRUPTS,PPP2R1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Hydroxamic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,ADIPOR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Phospholipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Interleukin-1 alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Infrared radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MMP12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"STC1 protein, human|STC1",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,DANCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,baicalein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HMGA2 gene|HMGA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Benzodiazepines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Breast cancer stage III,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Glycerol-3-Phosphate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Adhesions,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Neprilysin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"MFNG protein, human|MFNG",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Placental Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Anthocyanins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mesothelioma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lipopolysaccharides,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"Dysplasia, fibrous",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HGF gene|HGF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RBBP1L1 Protein|ARID4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TERT gene|TERT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,hypercholesterolemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,RETN gene|RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SYNJ2BP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,phenylpyruvate tautomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LIMK1 gene|LIMK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Camellia sinensis extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutant Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Dioxygenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SRCIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Receptors, Calcium-Sensing",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,17beta-HSD 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,RET gene|RET,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Immunotoxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,PNPLA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DNA,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,NRF1 gene|NRF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,L-2-amino-4-phosphonobutyrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"8-oxoguanine-DNA glycosylase, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PCDH10 gene|PCDH10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"NOS3 protein, human|NOS3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RUNX2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mitosis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,NOTCH1 gene,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,CDK4 gene|CDK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Riluzole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Androgens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,Prostaglandins E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
CAUSES,CD4 gene|CD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tiron,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,TOLLIP gene|TOLLIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CASP10 gene|CASP10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,sorafenib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Paclitaxel,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Pharmaceutical Preparations,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AFFECTS,Cytochrome P-450 CYP2E1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CCNB1 gene|CCNB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dendritic Cell Vaccine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,cyclin B2|CCNB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,atamestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BARD1 gene|BARD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,N-(4-aminophenethyl)spiroperidol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GACAT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Aspartate Transaminase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Therapeutic Intervention,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UBAP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FOXC1 gene|FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Bombesin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRIP1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
CAUSES,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,indole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,AKTIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LMO4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alternative Therapies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,JAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FOXM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"NAT2 protein, human|NAT2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Acetylcysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Diet,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,LTB4R2 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,fisetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Dopamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
PREDISPOSES,chemokine receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth-Factor-Binding Proteins|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BRCA1 gene|BRCA1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,XPA gene|XPA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,rhodioloside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HOXB5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Nitric Oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NES gene|NES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,YBX1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,proteomic profiling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mastectomy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,MIRN384 gene|MIR384,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SNAI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MFAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MAL gene|CD8A|MAL|MKL1|TIRAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hyperinsulinism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MTDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diabetic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TRANCE protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Genistein,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CD24,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Breast hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,mixed drink,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Thrombospondin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hodgkin Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Diet,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CYP2A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Wound Healing,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Candidate Disease Gene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Depo-Provera,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Hydrocortisone,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Estrogen receptor negative,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Malnutrition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Violence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Methotrexate,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,BP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tumor Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Permeability,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Transplantation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor I,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,SULT1A1|SULT1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Tumor Promoters,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,tibolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Indicators,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
PREDISPOSES,Menopausal Status,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,HYAL1 gene|HYAL1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Cell division,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SFRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,letrozole,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AUGMENTS,Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,SLC13A2|SLC13A5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sexual function,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,bone metabolism,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Androgens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Carcinoma in Situ,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MIRN21 gene|MIR21,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Lactate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,telomerase activity,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Seasoning,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carcinoembryonic Antigen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Atypia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Test Result,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,Pathologic stage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Janus kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PRL gene|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,B VARIANT NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Shock,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RARA gene|RARA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Antioxidants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gonadorelin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,progesterone receptor B|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,biological_process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
CAUSES,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MAP Kinase Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,VEGFA,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,soy protein isolate,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Polycyclic Hydrocarbons, Aromatic",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,MED28,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Immunoglobulin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MED28,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ARHI gene|DIRAS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,claudin 6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Superior Vena Cava Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,S100 Proteins|S100A1|S100B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Precancerous lesions,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,PLEKHF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Associated symptom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,WNT5A gene|WNT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,2q34,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,fucoidan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,5-7-oxo-zeaenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"ESR1 protein, human|ESR1",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,EGFR|ENAH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,coactivator-associated arginine methyltransferase 1|CARM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,ACKR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Chloroquine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa|UBASH3B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Does play,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Weight maintenance regimen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RAP1GDS1|KIFAP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Methionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIP,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,ING1 gene|ING1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,proneurotensin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dehydroepiandrosterone Sulfate,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,PRKD1 gene|PRKD1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,EGb 761,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TIAM1 gene|TIAM1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,mortalin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PTEN gene|PTEN,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
DISRUPTS,CACNA1A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,osteopontin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,biological_process,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Phenomenon or Process
AUGMENTS,XIST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CISH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Interleukin-6|IL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,COX5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adenoid Cystic Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,AHNAK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MRPS18A gene|MRPS18A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,no positive axillary nodes,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Vitamin B2 intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,chitotriosidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PROSTATE SPECIFIC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adjuvant response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,E-Cadherin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Platinum salt,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Insulin Receptor|INSR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ATM gene|ATM,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mineralocorticoid Receptor|DHCR24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,CREB3L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Melatonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antilipemic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,ITK gene|ITK,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CXCL10 gene|CXCL10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fibroadenoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MicroRNAs,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,FANCM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,6/6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Thyroxine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,antibody therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Gastrin|GAST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Peanuts - dietary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pancreatic carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KIF4A gene|KIF4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Repair Gene,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
AFFECTS,Acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Microcalcification,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Compete,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IL1B gene|IL1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IL4R gene|IL4R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Crystallins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MSX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,YBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,valdecoxib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Mitomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Enhancing Lesion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PRRT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Sulfuric Acid Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,EGFL7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CXCL13 gene|CXCL13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Neoplastic Process
AUGMENTS,beta catenin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,ERBB3 gene|ERBB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,LRRC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Nitric Oxide Synthase Type II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Thromboplastin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
CAUSES,Amyloid beta-Protein Precursor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CD24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CAPN9 gene|CAPN9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KIAA1199 gene|CEMIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,BMP1|PRCP|PGPEP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,baicalein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ACE gene|ACE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,alpha2HS glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PFAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Microdissection,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,VEGF gene|VEGFA,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Diet,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,tibolone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,collagenase 3|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Histopathology,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Chondroitin Sulfates,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Malathion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"VEGF protein, human|VEGFA",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,phenethyl isothiocyanate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Encounter due to breast reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Detection,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,CYLD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TBX3,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Elongation Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FOXC1 gene|FOXC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,patient retention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,gefitinib,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,USF1 gene|USF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Oxytocin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,WWOX gene|WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,usnic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Ferritin level,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Folic Acid Antagonists,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Norethindrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,toxicant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,DACH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cacodylic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Hyperinsulinism,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Venous Thrombosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,USH2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cigarette smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Antirheumatic Drugs, Disease-Modifying",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
PREDISPOSES,PTH gene|PTH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,NET1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SDC1 gene|SDC1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,MXD1|MAD1L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Flavonols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Pancreatic leak,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,TOP2A gene|TOP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Bilateral oophorectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Depo-Provera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GSTM1 gene|GSTM1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Neck Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,gamma-Glutamyl Hydrolase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,CATALASE,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Estrogen Receptor alpha,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Leeks (dietary),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thromboembolic event,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Phenomenon or Process
AFFECTS,Vasospasm,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,G-T mismatch-binding protein|MSH6,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Therapeutic Intervention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Biological Response Modifiers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP2D6 gene|CYP2D6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Micellar Paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Oxalates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"PHEMX protein, human|TSPAN32",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,MED19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Performance,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,ECT2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,LINC00461,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,USP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,DKK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIP5K1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Abnormal protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Feeding and dietary regimes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Malignant meningitis,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,ENPP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,SMAD7 gene|SMAD7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"NRIP1 protein, human|NRIP1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BITTER MELON FRUIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD71 antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,Factor VIII-Related Antigen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Immunologic Factor
PREDISPOSES,PVR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Juice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Glucocorticoids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,CYGB gene|CYGB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Food,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
DISRUPTS,LRP6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Relapse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cyclin-dependent kinase inhibitor 1B|CDKN1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Manual reduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,Natural Products,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AUGMENTS,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Interleukin-6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Paraoxonase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Interleukin-1 beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PARVA gene|PARVA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ZEB2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CKS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
DISRUPTS,beta-elemene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,mammaglobin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,lipocalin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,caspase-8|CASP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pancreatic Polypeptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"MPP3 protein, human|MPP3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,IL17F,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,claudin 6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Gangliosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Apolipoprotein A-I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,AFAP1L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AMD3465,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,shogaol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Osteoporosis, Postmenopausal",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Translocase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Taking medication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,N-Acetylneuraminic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MicroRNAs,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CYP2C8 gene|CYP2C8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EZR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Monoacylglycerol Lipases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ABRAXAS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Heat-Shock Proteins 70,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,bone morphogenetic protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,parathyroid hormone-related protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,HULC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PARITY,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Proanthocyanidins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cell transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Thyroid Hormone Receptor Beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Anthocyanidins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,26S proteasome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Macrophage Activation Syndrome,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Enrich (product),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"interleukin-1, beta",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"CEACAM5 protein, human|CEACAM5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Neurophysiology - biologic function,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,rucaparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,zoledronic acid,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Chemical
AFFECTS,Metaplastic carcinoma of breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,fucoidan,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,ERBB3 gene|ERBB3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00520 gene|LINC00520,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,TRIP6 gene|TRIP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Enzyme Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cholesterol hydroxylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
CAUSES,anastrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Thromboplastin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,MIR182 gene|MIR182,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ROR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,COL10A1 gene|COL10A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,chloroxoquinoline,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,ZNF10 gene|ZNF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KDM5B gene|KDM5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Genome,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,bis(4-hydroxyphenyl)sulfone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sex Hormone-Binding Globulin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AFFECTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PAQR4 gene|PAQR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZFP36L1|BRF1|MST1L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,nobiletin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CALCIUM HOMEOSTASIS,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Targeted Therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,PTTG1 gene|PTTG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hormones,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AUGMENTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
CAUSES,"Breast Cancer, Familial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Aptamer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Xenograft type of graft,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ASAP1 gene|ASAP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Risk Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Graft acceptance,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,TRPM4 gene|TRPM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SNORA71B gene|SNORA71B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,marizomib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,MARS gene|MARS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ergocalciferol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Transcriptome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Positive Transcriptional Elongation Factor B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ENO1 gene|ENO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SCUBE2 gene|SCUBE2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Proliferation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,AGR2,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Other
DISRUPTS,DLG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mevalonate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MKI67 gene|MKI67,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,dinoprost,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epicatechin-3-Gallate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pathologic Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"T-Cell Surface Glycoprotein CD4, human|CD4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TMEM165 gene|TMEM165,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Tumor-Associated Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,PROM1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Contralateral Prophylactic Mastectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDC2 Protein Kinase|CDK1,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MMP10 gene|MMP10,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,Androgen Receptor,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,ENC1 gene|ENC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Xenograft Model,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Cytologic atypia,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,"AGR3 protein, human|AGR3",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Smoked food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,platinum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HLCS gene|HLCS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Functional Food,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,UNC5B gene|UNC5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ITPKC gene|ITPKC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,cyclophosphamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Stat3 protein,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Unlikely,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CXCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PART1 gene|PART1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SPRY4-IT1 gene|SPRY4-IT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cyclovirobuxine D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Salts,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Extranodal Extension,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ADAMTS8 gene|ADAMTS8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Obstruction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Fluid intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Periodontitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chronic Obstructive Airway Disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,mammary gland involution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MIR100HG gene|MIR100HG,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,PALB2 gene|PALB2,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,MIR497 gene|MIR497,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,YY1 gene|YY1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Ganetespib,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Phosphoinositide Phosphatases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HAND2-AS1 gene|HAND2-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Expression procedure,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mastectomy,Stage IV Inflammatory Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Iodides,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,SRCIN1 gene|SRCIN1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Eicosanoids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Eicosanoid
DISRUPTS,ciclesonide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adipose Tissue Deposition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PLEKHA7 gene|PLEKHA7,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,CDC25B gene|CDC25B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast normal,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Neoadjuvant Systemic Therapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,MKI67 gene|MKI67,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,estrogens,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,Ferritin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"RNA, Circular",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,"Transcription, Genetic",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,HLA-F-AS1 gene|HLA-F-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Red Meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DSCAM-AS1 gene|DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,APLN gene|APLN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,heparanase,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
DISRUPTS,RING1 gene|RING1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,K-ras Oncogene|KRAS,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Patient age,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Metabolic Process, Cellular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,Digital Mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,EIF3A gene|EIF3A,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,PFKL gene|PFKL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genes,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Sleep Disorders, Circadian Rhythm",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,No effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Insulin Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,leptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EPHA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,rutin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemotherapy Regimen or Agent Combination,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ZEB1 gene|ZEB1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Long Interspersed Nucleotide Element-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Decreasing,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Heat shock proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AFFECTS,MLN4924,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDKN2B gene|CDKN2B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclin-Dependent Kinase 4,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Ataxia Telangiectasia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mutation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ACTL8 gene|ACTL8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,BCL6 gene|BCL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dietary Modification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SIRT3 gene|SIRT3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXO6 gene|FOXO6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathologic Complete Response,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,"Neoplasm, Residual",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Glucocorticoid Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,METTL3 gene|METTL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"STK11 protein, human|STK11",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Transferrin,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AUGMENTS,KIF18B gene|KIF18B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDLIM7 gene|PDLIM7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RFX5 gene|RFX5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,other medicated shampoos in ATC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,PUM1 gene|PUM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,gene interaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,prevention effectiveness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FGFR1 wt Allele|FGFR1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,AFAP1-AS1 gene|AFAP1-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IMPACT gene,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Medical record number:ID:Pt:^Patient:Nom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EEF1E1 gene|EEF1E1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"CD69 protein, human|CD69",Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Interleukin-12 Subunit p35,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Transformation, function",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Dovitinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,CASC16 gene|CASC16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CDC20 gene|CDC20,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,multidrug resistance-associated protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"CD9 protein, human|CD9",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,physiological aspects,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Possible,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,cell cycle regulator,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,MIR937 gene|MIR937,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERBB2 gene|ERBB2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,CBR3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RAD54B gene|RAD54B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Luteolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"GPER protein, human|GPER1",Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,LRP6 gene|LRP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Recurrent pregnancy loss,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pregnancy-Associated Plasma Protein-A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SCUBE2 gene|SCUBE2,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Physical function,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Disaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MORC2 gene|MORC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,G-Protein-Coupled Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ACTG2 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GATA3 Transcription Factor|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,IL18 gene|IL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABI1 gene|ABI1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,"BCAR3 protein, human|BCAR3",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cell Growth,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,SHARPIN gene|SHARPIN,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,COVID-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibrillar Collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antitumor Response,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,"DKK3 protein, human|DKK3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Matrix Metalloproteinase 13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LIG3 gene|LIG3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AUGMENTS,Phosphotransferases,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,WLS gene|WLS,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,collagen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Positron-Emission Tomography,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PLB1 gene|PLB1,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP41 gene|USP41,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,REPLETE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SMYD3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,SP7 gene|SP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"CDK7 protein, human|CDK7",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Oligonucleotides,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Alkaloids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BCL6B gene|BCL6B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWSG1 gene|TWSG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SPARC gene|SPARC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CTNNB1 gene|CTNNB1,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,BCL6B gene|BCL6B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Whole Grains,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ergocalciferol,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,Limonins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ipatasertib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,MYD88 gene|MYD88,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Poly-L-lactic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,rosuvastatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Hormone Therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hormone
AFFECTS,Reproductive Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"TNFSF13 protein, human|TNFSF13","Breast Cancer, Familial",0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"RNA, Long Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Biological Markers,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogen Receptor Modulators,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Effective Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,glucose oxidase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Carbohydrate
AUGMENTS,estradiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIR10B gene|MIR10B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MIR139 gene|MIR139,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,CDC20 gene|CDC20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,1 time,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,"CTGF protein, human|CTGF",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"CD69 protein, human|CD69",Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,paclitaxel liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TPI1 gene|TPI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acclimatization,Malignant neoplasm of female breast,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,imipramine,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,AMACR wt Allele,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,MKI67 gene|MKI67,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,TPI1 gene|TPI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,limited use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CDK6 gene|CDK6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,MAP1LC3C gene|MAP1LC3C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pathogenic Variant,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Virus
DISRUPTS,Pseudogenes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,cyclin B2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TTYH3 gene|TTYH3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,cyclooxygenase 2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Proliferation (morphologic abnormality),Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,HSPG2 gene|HSPG2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LINC01234 gene|LINC01234,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Individual Exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ELP3 gene|ELP3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Methylation Site,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Experimental Result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pneumocystis jiroveci pneumonia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DST gene|DST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CYP2S1 gene|CYP2S1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High glycemic index food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,RNA-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Tomography, Emission-Computed",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,ginsenoside Rg3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ULBP2 gene|ULBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MEF2C gene|MEF2C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antioxidants,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,skill,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Plasma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Body Substance
AUGMENTS,alpha Karyopherins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Mammary Carcinoma, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Bioavailable testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
DISRUPTS,SPOP gene|SPOP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Anthropometric Measures:-:Point in time:^Patient:-,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,CUL4B gene|CUL4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MMP13 gene|MMP13,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,TaqI POLYMORPHISM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Anthracycline Antibiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Antibiotic
PREDISPOSES,TIMM8A gene|TIMM8A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"TRIM25 protein, human|TRIM25",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,inhibitors,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Pathologic Response,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
AUGMENTS,RET,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Contrast used,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNA 205-5p,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,CLIC1 gene|CLIC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,HSPA8 gene|HSPA8,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,aflatoxin B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,"ZFP36 protein, human|ZFP36",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Decreased Expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ERBB2 gene|ERBB2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,LINC00473 gene|LINC00473,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,clopidogrel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"3,3'-diindolylmethane",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Alkaloids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,vemurafenib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,WBP2 gene|WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Histone deacetylase inhibitor,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AUGMENTS,ezrin,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,microphthalmia-associated transcription factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,WNT9B gene|WNT9B,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,beta-2 Adrenergic Receptors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Menopausal syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,CXCR4 gene|CXCR4,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,LINC00667 gene|LINC00667,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation Abnormality,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,lycorine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Performance,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Animal feed (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AUGMENTS,SPON2 gene|SPON2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Mucosa-Associated Lymphoid Tissue Lymphoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,mannose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MTOR wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CRABP2 gene|CRABP2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,BTG4 gene|BTG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Alanine Aminotransferase 1, human",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,ZSCAN1 gene|ZSCAN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP20 gene|USP20,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,AFAP1-AS1 gene|AFAP1-AS1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,KMT2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PFKFB3 gene|PFKFB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,treatment options,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,hydroxybenzoic acid,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
PREDISPOSES,20-40 years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Retinoblastoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Treatment Protocols,Luminal B Breast Carcinoma,0.0,Female Breast Cancer,Other
CAUSES,Toxin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Diesel Exhaust,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunoregulation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Problem,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,Singlet Oxygen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,BARRIER,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Bone Morphogenetic Protein Receptors,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,ZNF451 gene|ZNF451,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,"Genes, env|ERVW-1|ERVK-20|ERVK-18|ERVK-32",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,taxifolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,RAD52 gene|RAD52,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CCR7 gene|CCR7,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,macroautophagy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CXXC5 gene|CXXC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Androgen Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Increased risk,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,TYMSOS gene|TYMSOS,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,systemic administration,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,cinobufagin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Cancer Relapse,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Increased size (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IMPACT gene,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,Axillary node METASTASIS,Breast cancer stage II,0.0,Female Breast Cancer,Neoplastic Process
DISRUPTS,NR1D1 gene|NR1D1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CD103|ITGAE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Genes,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,anastrozole,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,risk factors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,brusatol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hepatitis C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Menopause,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Suppressor,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,HLA-G gene|HLA-G,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,DLGAP5 gene|DLGAP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,bruceine A,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,"IL5 protein, human|IL5",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,pimavanserin tartrate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Histone deacetylase inhibitor|HDAC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Transformation, function",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,BCPR Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,hydroxypropylbetadex (0.58-0.68 MS),Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Piperlongumine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Immune,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Antigens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,EZH2 gene|EZH2,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,BHLHE41 gene|BHLHE41,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,medroxyprogesterone acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AUGMENTS,SHC4 gene|SHC4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,USP4 gene|USP4,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnosis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Anoikis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dichloroethylenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SRRM4 gene|SRRM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Not significant,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,paraffin,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,multicatalytic endopeptidase complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PTK2 gene|PTK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Screening mammography,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,SKP2 gene|SKP2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP30 gene|USP30,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,thyme oil,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AIMP2 gene|AIMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,maduramicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,FOXO1 gene|FOXO1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,TWIST1 gene|TWIST1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,"PIK3CB protein, human|PIK3CB",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,cholecalciferol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"TLR2 protein, human|TLR2",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,NSUN2 gene|NSUN2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FOXA2 gene|FOXA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXO8 gene|FBXO8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORA73B gene|SNORA73B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Present,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,SCARNA4 gene|SCARNA4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PLK4 gene|PLK4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR130A gene|MIR130A,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,fiber,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"membrane protein, SARS-CoV-2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Mutant Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Bacteroides fragilis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,epiberberine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,progesterone,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,Benign foot rot,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Protease Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
PREDISPOSES,Bloody nipple discharge,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,decanoylcarnitine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
COMPLICATES,Fibrous Dysplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RBMS3 gene|RBMS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Non-infiltrating lobular carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,tegafur,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SF3A2 gene|SF3A2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,COL5A1 gene|COL5A1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Signs and Symptoms,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Score,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Multiple Sclerosis,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,NF-kappa B,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,MTA1 gene|MTA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Increased risk,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,obeticholic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,Hypolipidemic Agents,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Cessation of life,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ETNK1 gene|ETNK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Immunologic Factor
PREDISPOSES,"Receptor, Melatonin, MT1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Steroids,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Steroid
AUGMENTS,Protein Isoforms|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Behavior,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Folic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,protein-tyrosine kinase c-src|SRC,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Human Papilloma Virus Vaccine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AFFECTS,Testosterone,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Warfarin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MAD2L1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Bicarbonates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Carcinomatous peritonitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Deoxycytidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,phosphatidylinositol 3-kinase gamma,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Fluorouracil,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,PITPNM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Psoralens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RAI3 gene|GPRC5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,BRD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Janus kinase 1|JAK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Metastasis Suppressor Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,exemestane,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,invariant chain|CD74,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,helicase|HFM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,VIP gene|VIP,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
DISRUPTS,STK11 gene|STK11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,C-Peptide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Carcinogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,GPR161,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IRF2 gene|IRF2,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
CAUSES,"Embolism, Tumor",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,DNA Methyltransferase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Brain-Derived Neurotrophic Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,SOD3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Blood flow,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Pyrones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SMAD2 gene|SMAD2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
DISRUPTS,BRCA2|BLID,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,neuropeptide Y|NPY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,SIX2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SMAD2 gene|SMAD2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,"DNA, Double-Stranded",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,SMAD3 gene|SMAD3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,HIF1A gene|HIF1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Estrogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AFFECTS,Systemic disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,"Genes, Immunoglobulin",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TUNAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,andrographolide,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Progesterone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Hormone
PREDISPOSES,HOXB13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DDX26 gene|INTS6|DDX56,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,UBE2I,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ADORA2B gene|ADORA2B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, env|ERVW-1|ERVK-20|ERVK-18|ERVK-32",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,chymotrypsin A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Oral Solution,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Spironolactone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ceramides,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,Nitric Oxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IGF1R gene|IGF1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mutation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Adriamycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MIRN205 gene|MIR205,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ATP6V1C1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Therapeutic procedure,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Red meat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fusion Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Hepatitis C virus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Invasive Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Eukaryotic Initiation Factor-4E|EIF4E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of gastrointestinal tract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
DISRUPTS,MIRN200B gene|MIR200B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TP53BP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Pharmaceutical Preparations,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Iron,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MAGEC2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Thiopurine S-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ATP1B2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NANOG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Pteridines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,combretastatin A-4 disodium phosphate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,MMP14 gene|MMP14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Chronic heart failure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Receptors, Tumor Necrosis Factor, Type II",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,Ro 48-8071,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TAAR5|NR2E3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,FGF1 gene|FGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lymphatic Diseases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Placebos,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,VEGFC gene|VEGFC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of cervix uteri,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,SOX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Oxidoreductase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,DOCK1 gene|DOCK1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,GAD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Galactosyltransferases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,proteomic profiling,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Gynecologic Surgical Procedures,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,beta-cryptoxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NDP,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,MIRN203 gene|MIR203A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Promoter Regions (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Multiple Myeloma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Cholesterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,Norepinephrine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"Tuberculosis, Pulmonary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Retinoid X Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,aldehyde dehydrogenase 1|ALDH1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Integrin beta3|ITGB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CD29 Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,Calcitonin Receptor|CALCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Prolactin|PRL,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogen Antagonists,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,ABCC1 gene|ABCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tamoxifen,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,KIF20A gene|KIF20A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Glucosephosphate Dehydrogenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Leucovorin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,MLLT11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BRCA2 gene|BRCA2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,WBP2 gene|WBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Aspirin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,particle,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,6p12,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,E-Cadherin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Endobronchial metastases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Regulatory Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Fibrinogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,mdm2 protein|SLURP1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Cholangiocarcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Gene Mutation,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,Fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,IGFBP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diabetes Insipidus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"12-Hydroxy-5,8,10,14-eicosatetraenoic Acid",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
PREDISPOSES,Relationship problems,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Secondary malignant neoplasm of axilla,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Free Radicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SLOPE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Calcitonin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Adrenalectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adriamycin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,16 alpha-hydroxyestrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Estriol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Malignant disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Large Cell Lymphoblastic Lymphoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Caseins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Orchitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FCE 21336,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,leukemia,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,TAG 12,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Body measure result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,S-Phase Fraction,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Idarubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,alpha-Lactalbumin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Fucose,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,sterculic acid,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
AFFECTS,"Nuclear Receptor Subfamily 4, Group A, Member 1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Difluoromethylornithine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Aflatoxin B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,fibrosarcoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Shock,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Enovid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Platinum,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,ERVW-1|ERVK-20|ERVK-18|ERVK-32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Interferons,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypophysectomy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Cellular Retinoic Acid Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cerebellar degeneration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Response Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,dromostanolone propionate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Stimulant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Trace Elements,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of breast,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Clinical finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BAG3,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
DISRUPTS,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Ductal Breast Carcinoma,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
CAUSES,Telomerase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Readiness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FGFR1 gene|FGFR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Operative Surgical Procedures,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,blood lipid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,placental protein 11|ENDOU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PTHLH gene|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Immune status,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Antihistamines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,Pleural effusion disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,butyrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NCOA3 gene|NCOA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Specific antibody,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,Sulfhydryl Compounds,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Chemical
PREDISPOSES,stanniocalcin 2|STC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carcinogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,"Genital Diseases, Female",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,fluoranthene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,17q21,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Sterically Stabilized Liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Nitrosamines,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Early Diagnosis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
CAUSES,Small T-Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
DISRUPTS,NME1 gene|NME1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Serine Protease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Enzyme
CAUSES,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,sarcoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
CAUSES,Prostate-Specific Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,Cyclin Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Immunotoxins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical
AUGMENTS,RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Histidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Androgens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Silicones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Tumor Suppressor Genes,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Somatropin|GH1|GGH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Radiation therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NRG1 gene|NRG1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,"Ether, Ethyl",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,cyclooxygenase 2,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,c-myc Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Nucleic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,small molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Plants, Edible",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Raloxifene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,COMT gene|COMT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, Homeobox",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Risk factor, cardiovascular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pregnancy History,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AR gene|AR,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
CAUSES,SHBG gene|SHBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,telomerase activity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Mutant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gene Amplification,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Watermelon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Transcriptional Repression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,LTA gene|LTA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Genomic Instability,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Nuclear Matrix-Associated Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,HSD17B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Fibrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SLC39A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neuropeptide Y Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,AVP,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Chocolate milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"ESR1 protein, human|ESR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,fulvestrant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Coping Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Testosterone Propionate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
AUGMENTS,Peptide Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,dominant allele,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Matrix Metalloproteinases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SLIT3|SLIT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CTCFL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,5-lipoxygenase-activating protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Thyroid Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Therapeutic procedure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Tissue-Inhibitor of Metalloproteinase-1|TIMP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,VEGF gene|VEGFA,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cheese,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,WNT5B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fluctuation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Diagnostic radiologic examination,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Alanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CXC Chemokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adhesions,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,SLC3A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,EP300 gene|EP300,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,PTN gene|PTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Phytoestrogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Malignant neoplasm of prostate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Ha-ras Oncogenes,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Gonadotropins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Testicular Diseases,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
AUGMENTS,Endopeptidases,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,"Receptors, Progesterone|PGR",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,Tissue factor antibody,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,Insulin-Like Growth Factor II|CD74|GCNT2|TCN2|VIPR1|TAF8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"LGALS3BP protein, human|LGALS3BP",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,cysteinylglycine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Aspirin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,myricetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin E,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Food
PREDISPOSES,Adriamycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,prolyl-proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hormone Receptor,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,Heterocyclic Amines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Eating,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Siramesine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CALCIUM PHOSPHATE CRYSTALS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Quantitative Trait Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LGI1 gene|LGI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,BMI1 gene|BMI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,5-Trimethoxyamphetamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,5'-NUCLEOTIDASE|TRIM33,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,ADAMTS4|ADAMTS3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,alpha 1-Antitrypsin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prolactin Receptor|PRLR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Benzodiazepine Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SKI gene|SKI,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,LFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Functional RNA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TNFSF11 gene|TNFSF11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,gemcitabine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Encounter due to drug use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"Receptors, Progesterone|EREG|ESR1",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Dancing,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,valylvaline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Toremifene,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,glypican 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,doxifluridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Doxorubicin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Transient Receptor Potential Channels,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Phosphorylcholine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Fruit, Citrus",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Stanolone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,4-octylphenol,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Aromatase Inhibitors,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Hormone
CAUSES,RA 25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Pressure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,letrozole,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glucocorticoid Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Estrogens,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SKP2 gene|SKP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,IL2 gene|IL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PARP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TP53 gene|TP53,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Apigenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Histiocytoma, Malignant Fibrous",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cellular process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,ADIPOR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ALK gene|ALK,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Drug resistance,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,17q21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BHLHE41,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,"Cholesterol, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,HIF1A gene|HIF1A,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,arrestin3|ARR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LDL Cholesterol Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,ERBB4 gene|ERBB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,versican|VCAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Insulin, Regular, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,vinorelbine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,HRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HOXB9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Retinoblastoma Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Tumor Suppressor Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,Phosphatidylinositols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,thyroid microsomal antibodies|TPO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"DNA, Single-Stranded",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,bakuchiol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estrogens,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Hormone
AUGMENTS,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Herceptin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FABP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KLF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,epidermal growth factor receptor VIII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Angiogenesis Inhibitors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,GAPD gene|GAPDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,HRG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Oncogene ErbB2|ERBB2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,PANDAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Lymphoma, Large-Cell, Diffuse",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Proto-Oncogene Proteins p21(ras),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,protein kinase C zeta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,parathyroid hormone-related protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CNS disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,"Antiretroviral Therapy, Highly Active",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cytotoxic T-Lymphocyte-Associated Protein 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,Vitamin D Deficiency,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
PREDISPOSES,APP gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,IL4 gene|IL4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,KLF8 gene|KLF8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Membrane Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,KNG1 gene|KNG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Proteome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,germacrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ADAR1|ADAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Fibroblast Growth Factor Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Acute inflammation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Proteins,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,COX7A2L gene|COX7A2L,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,chemokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,PORPHOBILINOGEN SYNTHASE|ALAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Clinical Treatment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hyaluronan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,DDX3X,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,[M]Skin appendage adenoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,mead acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Metabolic syndrome,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Disease or Syndrome
AFFECTS,Protein antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,SLC19A3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,May-Hegglin anomaly,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIRN182 gene|MIR182,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Sulfonylurea Compounds,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,bone morphogenetic protein 4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,multicatalytic endopeptidase complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BMI1 gene|BMI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,beta catenin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,angiogenin|ANG,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,DOK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NKX2-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antihypertensive Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
CAUSES,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,apolipoprotein E-2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,pyridoxine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GPR55,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Dyslipidemias,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Lipid
AFFECTS,"Cystadenocarcinoma, Serous",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Cathepsin L|CTSL,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Adenosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Anthracyclines,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Inflammatory disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,CCT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DEFA1|CBX5|DEFA1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MFAP5 gene|MFAP5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stopped work,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,cyclin-dependent kinase 3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,preference,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,Gene Expression,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,DMPK|IGHD1-7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NF-kappa B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,TRIM28,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Consanguinous Mating,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Biotin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PAQR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PTF1A,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,temozolomide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease Progression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,SUMO1P3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,SMAD3 gene|SMAD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Secretory Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,cilium biogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Echinococcosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fatty Acid-Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Immune defect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC4A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Benzene,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,5'-NUCLEOTIDASE|NT5E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tumorigenesis,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,KISS1 gene|KISS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sleep Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,copper-binding protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ID2 gene|ID2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIRN21 gene|MIR21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,PRDX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,phospholipase C delta 1|DLK1|DLL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tamoxifen,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Pharmacologic Substance
AFFECTS,Interleukin-18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ARHGEF5 gene|ARHGEF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CCAT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SENP2 gene|SENP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Acetate,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Fibroblast Growth Factor Receptor 1|FGFR1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,TRPS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,nuclear receptor coactivator 1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Thioctic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,DNA amplification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,inorganic phosphate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RBM38,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,F2-Isoprostanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,stromelysin 3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,IkappaB Kinase beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,BCL2 gene|BCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factor beta,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Pathogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MDM2 gene|MDM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ADAMTS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinogenesis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,ETS1 gene|ETS1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Cantaloupes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Need for isolation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Colorectal cancer metastatic,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Quinones,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Glucocorticoid Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,D4-GDI,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,Benzodiazepine Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,E2F4 gene|E2F4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DMBT1 gene|DMBT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,retinoic acid receptor beta 2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Chemical
CAUSES,alpha Catenin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Phosphoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cyclic AMP-Responsive DNA-Binding Protein|CAMP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BANCR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,LINC00310,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gonadotropins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SIRT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,attenuation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Quercetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Smoking,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Rice,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PTGER1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Pancreatitis,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,fulvestrant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3|IGFBP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,GAB2 gene|GAB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Malignant Neoplasms,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Neoplastic Process
AUGMENTS,Lysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Is informed,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NFKB1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Tumor Promoters,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AFFECTS,Signaling Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fatty fish,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Combined Oral Contraceptives,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Serpins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA1 Protein|BRCA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hydroxyl Radical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Lindane,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Irritable Mood,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Cytochrome P-450 CYP1A1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Gelatinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Transcription Repressor/Corepressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Local excision,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Transcript,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TWSG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Endometriosis, site unspecified",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,G22P1 gene|XRCC6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Invasive Lesion,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,PTGIS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Disease Progression,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,nuclear receptor coactivator 1|SRC,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TBXAS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"TERT protein, human|TERT","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CBS gene|CBS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,childhood brain tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,MNX1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,MMP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EEF1A2 gene|EEF1A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Light,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Coconut milk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gonadal Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,SKP2 gene|SKP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Malignant neoplasm of breast,bilateral breast cancer,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Epithelial hyperplasia,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,"RNA, Messenger",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Testosterone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
PREDISPOSES,FAU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GLO1 gene|GLO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GNRHR gene|GNRHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"RNA, Messenger","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,PPAR gamma|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,2-hydroxyestrone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Non-Aspirin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,TACSTD2 gene|TACSTD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Bioluminescence,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CXCR3 gene|CXCR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Epstein-Barr Virus Infections,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,RUNX2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,MED28,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,Proteins,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IL23R gene|IL23R,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Family problems,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TOX3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,BRCA2 gene|BRCA2,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Gene or Genome
AUGMENTS,MIRN27A gene|MIR27A,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AUGMENTS,C19orf12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AR gene|AR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
PREDISPOSES,Sexual exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,vitamin supplement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Physical therapy exercises,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,prohibitin|PHB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DDX3X,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RHOC gene|RHOC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Neprilysin|MME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ionizing radiation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Vaccination,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,WNT2 gene|WNT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,daidzein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Agent,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,XRCC3 gene|XRCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNA Sequence,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Nucleotide Sequence
AUGMENTS,VEGFA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Inorganic arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prolactin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AUGMENTS,drospirenone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SLC5A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,STK11 gene|STK11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Norethindrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ADM gene|ADM,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Vascular Endothelial Growth Factor C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Gonadal Steroid Hormones,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
PREDISPOSES,chronic stressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Expressed Sequence Tags,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Metformin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,FOS gene|FOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,MIRN370 gene|MIR370,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,mRNA Expression,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ADAM12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Lamins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Homologous Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Insulin, Regular, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Metric,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
AFFECTS,"Chemotherapy, Adjuvant",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,ixabepilone,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,pertuzumab,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,BAG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Bulimia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Tissue Model,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"2-methyl-5,6-cyclopentapyrimidine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,crocetin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Study models,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,DIO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Prevention,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,French fries,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclooxygenase 2 Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Opioids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,FOXP3,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Estrogen Receptors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Digoxin,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,AGAP2-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aspirin,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,CNTN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prolactin|PRL,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,Androgens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epirubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,IL1A gene|IL1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,allograft inflammatory factor-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Transforming Growth Factor beta,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
CAUSES,Tobacco smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genes,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,matriptase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of breast,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
AFFECTS,Olive oil - dietary,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,VDR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,apolipoprotein E-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical Viewed Functionally
AUGMENTS,FOXQ1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,letrozole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
CAUSES,Antimony,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sirolimus (substance),Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Substance
AFFECTS,Cessation of life,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,proto-oncogene protein c-crk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Antipsychotic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Telomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Gelatinase B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sterically Stabilized Liposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Materials,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Substance
AFFECTS,TCF4 gene|TCF4|TCF7L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Functional RNA,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Insulin-Like Growth Factor I|IGF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Phosphatidylethanolamine Binding Protein|ZHX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PGLS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,2'-Deoxythymidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunoliposome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Fibroblast Growth Factor 7,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,YARS gene|YARS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,inhibin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Interleukin-4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHEK2 gene|CHEK2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Gene or Genome
CAUSES,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Harvest of stem cells,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,calcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Dioxins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TGM2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,methionine synthase reductase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Carcinoma in Situ,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
AFFECTS,GC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Positive Lymph Node,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,perchlorate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ASAP1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Calcium Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sexual Dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FTY 720,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIRN210 gene|MIR210,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,C1QBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CCL2 gene|CCL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PITX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KISS1 gene|KISS1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Dissociation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mammography,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,"PTTG1 protein, human|PTTG1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CA-15-3 Antigen,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Immunologic Factor
AFFECTS,Protein Expression,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"PER2 protein, mammalian",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,bilateral breast cancer,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estrogen Receptor Status,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TP53 gene|TP53,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,MAPK12 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,membership,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,astaxanthine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,tomography,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,CD151,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Promoter (Genetics),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,thrombocytosis,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,CHD8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Single Nucleotide Polymorphism,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Endometrial Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,Aryl Hydrocarbon Receptor|AHR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,aldehyde dehydrogenases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Environmental Tobacco Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AOX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTGS2 gene|PTGS2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,hepcidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PROTEIN KINASE|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RHBDD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Obesity,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AFFECTS,GABARAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SEMA4C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Systemic Therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AUGMENTS,E2F5 gene|E2F5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Gynecological history NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Disease,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Fertility Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,Fibrinogen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TOP2A gene|TOP2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cataract,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Antithrombin III,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,METHOTREXATE TREATMENT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Glutamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCND1 gene|CCND1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,disorder control,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Environmental Tobacco Smoke,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,citron rho-interacting kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MUTYH,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Opioids,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,IMPAD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTPRC gene|PTPRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,desires,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AFFECTS,CXCL14 gene|CXCL14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TMEM68,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ovariectomy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,Bone Morphogenetic Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ENPP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,syringin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,KPNA2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Propofol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ELK3 gene|ELK3|KCNH8,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,"Metabolic Detoxication, Drug",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,FRZB,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Therapeutic regimen,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,PSMD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CYP4Z1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,FOXP3,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Infiltration,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Nuclear Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SNHG6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,beta-Chemokines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Redness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CYP4Z2P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RANTES|CCL5,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,PDCD1 gene|PDCD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CST1|CLSTN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Azurin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Macrophage Chemotactic Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Peptide YY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,LINC00968,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Glucose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Intraductal Hyperplasia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Moderate Exercise,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PHLDB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitronectin|VTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LINC00707,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,C1orf106,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sedentary lifestyle,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,CUL2 gene|CUL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,heparanase|HPSE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"PIK3CA protein, human|PIK3CA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,metabolomics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lymphocytic infiltration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Porifera,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carbon Dioxide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,survivin|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Phosphotransferases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,ADCY4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SRC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CLDN1 gene|CLDN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SIDT1 gene|SIDT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Respiration,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Minerals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,"Translation, Genetic",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,Integrin alpha4beta1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,E-Cadherin,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Ablation,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,tacrolimus binding protein 4|FKBP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"FBXW7 protein, human|FBXW7",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,protein kinase C nu|DIO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Toll-Like Receptor 5,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,"Genes, Regulator",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC01614,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RASAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EIF4A1|EIF4A2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,SFN gene|SFN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,B lymphocyte-induced maturation protein 1|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Immunity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Desire for food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Short Sleeper Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,other medicated shampoos in ATC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Matrix Metalloproteinase 9,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Minisatellite Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,derivatives,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"RNA, Messenger",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Pharmaceutical Preparations,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Pharmacologic Substance
AFFECTS,stevioside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,TP53,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Breast Microcalcification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"CD69 protein, human|CD69",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,hydroxybenzoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Household composition,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ELAVL1 gene|ELAVL1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MicroRNA 335-5p,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Stat3 protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Healthy Lifestyle,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,copper,Lobular carcinoma in situ of breast,0.0,Female Breast Cancer,Other
PREDISPOSES,"RNA, Long Untranslated",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,gamma-Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,TSIX gene|TSIX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,multiple pathologies,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Adiponectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,peer support,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCL18 gene|CCL18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,rasagiline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"ITK protein, human|ITK",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DOK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RPS6KA6 gene|RPS6KA6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Growth Hormone Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,veliparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,elements of cancer genetics risk assessment and counseling,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Clinical information:Finding:Point in time:^Patient:Narrative,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,artesunate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Pads,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cannabinoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Checkpoint kinase 1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,PLSCR1 gene|PLSCR1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,vinorelbine,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,CXXC5 gene|CXXC5,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AUGMENTS,MYH10 gene|MYH10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Marital Status,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Single Nucleotide Polymorphism,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,assessment.initial,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ethyl acetate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,N-acetyltransferase 1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,BRCA1 Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PROM1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Adjuvant Therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,Genes,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
DISRUPTS,CLDN15,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,DNASE1L2 gene|DNASE1L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Syndrome,"Breast Cancer, Familial",0.0,Female Breast Cancer,Disease or Syndrome
AUGMENTS,diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,WDR41 gene|WDR41,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,NEUROD1 gene|NEUROD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZNF326 gene|ZNF326,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Multiple malignancy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,C5 gene|C5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,water,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Fatty Acids, Essential",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
PREDISPOSES,catechin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Energy Metabolism,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,methacrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TGFB1 gene|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hypersensitivity,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,NEDD9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SHC3 wt Allele|GDF1|RNH1|PPP1R13L|SHC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,timosaponin AIII,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RCC2-AS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SPX gene|SPX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNF5 gene|RNF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MVP wt Allele|RPSA|LRP1|PTPRA|MVP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mastitis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Insulin Resistance,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,phosphorus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chronic inflammatory disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Tumor Antigens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
CAUSES,Peptide Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Anticoagulants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Human cells,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Beta protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,paclitaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,AGTR1 gene|AGTR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Educational Status,malignant neoplasm of breast staging,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,LINC01705 gene|LINC01705,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ATF3 gene|ATF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,pseudouridine synthase 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CONOTRUNCAL ANOMALY FACE SYNDROME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,AXL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,parathyroid hormone,Carcinoma breast stage IV,0.0,Female Breast Cancer,Hormone
AFFECTS,PTTG1 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PDCD4-AS1 gene|PDCD4-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR30E gene|MIR30E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SLC6A2 protein, human|SLC6A2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,cytokine,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,SETD5 gene|SETD5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CPEB1 gene|CPEB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MIR497 gene|MIR497,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SYVN1 gene|SYVN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Heating,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SOX4 gene|SOX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CYP27A1 gene|CYP27A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SEMA7A gene|SEMA7A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Hemeproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cellular signal transduction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,FABP7 gene|FABP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Advanced Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,metformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ZC3H13 gene|ZC3H13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ING4 gene|ING4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Glucocorticoids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GAS6 gene|GAS6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NUDT3 gene|NUDT3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,hormone response element,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,ADIPOQ wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Risk Scores,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Neoadjuvant Chemotherapy,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,Geographic pattern,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,LINC00511 gene|LINC00511,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,IQGAP1 gene|IQGAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CARNS1 gene|CARNS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,dihydroartemisinin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TWIST1 gene|TWIST1,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,IMPACT gene,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,HNF1A-AS1 gene|HNF1A-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,cyclic compound,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,GFUS gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TP53,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,SEMA7A gene|SEMA7A,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,LINC00665 gene|LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Biological Factors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,LINC00665 gene|LINC00665,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Lupus Coagulation Inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"GAS41 protein, human|YEATS4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Bariatric Surgery,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,hippo signaling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,valine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Social Risk Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Sodium metavanadate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Anthracyclines,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
CAUSES,Epigenome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,prenatal exposure,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Post-mastectomy radiotherapy,Locally advanced breast cancer,0.0,Female Breast Cancer,Other
AUGMENTS,PCAT1 gene|PCAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCC9 gene|ABCC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Piwi-Interacting RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Prognosis bad,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,Imaging Techniques,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Paste,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SNHG6 gene|SNHG6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,POU4F1 gene|POU4F1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PPARGC1B protein, human|PPARGC1B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,multiple pathologies,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Neurofibromatosis 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC00511 gene|LINC00511,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Syndecan-4,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Other
CAUSES,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Vitiligo,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Matrix Metalloproteinase 9,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,R & C,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,Negative,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,MIR137 gene|MIR137,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,FZD2 gene|FZD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NME1 gene|NME1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,triclosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MALAT1 gene|MALAT1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,IMPACT gene,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Gene or Genome
AFFECTS,lapatinib,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,DNAJA1 gene|DNAJA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,hyaluronic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Handling,"Breast Cancer, Familial",0.0,Female Breast Cancer,Other
PREDISPOSES,pamidronate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LRRC3B gene|LRRC3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Non-Cancer Related Death,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,HSP90AA2P gene|HSP90AA2P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,estrophilin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,STAT5A gene|STAT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"IL5 protein, human|IL5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,FOXP3 gene|FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"WWTR1 protein, human|WWTR1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Very Important,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDKL3 gene|CDKL3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
COMPLICATES,FBXL16 gene|FBXL16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,fulvestrant,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,"CD69 protein, human|CD69",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Primary MicroRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,CDH4 gene|CDH4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SEPTIN9 gene|SEPT9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,cadmium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
AFFECTS,everolimus,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,RUNX2 gene|RUNX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Teratogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FBXL20,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ZNF24 gene|ZNF24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,6-Phosphofructokinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,phytochlorin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SNAI2 gene|SNAI2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CK-34 beta E12,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,H1-5 gene|HIST1H1B,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,STC1 gene|STC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Carcinomatosis,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,Interleukin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TRIM31 gene|TRIM31,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cyclin-Dependent Kinase Inhibitor Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,DNA Modification Methylases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Integral Membrane Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,>65 years,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,cholesterol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Lipid
AFFECTS,Functional modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,YAP1 gene|YAP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Monosaccharides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Aurora Kinase A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antral Follicle Count,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,mifepristone,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Aquaporin 1|AQP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,removal technique,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
DISRUPTS,UNC 0638,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MCM4 gene|MCM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EIF4EBP1 gene|EIF4EBP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stat3 protein,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,echinacoside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Protein Phosphatase 2A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CDK1 gene|CDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Growth Differentiation Factor 15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Metabolite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CI 994,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aryl Hydrocarbon Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Breast Cancer Model,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AUGMENTS,VEGFA gene|VEGFA,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Promoter Regions, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,rasagiline,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit 1, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Early Diagnosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,SP6 gene|SP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRIM32 gene|TRIM32,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,tissue markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ATP11B gene|ATP11B,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,ATG4A gene|ATG4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"TFF3 protein, human|TFF3",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ATP2B1 gene|ATP2B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MRPS30-DT gene|MRPS30-DT,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MIR342 gene|MIR342,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"BMI1 protein, human|BMI1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,"Antibodies, Anti-Idiotypic",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Hepatitis B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypoxia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,STING1 gene,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,CLTC gene|CLTC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GAS5 gene|GAS5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,WTAP gene|WTAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,PPP1R14C gene|PPP1R14C,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,liraglutide,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,DSTN gene|DSTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,norethindrone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TRIM28 gene|TRIM28,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,erbB-2 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PSAT1 gene|PSAT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00466 gene|LINC00466,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,NAA25 gene|NAA25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oncogenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CD29 Antigen|B3GNT2|B3GNTL1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
DISRUPTS,TLN1 gene|TLN1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Binding Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ergocalciferol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,vexibinol,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,DANCR gene|DANCR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mammographic Breast Density,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Other
DISRUPTS,WASF3 gene|WASF3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Diet, Healthy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radiation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
COMPLICATES,Acne,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,"Peroxisome Proliferator-Activated Receptor Gamma, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ATP6AP2 gene|ATP6AP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PINK1 gene|PINK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,AKAP3 gene|AKAP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Diet, High-Fat",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SETDB1 gene|SETDB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,KLF8 gene|KLF8,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Late chronotype,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ginsenoside M1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,VARIANT OF UNKNOWN SIGNIFICANCE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,NEK2 gene|NEK2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Interleukin-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Catabolism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,pimozide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Aurora Kinase A,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,andrographolide,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Apoptosis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,MAFG-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FOXD3-AS1 gene|FOXD3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Protac,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ADGRF1 gene|ADGRF1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Liver Cirrhosis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Breast present,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MND1 gene|MND1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,1 time,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,survivin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,MAFG-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,calcium,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,CDK11A gene|CDK11A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,oleanolic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,MBNL1-AS1 gene|MBNL1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"SDC1 protein, human|SDC1",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,LINC02620 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Scorpion Venoms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Toxic Epidermal Necrolysis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
PREDISPOSES,Primary Sj??gren's syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,TRIM4 gene|TRIM4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Oxysterols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MFNG gene|MFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Disease,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Heat-Shock Proteins 70,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,CBL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,erbB-2 Receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,Cytochrome P450,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiogenic Process,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Phenomenon or Process
AUGMENTS,MAZ gene|MAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FANCM gene|FANCM,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,BIRC5 gene|BIRC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,NR2E1 gene|NR2E1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,TNFRSF9 gene|TNFRSF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,multiple pathologies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NAT10 gene|NAT10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,caveolin 1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,IGHE gene|IGHE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hematoxylin,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
COMPLICATES,NUP210 gene|NUP210,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Elective Surgical Procedures,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,MIR409 gene|MIR409,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CENPK gene|CENPK,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Operation on breast,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,metformin,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,TRIO gene,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Positron Emission Tomography and Magnetic Resonance Imaging,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,JMJD6 gene|JMJD6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,MCAM gene|MCAM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ROS1 wt Allele|ROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,UBE2C gene|UBE2C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ROBO3 gene|ROBO3,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
DISRUPTS,carbidopa,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,"TRIM25 protein, human|TRIM25",estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,trastuzumab,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,"GTP-Binding Nuclear Protein Ran, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,stigmasterol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Small Molecule,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Polypeptides,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Coitus,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CD274,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTPN7 gene|PTPN7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,COL11A1 gene|COL11A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZNF217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,benzopyrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Endometriosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,GNG5 gene|GNG5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Acclimatization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Biological Response Modifier Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,iron increased,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ICOS gene|ICOS,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Neonicotinoid insecticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Invertebrate
PREDISPOSES,SYNJ2BP-COX16 gene|SYNJ2BP-COX16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IL1RN gene|IL1RN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,WFDC21P gene|WFDC21P,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,ST8SIA1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Dietary Selenium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant neoplasm of breast,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AUGMENTS,tamoxifen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,TBATA gene|TBATA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,WNT9B gene|WNT9B,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,olaparib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Benign Prostatic Hyperplasia,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SAV1 gene|SAV1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,pyridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RNF126 gene|RNF126,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAC1 protein|PDC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,lapatinib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Hormones,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Hormone
AFFECTS,DNA Binding Agent,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Neuregulins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PFKP gene|PFKP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ultrasound-Guided Core Biopsy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,ADCY5 gene|ADCY5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,progesterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,PRDM16 gene|PRDM16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Adult Liver Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGF2BP2 gene|IGF2BP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Lignans,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cancer/Testis Antigen,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
CAUSES,ABCB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,acrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adverse reaction to drug,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Lymphatic Invasion,Invasive Ductal Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Uveitis,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,laser irradiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Amides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carbohydrates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Endocrine Disruptors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
PREDISPOSES,"DNA, Catalytic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,PHGDH gene|PHGDH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High Level,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
CAUSES,Selective Estrogen Receptor Down Regulator,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Adjuvant Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"PON2 protein, human|PON2",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,KLF9 gene|KLF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,pimagedine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RNF43 gene|RNF43,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,myosin VI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,doxorubicin liposome,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Proteome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Place of Birth,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CLDN4 gene|CLDN4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Estrogen Receptor alpha,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of endometrium,hereditary breast/ovarian cancer - BRCA1,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,CHMP4A gene|CHMP4A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,PCAT19 gene|PCAT19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of lung,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
PREDISPOSES,vitamin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Very low density lipoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"NEK9 protein, human|NEK9",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PZP gene|PZP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fixatives,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
CAUSES,ethanol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AEBP1 gene|AEBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,dose-response relationship,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,erbB-2 Receptor|ERBB2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,GABRD gene|GABRD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR93 gene|MIR93|MIR9-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,benzopyrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antisense RNA,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,3 times,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,RNA,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Tn antigen,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Immunologic Factor
DISRUPTS,royal jelly,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,BARRIER,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,Apoptosis Inhibiting Proteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Aurora Kinase A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Cell-Free DNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Structural modification,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,KRT1 gene|KRT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,personal health,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,metformin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,SOAT1 gene|SOAT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,interferon type II|IFNG,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,bruceine D,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,bone morphogenesis,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,Proto-Oncogene Proteins p21(ras)|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Feces,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cervical Cancer Screening,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Ultrasonography,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,SNHG11 gene|SNHG11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,sevoflurane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Postoperative chemotherapy,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
DISRUPTS,Peptides,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of breast,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AFFECTS,calcium,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Dietary Zinc,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Platelets, CTCAE",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,"Analgesics, Opioid",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,hydrocortisone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Osteopenia,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Other
AFFECTS,cantharidin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CD24 gene|CD24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,pregnane X receptor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,MIR195 gene|MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,White meat intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SPATA13 gene|SPATA13,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,"RNA, Untranslated",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Carcinoembryonic Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
PREDISPOSES,RARB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"IL7 protein, human|IL7",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,fos-related antigen 1|FOS,Carcinoma breast stage IV,0.0,Female Breast Cancer,Immunologic Factor
PREDISPOSES,USP10 gene|USP10,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Aurora Kinase A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,risk factors,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,echinacoside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Administration, Oral",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Matrix,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,CKS2 gene|CKS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,CYP3A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,abemaciclib,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cell markers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,beta-eudesmol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,TIPARP gene|TIPARP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,CDC2 Protein Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,LILRB1 gene|LILRB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,antineoplaston A10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TENM1 gene|TENM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,vasomotor symptom,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,lindane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of breast,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Neoplastic Process
AFFECTS,ULBP2 gene|ULBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,PDGFRB gene|PDGFRB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tumor Suppressor Genes,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,doxorubicin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CHRNA6 gene|CHRNA6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC-ROR gene|LINC-ROR,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
PREDISPOSES,GPNMB gene|GPNMB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Decreased Immunologic Activity [PE],Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,POU4F1 gene|POU4F1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,BCSC-1 Protein|VWA5A,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Intrapartum fetal hypoxia,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,FNDC5 gene|FNDC5,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AUGMENTS,SNORA73B gene|SNORA73B,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,"PIK3CB protein, human|PIK3CB",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,metacresol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,paired basic amino acid cleaving enzyme,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Hypolipidemic Agents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
PREDISPOSES,HDAC2 gene|HDAC2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Cancer Prevention,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,elongin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"BSG protein, human|BSG",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,astaxanthin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"Receptor, PAR-1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,HINT1 gene|HINT1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,LILRB2 gene|LILRB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Comorbidity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"glutamate carboxypeptidase II, human|FOLH1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,pyruvate dehydrogenase kinase 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Low-Density Lipoproteins,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Fat-free mass,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"PKN1 protein, human|PKN1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Receptors,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,cyclooxygenase 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,"N-succinyl-1,2-dioleoylphosphatidylethanolamine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Binding Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,alpha-adrenergic receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Oral form sodium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Phentolamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TET1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,caffeic acid phenethyl ester,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Secondary malignant neoplasm of skin NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Cyclin-Dependent Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"MCL1 protein, human|MCL1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BUB1 gene|BUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Protein Isoforms|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Pharmaceutical Preparations,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,CCAAT-Enhancer-Binding Proteins|EBP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Methylation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,EB 1089,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,RAD51C gene|RAD51C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RARRES1|GPRC5A|MED15,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,heparanase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Quantitative Trait Loci,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,alkylglycerophosphoethanolamine phosphodiesterase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Biological Phenomena,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CDK7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fibrosing adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FGF10 gene|FGF10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TACC2 gene|TACC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Anticoagulants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,targeted prevention,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,pigment epithelium-derived factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MicroRNAs,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,MIRN23A gene|MIR23A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Vitamin D,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Food
AFFECTS,NEDD9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vegetable Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,XBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,RBM5 gene|RBM5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,perfluorooctanoic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Genes,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
AFFECTS,Docosahexaenoic Acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,RECK,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Agent,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,MIRN326 gene|MIR326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,GRN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HOTAIR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,SP1 gene|SP1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Mucins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Chemotherapeutic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Phosphatidylethanolamine N-Methyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Carcinogens,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hazardous or Poisonous Substance
AUGMENTS,Estrogen Receptor beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,SP1 gene|SP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,discoidin domain receptor 2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Annexin A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Excision,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,ABL2|RERE,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,SPAG5,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,Benign ovarian cyst,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,hormonal changes,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AUGMENTS,PKM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Methylnitrosourea,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,THY1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
AFFECTS,Weaning,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Adaptor Signaling Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,PARP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HOXA9 gene|HOXA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIRN195 gene|MIR195,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,XRCC5 gene|XRCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PAWR gene|PAWR,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Gene or Genome
AFFECTS,N-Acetylneuraminic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,IGKV1-16|FAM49B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FOXA1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Metalloproteases,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Paclitaxel,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,Radioisotopes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PITPNM3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,HIC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CpG Islands,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Organochlorine pesticide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MCM3AP|FIG4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TNFRSF12A,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CTSG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Sporadic Breast Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MYC Family Genes|MYC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Kinesin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2 gene|ERBB2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Gene or Genome
CAUSES,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Phosphatidylinositols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IL33,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Developmental Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,OPRM1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,K-ras Oncogene|KRAS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Growth Factor Gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,High energy food,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Medical follow-up,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ADGRF5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,sulfamate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Malondialdehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"3,4-Methylenedioxyamphetamine",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Malignant transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Nucleic Acids,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,pioglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Interleukin-8,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,rosiglitazone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Telomerase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cocci,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,KRT5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CCL28,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,calusterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,"Leukemia, Myelocytic, Acute",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Metals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Soy Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Serine Proteinase Inhibitors,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DELIVER,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,bone sialoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Physical findings,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,prohibitin|PHB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Maximal Voluntary Ventilation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NCOA2 gene|NCOA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hepatocyte Growth Factor,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
AFFECTS,Acylation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Primary biliary cirrhosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ELP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DDT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Conception,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Lactalbumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,paclitaxel liposome,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,CTU1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glucose Transporter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Drug resistance,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Pharmacologic Substance
DISRUPTS,Thrombospondins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Cesarean section (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,particle,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Thrombospondin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,GSTO2 gene|GSTO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Running,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Asthenia,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,midkine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Prolactinoma,bilateral breast cancer,0.0,Female Breast Cancer,Other
AFFECTS,Misonidazole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Abdominal obesity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Complement System Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,cholanthrene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adriamycin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Lymph Node Involvement,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogen Receptors|EREG|ESR1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Caffeine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Carcinoma, Cribriform","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
AFFECTS,"3,4-Methylenedioxyamphetamine",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Dietary Fats,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Endocrine Surgical Procedures,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,PROTEIN INTAKE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ras Oncogene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
COMPLICATES,Malignant Neoplasms,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Cholestyramine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Diethylstilbestrol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Immunologic Deficiency Syndromes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Estrogenic,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
AFFECTS,radical mastectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Markers, DNA",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,Serum,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Body Substance
AFFECTS,Rheumatoid Arthritis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,ptaquiloside,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,monoclonal antibody CC49,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AUGMENTS,Fibroblast Growth Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,Radiation,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Prolactin|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Cycasin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Bromocriptine,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,impaired glucose tolerance,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,Prolonged periods,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,leukemia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Transferase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Trimetrexate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Stabilization,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,ras Oncogene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Paroxetine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Bone Density,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,PTPRF,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,N-Acetylneuraminic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,SYK gene|SYK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,heparanase|HPSE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Fenretinide,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,"Estrogens, Catechol",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Metalloproteases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Proline,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Free Radicals,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Sedentary lifestyle,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Acetate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Vitamin E intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
PREDISPOSES,Physical activity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,parathyroid hormone-related protein|PTHLH,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,alpha-Linolenic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,BCAS2 gene|BCAS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Nitrites,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ingestion,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Endopeptidases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,P-Glycoprotein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Sarcoidosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,LGD 1069,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Tetranucleotide Repeats,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Endometrial adenocarcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,chemokine receptor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"polio, NOS",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SMAD4 gene|SMAD4,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,ETS Variant Gene 6 Protein|ETV6,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,parathyroid hormone-related protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Leukemia P388,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Cardiovascular Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
CAUSES,Peptides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Treatment/Psychosocial Effects,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Silicones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,chromosome 11q,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Chemotherapeutic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Lymphocyte antigen CD82|CD82,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,6-nitrochrysene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,GSTP1 gene|GSTP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,17q23,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Tenascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,PTEN gene|PTEN,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Dissection,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Agent,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Chemical Viewed Functionally
CAUSES,beta-hexachlorocyclohexane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,inhibitors,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,SLC12A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Epidermal Growth Factor Receptor|EGF,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Biologically Active Substance
AFFECTS,Adrenalectomy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Thyroidectomy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant Neoplasms,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Neoplastic Process
DISRUPTS,BCL2 gene|BCL2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Polyamines,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Restriction fragment length polymorphism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Transforming Growth Factor alpha,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,"Fats, Unsaturated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Prostaglandins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Eicosanoid
AFFECTS,WWOX gene|WWOX,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Therapeutic agent (substance),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical Viewed Functionally
DISRUPTS,Selective Estrogen Receptor Modulators,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Premature Birth,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
CAUSES,"Cell Transformation, Neoplastic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,"PRSS8 protein, human|PRSS8",Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Axillary Lymph Node Dissection,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Radioisotopes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Angiogenic Switch,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,"Liver Failure, Acute",Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
CAUSES,Estradiol,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Gene Amplification,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Gene Mutation,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,CD55|TCN2,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AFFECTS,Pharmaceutical Adjuvants,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Pharmacologic Substance
AUGMENTS,Durapatite,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cysteine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Protein Tyrosine Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,"Estrogens, Synthetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Growth Factor Receptors,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Biologically Active Substance
DISRUPTS,SELPLG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Gruyere cheese,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Study models,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,chemokine receptor D6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DPYS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HFE,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
DISRUPTS,"Linoleic Acids, Conjugated",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Chemical
CAUSES,Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,NUCLEAR MITOTIC APPARATUS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CLEC14A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Thrombospondins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Angiotensinogen|AGT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Sermorelin|GH1|GGH,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Night shift worker,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ASAP1|MYCBPAP,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,NELFB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ITGB3BP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ubiquitin-protein ligase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,isopeptidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Specific antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,Breast radiotherapies,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AUGMENTS,glutathione S-transferase pi,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"O-(glucuronic acid 2-sulfate)-(1--3)-O-(2,5)-andydrotalitol 6-sulfate",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Tumor Suppressor Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,ADH1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Adenomatous Polyposis Coli,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,methyl group,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,gamma-Tocopherol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Polymorphism, Genetic",Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,CXCL12 gene|CXCL12,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
CAUSES,Fibroblast Growth Factor Receptor 2|FGF7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,STK6 gene|AURKA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Tocopherols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Regulatory Sequences, Nucleic Acid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Environmental Estrogen,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Hormone
AUGMENTS,Genistein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Disease,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Disease or Syndrome
AFFECTS,exemestane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PREDICTED,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,RNF115,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Aromatic Amines,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,NOD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Hyperandrogenism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDK10 gene|CDK10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Grapes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PDIA6,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,Thalidomide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,multicatalytic endopeptidase complex,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Fatty-acid synthase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Benzene,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,andrographolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Atrophy of vagina,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,APC gene|APC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,docetaxel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"FOLR1 protein, human|FOLR1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,RIN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HSD17B2 gene|HSD17B2|HSD17B7P2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Dietary Modification,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Aborted pregnancy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Second Primary Cancers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,5'-NUCLEOTIDASE|NT5E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Glial Fibrillary Acidic Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Oncogene Proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Interleukin-8|EREG|ESR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SNAI1,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Tumor proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,PPIA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CYP2C19 gene|CYP2C19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,S-Adenosylmethionine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Alpha tocopheryl succinate,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,NCSTN gene|NCSTN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Stearates,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,estrone sulfate,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,DEK gene|DEK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dihydrofolate Reductase|DHFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Acrylamide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Silicon,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
DISRUPTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Xenograft procedure,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Long chain fatty acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,ERBB2 gene|ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Prognostic Factor,bilateral breast cancer,0.0,Female Breast Cancer,Other
PREDISPOSES,RAB27B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PARP1|COL11A2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,D4-GDI,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TIMM17A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Heat shock proteins,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,ADM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,erbB-2 Receptor|ERBB2,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,docetaxel,Breast cancer stage II,0.0,Female Breast Cancer,Other
AUGMENTS,BCAR1 gene|BCAR1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,exemestane,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,SOX4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,TEK gene|TEK,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alleles,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Sleep Deprivation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,MST1R gene|MST1R,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,ITGA5 gene|ITGA5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Interstitial Collagenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,epithelial cell differentiation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Human Papilloma Virus Vaccine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
CAUSES,Quinones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ERBB2|NEU1|NEURL1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
CAUSES,Garlic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,VCP gene|VCP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GLI1 gene|GLI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,VEGFA,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Body mass index procedure,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,"PTH protein, human|PTH",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,AVP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Genes,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,SPDYA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,CD24,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,cytochrome P-450 CYP1B1|CYP1B1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ORALIT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lithium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,nuclear receptor coactivator 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,phenylalanylphenylalanine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Norepinephrine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Carcinoid Tumor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,High Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,IL8 gene|CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
DISRUPTS,caveolin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MAPK15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Velcade,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNAJA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,GATA3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,collagenase 3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,HSPA1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"progesterone, micronized",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
CAUSES,"Carcinoma, Ductal, Breast",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,casein kinase II,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Paget's Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
AFFECTS,Tristetraprolin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,SUSD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"[M]Adenocarcinoma, metastatic, NOS",Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
AUGMENTS,"CTTN protein, human|CTTN",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,iturin A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SNX9 gene|SNX9,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,PSPHP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PML gene|PML,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Post-Transcriptional Regulation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Genistein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Naphthalene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Purines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,toll-like receptor 4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Interleukin 6 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Epstein-Barr virus DNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Growth stimulant,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SLOPE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,CLOCK,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PTGER2|SPAG11B,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Vitamin D Deficiency,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Food
CAUSES,BRCA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,MIRN10A gene|MIR10A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SULF2 gene|SULF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Metaplastic carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,CD4 gene|CD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,AMOTL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tubeimoside I,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,1/24,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RORA gene|RORA,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,SH3PXD2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LY6K,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"DICER1 protein, human|DICER1","Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,cofilin|CFL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Little's Disease,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,MLLT11,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,FOXP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Uridine Diphosphate Sugars,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AUGMENTS,FBXO42,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CMTS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ARGININOSUCCINATE LYASE|ASL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Functional RNA,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mitogen-Activated Protein Kinase 13|MAPK13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Platinum,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,9-deoxy-delta-9-prostaglandin D2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Eicosanoid
DISRUPTS,EGFR gene|EGFR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Transcript,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
DISRUPTS,bone morphogenetic protein 6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOD1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vitamin B1 Intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
DISRUPTS,CDKN1C gene|CDKN1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TP53 gene|TP53,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,ESR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,RHOC gene|RHOC,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,costunolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LATS2 gene|LATS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,RELN gene|RELN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,anthracene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MEG3|FAM129B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,chemokine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ZNF143,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fibrosing adenosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EIF2S1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Increased effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"PER2 protein, mammalian|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,NF-Kappa B p65,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Hazards, Environmental",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,mitochondrial DNA replication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,NF-AT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,peptide T amide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,ERBB2,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,"HDAC5 protein, human|HDAC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,indoleamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FYN gene|FYN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FOXO3A gene|FOXO3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,EHMT2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ethylene glycol,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
PREDISPOSES,Pasta intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Beads,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Thioridazine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SCARA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CDCA7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,DDAVP,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Pyruvate Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,hepatitis B virus X protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Prolactin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,nicotinamide phosphoribosyltransferase|NAMPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Morphine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NOTCH1 gene,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
AFFECTS,Doxorubicin,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Estrogens,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Hormone
AFFECTS,LAPTM4B gene|LAPTM4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Activated-Leukocyte Cell Adhesion Molecule,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,B-pyridine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Alkanes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Fusion Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Prior Therapy,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,SNHG14,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,parathyroid hormone-related protein|PTHLH,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
COMPLICATES,Vitamin D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AUGMENTS,ACKR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,LACTB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IkappaB Kinase beta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PAWR gene|PAWR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Granulocyte Colony-Stimulating Factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,BCL6 gene|BCL6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Growth Factor,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
AFFECTS,"Diet, Fat-Restricted",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,ITGB3 gene|ITGB3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MIRN423 gene|MIR423,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NNT-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KISS1R,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IL32,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ferrocene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PPP2R2A,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,schizandrin B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CHI3L1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,osteoactivin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,N-myristoyltransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,caspase-3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Platelet Factor 4|PF4,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Chromosomal Rearrangement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Tomography, Emission-Computed",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,P3H1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,lymphocyte product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DICER1 gene|DICER1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,IkappaB Kinase epsilon,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Peutz-Jeghers Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,Pancreatic carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
CAUSES,SYK gene|SYK,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,ZNF326,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ZIC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Polymerase|ERVK-9|ERVK-19|ERVK-11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HNRPM gene|HNRNPM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,LBH589,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pharmaceutical Preparations,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,ADRA1D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Saethre-Chotzen Syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AFFECTS,"UBD protein, human|UBD",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,8-hydroxy-2'-deoxyguanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thromboplastin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,WWC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Mammographic breast density,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
CAUSES,PGC,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ERR1 protein|ESRRA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estradiol Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Oncogenes,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
COMPLICATES,Sterol Regulatory Element Binding Protein 2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,cryptochrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,MMP2 gene|MMP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,alpha-Fetoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Fusion Protein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,BLM gene|BLM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,DDR2 gene|DDR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SMYD3 gene|SMYD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"HDAC5 protein, human|HDAC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,TAZ gene|TAZ,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,REPS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ARHI gene|DIRAS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Somatostatin analog|SST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CYP2B6 gene|CYP2B6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Atherosclerosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,versican|VCAN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Urokinase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,ARHI gene|DIRAS3,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,participation,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Tenascin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Organic solvent product,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Fat tissue increased,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Androgen Receptor|AR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Tegafur,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,Desipramine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Serpins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Angiogenesis Factor,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,Size of lymph node,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADH1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Malignant neoplasm of prostate,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,"Transcription, Genetic",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,decisiveness,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,caffeinated beverage,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,High Density Lipoproteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Pharmacotherapy,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AFFECTS,Monocyte Chemoattractant Protein-1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,"Gene Products, Protein",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Oncogene, RET|RET",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cultural differences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Epiregulin|EREG,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,Fertility,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Buformin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RGS17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,protein kinase D,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"CHEK1 protein, human|CHEK1",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,RGS17,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Vitamin E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Food
AFFECTS,Cytochrome P-450 CYP2D6,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
CAUSES,Invasive Carcinoma,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AUGMENTS,Nucleolar Organizer Region,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Mayonnaise,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,ING1|LTB|CENPK,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Hormone level abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Fibromyalgia,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Signal Pathways,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Body mass index,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
AFFECTS,Increased Metabolic Rate,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
PREDISPOSES,PROM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,monocyte activation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,retinoic acid receptor alpha,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Signaling Molecule,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,STARD3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estratest,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
CAUSES,Nucleosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GLO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Myristic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AUGMENTS,Cell Cycle Checkpoint Genes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Gonadotropin-Releasing Hormone Analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Doxorubicin,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
AFFECTS,BMP4|BMP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NOS3 gene|NOS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Recreation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Malignant neoplasm of thyroid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Primigravida,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Alcohol consumption,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,PPARGC1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CD4 gene|CD4,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,DDIT4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Axillary Lymph Node Involvement,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrogen Receptor beta|ESR2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Leukocyte Elastase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,[D]Mammogram abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,NEUROD1|TUBB4B,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,Hay fever,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Down-Regulation,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Recombinant Interferon-gamma|IFNG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,URI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LAPTM4B gene|LAPTM4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCC5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,IL17F,Sporadic Breast Carcinoma,0.0,Female Breast Cancer,Other
AUGMENTS,POP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CSH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,patient characteristics,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,Smoking Behavior,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"PSMD10 protein, human|PSMD10",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,CLDN1 gene|CLDN1,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
CAUSES,XRCC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Estrone,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
PREDISPOSES,PRL gene|PRL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Sex Hormone-Binding Globulin,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Hormone
AFFECTS,Liver and Intrahepatic Biliary Tract Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AFFECTS,Mangifera indica extract,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Cytotoxic agent,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,NAP1L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNAJC27,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Secondary malignant neoplasm of lymph node,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Neoplastic Process
AFFECTS,Endocrine therapy,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Hormone
PREDISPOSES,TRANSCRIPTION FACTOR,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,RBL2 gene|RBL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Folate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MASS LESION,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"Anesthesia, Conduction",Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,TGFBR2 gene|TGFBR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Stathmin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sequela of disorder,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
PREDISPOSES,Cigarette Smoking,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,astragaloside IV,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PRRX2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,crocin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ING5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Radiation therapy,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,Annexin A2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Breast Microcalcification,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Endocrine Gland Neoplasms,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,TRANSCRIPTION FACTOR,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Proton therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,brucine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
CAUSES,Oncogenic Viruses,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Virus
PREDISPOSES,histone deacetylase 3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Growth Factor Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Encounter due to Screening for malignant neoplasm of breast,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Infiltration,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Metals, Heavy",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,KLHL7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RETN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PIP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Glutamic Acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,stem cell therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Fibroblast Growth Factor 7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Biologically Active Substance
AFFECTS,genetic element,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"SBEM protein, human|MUCL1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,WT1 gene|WT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cytochrome P-450 CYP2D6,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,PTGS2 gene|PTGS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,CHES1 gene|FOXN3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ACACA|BMS1,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,decorin|DCN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,inhibitors,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
DISRUPTS,Phospholipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
PREDISPOSES,Financial circumstances,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,beta catenin,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,2q33-q34,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PERP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,XRCC5 gene|XRCC5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,NEK2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Interleukin-10,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Osteonectin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Candidate Disease Gene|AR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Carcinoma in situ of breast,0.0019980019980019,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"Subarachnoid Hemorrhage, Aneurysmal",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Placental Hormones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,thiopurine,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,NFKBIA gene|NFKBIA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Body mass index,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Other
AFFECTS,Mutation,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Cholesterol Esters,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AUGMENTS,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Boiled potato,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypothyroidism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,TNFRSF1B gene|TNFRSF1B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CHEST SYMPTOM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ERBB2|NEU1|NEURL1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Morphogenesis,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,Ritonavir,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Estrogen-progestin preparation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Soluble ErbB-1|EGFR,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,RANTES,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Microsatellite Repeats,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,CCAAT-Enhancer-Binding Protein-delta,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Local Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Thymidylate Synthase,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,CD68,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DES EXPOSURE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ZNF365 gene|ZNF365,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LHX1 gene|LHX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ERCC3 gene|ERCC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,RNASE3L gene|DROSHA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SABER,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,BABAM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Estrogenic,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,Xenobiotics,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ductal Carcinoma,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,oncoprotein p21|CDKN1A|SLC12A9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Hematoxylin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Single Nucleotide Polymorphism,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,Dietary Modification,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,Mitogens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SCREEN TECHNIQUES,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,erbB-2 Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Adenomatous goiter,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PFKFB4,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Mutagens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,ETV4 gene|ETV4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Ovulation Induction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,SRC gene|SRC,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Gene or Genome
PREDISPOSES,Disintegrins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,FCGR3A gene|FCGR3A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,S 1 (combination),Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,CONSTITUTIONAL ORIGIN,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,HSPA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Abdominal circumference,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,tibolone,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,LAMTOR3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Bone Morphogenetic Proteins,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Epstein-Barr Virus Infections,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Cooking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Lymphedema,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Diuretics,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,TRANCE protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Trihalomethanes,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
PREDISPOSES,Syndrome,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Disease or Syndrome
CAUSES,Angiogenesis Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PMS2 gene|PMS2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,fatty acid amide hydrolase,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Chemical
PREDISPOSES,Histologic type,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,Endocrine System Diseases,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,"Iron, Dietary",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,JMJD6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cadaverine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
COMPLICATES,cytokine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,XRCC1 gene|XRCC1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,FRA16D,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,S100A7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Thioglucosides,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dietary fat intake,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,PNU,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MED19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,CYTOR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Phytoestrogens,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Hormone
PREDISPOSES,ID2 gene|ID2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Fruit,Breast cancer recurrent,0.0049950049950049,Recurrent Breast Cancer,Other
PREDISPOSES,UBE2N,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,GJB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"Chemotherapy, Adjuvant",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,LATS1 gene|LATS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MDM2 gene|MDM2,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,ENPP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KRT8,Breast cancer invasive NOS,0.0099900099900099,Female Breast Cancer,Other
AFFECTS,PTCSC3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ubiquitin-protein ligase,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,Arsenic,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,AQP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,salinomycin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,HMGN2 Protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
CAUSES,Mandibular right first molar abutment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Genome, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cathepsins B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,FAM84B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,AQP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Ca(2+)-Transporting ATPase|CA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,therapeutic use,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,GJB2 gene|GJB2,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,verbenone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PTH-Parathyroid hormone level result,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
AFFECTS,Recurrent Carcinoma,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,moderate drinking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,RBM12B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CASC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,EIF4EBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIRN106A gene|MIR106A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FUT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,1-Phosphatidylinositol 4-Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Cullin 1,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Transferrin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PIEZO2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Vinegar,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,v-myb Genes|MYB,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Interferon Type I,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,UCHL3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Kinesin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,BCL11A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Circadian Rhythm Disorders,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Dipeptidyl-Peptidase IV|DPP4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,lysyllysine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDK6-associated protein p18,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,ubiquitin-protein ligase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,FAM13A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LINC01133,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,APOBEC3B,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
DISRUPTS,honokiol,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,reverse transcription polymerase chain reaction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TSLP protein, human|TSLP",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Secondary malignant neoplasm of spinal cord,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,bone sialoprotein,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Ephrin B Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Obesity,Contralateral breast cancer,0.0019980019980019,Female Breast Cancer,Other
PREDISPOSES,ATXN3,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,PCB 118,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CERS6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ingredient,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,PIM1 gene|PIM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,cardamonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,"Oligonucleotides, Antisense",Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,RAB1A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cyclin-Dependent Kinase Inhibitor 2A|CDK4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Solvents,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,DSCAM-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Pancreatic carcinoma,Ductal Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Neoplastic Process
PREDISPOSES,centromere protein F,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,paracrine,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Adrenergic Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MIRN133B gene|MIR133B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCB 101,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Docosahexaenoate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Bleomycin|BLM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,MDM1,Familial cancer of breast,0.0039960039960039,Female Breast Cancer,Other
PREDISPOSES,WISP1 gene|WISP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Paracrine Communication,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,Cisplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Cathepsins|CTSS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,LIMS1 gene|LIMS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,SORBS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,erbB-2 Receptor|ECD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SIX1 gene|SIX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hydrogel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SULF1 gene|SULF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Dopamine Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neuroreactive Substance or Biogenic Amine
AFFECTS,p65|RELA|SYT1|GORASP1|WNK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MAGI2-AS3 gene|MAGI2-AS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cell-Free DNA,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Annexin A1|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,beta-site APP cleaving enzyme 1,"Carcinoma, Ductal, Breast",0.0029970029970029,Female Breast Cancer,Enzyme
PREDISPOSES,SOX5,Breast cancer metastatic,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,OGDHL,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Postmenopause,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AFFECTS,SP 1049C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,systemic administration,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,Chronic disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
AUGMENTS,Parabens,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,talazoparib,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,insulin isophane,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,KDM6A gene|KDM6A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Interferon Signaling Process,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
PREDISPOSES,Fibroblast Growth Factor 2|FGF2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,UGT1A4 gene|UGT1A4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Alcohol intake above recommended sensible limits,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ATOX1 gene|ATOX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"KISS1R protein, human|KISS1R",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Infertility risk,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,levothyroxine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,DNA Repair Gene,Hereditary Breast and Ovarian Cancer Syndrome,0.0,Female Breast Cancer,Gene or Genome
CAUSES,DNA Modification Methylases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,ceramide kinase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,"Promoter Regions, Genetic",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,GAS1 gene|GAS1,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,Primary Neoplasm,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,cisplatin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,F2R gene|F2R,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,"Receptor, Notch4",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,LINC00668 gene|LINC00668,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,chitosan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,tumor protein D52|TPD52,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,IGFBP7|SFPQ,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,SH2B3 gene|SH2B3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,Carcinogens,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Hazardous or Poisonous Substance
AFFECTS,physiological aspects,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,prothrombin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,cisplatin,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,MRTFA gene|MKL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,FDG-Positron Emission Tomography and Computed Tomography Scan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,lead,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Inorganic Chemical
CAUSES,SEPT7 gene|SEPT7,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AUGMENTS,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Apolipoprotein E|APOE,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,GATA3 gene|GATA3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,methylene chloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,AGO1 gene|AGO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,tryptophan,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Antineoplastic Agents,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AUGMENTS,CSK gene|CSK,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Receptors, Progesterone",Breast cancer stage III,0.0009990009990009,Female Breast Cancer,Hormone
AFFECTS,Microinvasive tumor,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Estrogen Receptors,Breast cancer stage III,0.0009990009990009,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Estrogen Antagonists,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,OSW 1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Saponin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ATF4 gene|ATF4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Genes, Essential",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Late Relapse,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,PBX1 gene|PBX1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,VLDLR gene|VLDLR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,WNT6 gene|WNT6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,EXT1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SIRT3 gene|SIRT3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,TGFB1 gene|TGFB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZBTB1 gene|ZBTB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Cyclin B1|CCNB1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Growth pattern,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Biological Markers,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Other
DISRUPTS,ELK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Hypoxia,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Ginkgo biloba extract,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,CXCR2 gene|CXCR2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Fenamole,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Rocky,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,IQGAP1 gene|IQGAP1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,PSMG3-AS1 gene|PSMG3-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lactones,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sapphire,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Antioxidants,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,HER2/Neu Positive,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,FBXW5 gene|FBXW5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,MIR451A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Protein Kinases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,EPDR1 gene|EPDR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,bis(4-hydroxyphenyl)sulfone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SPINT1-AS1 gene|SPINT1-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCR1 gene|CXCR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MIR26B gene|MIR26B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,TUFT1 gene|TUFT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Alternative Splicing,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,S100P,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,glycogen synthase kinase 3 beta,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,Ingredient,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,ZG16B gene|ZG16B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,triptolide,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,Photosensitizing Agents,Carcinoma breast stage IV,0.0,Female Breast Cancer,Chemical Viewed Functionally
AFFECTS,Isolate - microorganism,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,Potassium Channel,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,KMT5A gene|KMT5A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNHG7 gene|SNHG7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,resistin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Treatment Status,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
DISRUPTS,SETD2 gene|SETD2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"BMPR1B protein, human|BMPR1B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PKM gene|PKM,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Lymphangiogenesis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Nucleic Acid Probes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,shikonin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Suppressor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,berbamine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Germ-Line Mutation,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,"Discoidin Domain-Containing Receptor 2, Human|DDR2",Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AUGMENTS,MEDAG gene|MEDAG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Control,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,MicroRNAs,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,Protein Quaking,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malaria,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,arginine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,STIP1 gene|STIP1|TFIP11|NECAB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of oropharynx,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,prolactin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Non-infiltrating lobular carcinoma,Recurrent Breast Carcinoma,0.0009990009990009,Recurrent Breast Cancer,Neoplastic Process
DISRUPTS,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Collagen Type IV,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,TPX2 gene|TPX2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,IFNGR1 gene|IFNGR1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,proline,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,VEGFA gene|VEGFA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Echogenic,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,crocin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,Open Reading Frames,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MIR374B gene|MIR374B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,AQP3 gene|AQP3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Metric (substance),Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Substance
PREDISPOSES,FGD5-AS1 gene|FGD5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SNHG15 gene|SNHG15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,methylate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ginsenoside Rh1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNA 19B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,cryptotanshinone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,cyclin A2|CCNA2,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,alpha-hydroxyglutarate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ZNF213 gene|ZNF213,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SRSF1 gene|SRSF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,FAT3 gene|FAT3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Low expression,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,MYC,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Tumor Burden,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
CAUSES,Transgenes,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
DISRUPTS,metformin,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,IL6ST gene|IL6ST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Cytokinesis,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Biologically Active Substance
AFFECTS,NME1 gene|NME1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Challenge:Type:Point in time:^Patient:Nominal,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
AUGMENTS,CUL4B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,HOXB7 gene|HOXB7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,"BAG Family Molecular Chaperone Regulator 3, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dietary carbohydrate intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Mouse Model,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,cinnamic aldehyde,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,FBXO15 gene|FBXO15,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,RNA Polymerase I|ERVW-4,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,FGD5-AS1 gene|FGD5-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,TRAPPC10 gene|TRAPPC10,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AUGMENTS,CT83 gene|CT83,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Thyroid microsomal antibodies,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,cytokine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
DISRUPTS,PSMC2 gene|PSMC2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,Cell Adhesion Molecules,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,FTO gene|FTO,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,4-aminohippuric acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Increased risk,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,PTPRT gene|PTPRT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Serine-tRNA Ligase|TRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Coal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,PCYT1A wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,BRD4 gene|BRD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PDCD11 gene|PDCD11,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Beta-glucuronidase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ruyiping,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Multiparity,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Glucocorticoids,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Genes,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,MIR31 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,AEBP2 gene|AEBP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Breast Density,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,erbB-2 Receptor|ERBB2,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AUGMENTS,GATA3 gene|GATA3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,HOXA1 gene|HOXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Progranulins,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,DPP8 gene|DPP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ACE2 gene|ACE2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PCNT gene|PCNT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TIMM17A gene|TIMM17A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,CXCR5 gene|CXCR5,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,DPP7 gene|DPP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Phytochemical,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
DISRUPTS,MIR34A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Neoadjuvant Therapy,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
PREDISPOSES,PALB2 gene|PALB2,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
AFFECTS,Lymphocyte antigen CD82|CD82,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Immunologic Factor
AFFECTS,SMUG1 gene|SMUG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,GABPA|NFE2L2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SEMA4C gene|SEMA4C,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
DISRUPTS,SEPTIN9 gene|SEPT9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,UBQLN1 gene|UBQLN1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,cyclin-dependent kinase inhibitor 1B|IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,human papillomavirus,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Virus
AFFECTS,PITPNM1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ADAR gene|ADAR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,RBMS3 gene|RBMS3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SOX10 gene|SOX10,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Growth,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
PREDISPOSES,MAL2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Ribosomal Proteins,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Interventional procedure,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,T-Cell Receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Immunohistochemistry,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
DISRUPTS,CDK1 gene|CDK1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Indicators,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Indicator, Reagent, or Diagnostic Aid"
AFFECTS,ketamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,ADAMTS9-AS1 gene|ADAMTS9-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,NAA50 gene|NAA50,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Analgesics, Opioid",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Inflammatory Bowel Diseases,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,FBXL16 gene|FBXL16,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Triglycerides,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Lipid
AUGMENTS,"N-methylsulfonyl-12,12-dibromododec-11-enamide",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PVT1 gene|PVT1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dietary Polyphenol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,VIRMA gene|VIRMA,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Core needle biopsy,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
AUGMENTS,HOTAIR gene|HOTAIR,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
PREDISPOSES,MicroRNAs,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
DISRUPTS,CSTB wt Allele|CST6,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
CAUSES,Molecular Target,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Thioredoxin 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,LINC00174 gene|LINC00174,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Carcinoma breast stage IV,0.0,Female Breast Cancer,Neoplastic Process
AFFECTS,quiescence,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,chromosome loss,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,BCLAF1 gene|BCLAF1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,decitabine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,NR2F1-AS1 gene|NR2F1-AS1,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,docetaxel,Triple-Negative Breast Carcinoma,0.0,Female Breast Cancer,Other
AFFECTS,GNG13 gene|GNG13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,False Positive,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
AFFECTS,IGLC2 gene|IGLC2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Neoplasm Metastasis,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AUGMENTS,chemokine receptor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Food Consumption,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"herstatin protein, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,IRAK3 gene|IRAK3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,cytidylyl-3'-5'-guanosine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MicroRNA 1246,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AFFECTS,curcumin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Orosomucoid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,WTAP gene|WTAP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Married (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"NOS1 protein, human|NOS1|NANOS1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Androgen Receptor,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AFFECTS,ESR1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Premature Menopause,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CALCIUM/VITAMIN D,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Food
PREDISPOSES,CGAS gene|CGAS,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Postmenopausal status NOS,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,"TNF protein, human|TNF",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Cellular Apoptosis Susceptibility Protein,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,carbohydrate analog,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
DISRUPTS,TRIM72 gene|TRIM72,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Fatty-acid synthase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Chemical
PREDISPOSES,Fatty pancreas,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,MicroRNA 205-5p,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,cholesterol,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Lipid
DISRUPTS,MIR451A wt Allele,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,secretory protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Calcium Signaling,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,DUSP8 gene|DUSP8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
COMPLICATES,Adrenal Gland Hyperfunction,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Sodium Butyrate,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ethanol,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Body position,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,PSAT1 gene|PSAT1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,CCNE1 gene|CCNE1,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AUGMENTS,dehydrodolichyl diphosphate synthase,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,Oxysterols,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,sinomenine hydrochloride,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SIN3A gene|SIN3A,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Malignant neoplasm of breast,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Neoplastic Process
PREDISPOSES,MicroRNAs,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,YTHDF3 gene|YTHDF3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,"RNA, Long Untranslated",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,>40 years,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Other
AUGMENTS,PNO1 gene|PNO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,GSDME gene|GSDME,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,TRANSCRIPTION FACTOR,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,FERMT1 gene|FERMT1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Cell Cycle Checkpoints,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,G-Protein-Coupled Receptors,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,MIR449A gene|MIR449A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Hypersensitivity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Warburg Effect,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,CDK18 gene|CDK18,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Revival,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Genes,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,ILF3 gene|ILF3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,ROS1 gene|ROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,fluid flow,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,CCNA2 gene|CCNA2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,NSRP1 gene|NSRP1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,SOX13 gene|SOX13,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Segmental Mastectomy,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AUGMENTS,Methylnitrosourea,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,MAFG-DT gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,LINC00665 gene|LINC00665,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,JAG1 gene|JAG1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,PIEZO1 gene|PIEZO1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,CHAC1 gene|CHAC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Retinoblastoma Protein|RB1,Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,Discoidin Domain Receptor 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,inecalcitol,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SDC1 gene|SDC1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,specific immunity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,H19 gene|H19|HILS1,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,CDH2 gene|CDH2,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
AFFECTS,Diagnosis,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Other
CAUSES,Molecular Target,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Candidate Disease Gene,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
AFFECTS,"Membrane Potential, Mitochondrial",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,asparagine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SERPINB2 gene|SERPINB2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Leisure physical activity,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,DST gene|DST,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ISYNA1 gene|ISYNA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"TLR2 protein, human|TLR2",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,TFE3 gene|TFE3,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,"FRAP1 protein, human|MTOR",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Vitamin D Analog,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Food
AFFECTS,ST8SIA6-AS1 gene|ST8SIA6-AS1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,Primary Sj??gren's syndrome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,margetuximab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,"ERCC5 protein, human|ERCC5",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,PROM1,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,gamma-Glutamylcyclotransferase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,SLC16A3 gene|SLC16A3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ELOVL5 gene|ELOVL5,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,Transforming Growth Factor beta Receptors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Biologically Active Substance
PREDISPOSES,Adipokines,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,PTPN18 gene|PTPN18,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,ezogabine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SPI1 gene|SPI1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,SARS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,VDR,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,tumor growth,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Neoplastic Process
AFFECTS,"Radiosurgery, Stereotactic",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,SEMA3B-AS1 gene|SEMA3B-AS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Antibody-Drug Conjugates,HER2-negative breast cancer,0.0,Female Breast Cancer,Pharmacologic Substance
PREDISPOSES,Phytochemicals,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Chemoimmunotherapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AUGMENTS,hla gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,testosterone,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Hormone
PREDISPOSES,Tandem Repeat Sequences,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SAA1 gene|SAA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Wild Type,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Offered,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,PRSS22 gene|PRSS22,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
PREDISPOSES,glutamic acid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
AFFECTS,Pesticides,Malignant neoplasm of female breast,0.0,Female Breast Cancer,Other
PREDISPOSES,copper,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Thyroid dysfunction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,"PTK2 protein, human|PTK2",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,navitoclax,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Heterogeneous-Nuclear Ribonucleoprotein U,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,MIR217 gene|MIR217,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,dihydrotanshinone I,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
CAUSES,TP53 gene|TP53,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
AFFECTS,inhibitors,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
AUGMENTS,pertuzumab,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Circulating MicroRNA,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
PREDISPOSES,Emotional hypersensitivity,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,"Element, Ion, or Isotope"
AUGMENTS,USP46 gene|USP46,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,BCAR4 gene|BCAR4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Genetic Carriers,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,chromium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,TMEM9 gene|TMEM9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,USP10 gene|USP10,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
CAUSES,Neoplastic Cell Transformation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,Hormone Receptor Positive,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Hormone
AFFECTS,Positive Regulation of Apoptosis,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,IFNK gene|IFNK,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Gene or Genome
AFFECTS,sulfoenolpyruvate,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Surviving free of recurrence of neoplastic disease,contralateral breast cancer,0.0029970029970029,Female Breast Cancer,Neoplastic Process
PREDISPOSES,IGSF9 gene|IGSF9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Liver carcinoma,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Neoplastic Process
DISRUPTS,icariin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,TP53 gene|TP53,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Pyruvate Kinase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Dietary Intake,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Performance,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,omega-3 fatty acids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Chemical
CAUSES,Pyrimidine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"Soluble Interleukin-6 Receptor Subunit Alpha, Human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,CMTM7 gene|CMTM7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Genes, Duplicate",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Sphingolipids,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Lipid
AFFECTS,NAD+ kinase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,GDF2 gene|GDF2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,ENPP1 gene|ENPP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,ANXA1 gene|ANXA1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Fibronectins,Inflammatory Breast Carcinoma,0.0009990009990009,Female Breast Cancer,Other
CAUSES,fructose,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
PREDISPOSES,GLIS3 gene|GLIS3,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,ABCG1 gene|ABCG1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Mucin-1 Antigen,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Immunologic Factor
AFFECTS,"estrogen receptor alpha, human",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,DACH1 gene|DACH1,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Gene or Genome
PREDISPOSES,Skin tanning,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,"DKK3 protein, human|DKK3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,DPT gene|DPT,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,MYC,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Experimental Result,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,Diagnostic assessment,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Puberty,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Oral health,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CLDN6 gene|CLDN6,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,TNF receptor-associated factor 6|TRAF6,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,"RNA, Circular",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
CAUSES,NORAD gene|NORAD,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,AKR1A1 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,CXCL8,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ethanol,Female Breast Carcinoma,0.0049950049950049,Female Breast Cancer,Other
AUGMENTS,LONG INTERGENIC NONCODING RNA PINKY|PNKY,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Nucleic Acid, Nucleoside, or Nucleotide"
AUGMENTS,Acetyl-CoA Carboxylase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Secretome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,histone deacetylase 2,Invasive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Other
PREDISPOSES,Cancer Vaccines,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
PREDISPOSES,"interleukin-1, beta|IL1A|IL1B",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,MIR223 gene|MIR223,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,abemaciclib,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AFFECTS,SPARCL1 gene|SPARCL1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SFRP2 gene|SFRP2,Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Gene or Genome
AFFECTS,"YAP1 protein, human|YAP1",Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MAP kinase kinase kinase 7,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,"SFRP1 protein, human|SFRP1",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Treatment Protocols,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Immunologic Factors,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Immunologic Factor
PREDISPOSES,cathepsin Z,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
PREDISPOSES,Basis,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
AFFECTS,TPBG gene|TPBG,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Estrogen Receptor Status - Clinical Trial Eligibility Criteria,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Pathologic Processes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Phenomenon or Process
AFFECTS,DSCR9 gene|DSCR9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,"DDIT3 protein, human|DDIT3",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,nerve growth factor,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Biologically Active Substance
AFFECTS,Ultrasonography,malignant neoplasm of breast staging,0.0,Female Breast Cancer,Other
PREDISPOSES,Nicotinamide N-Methyltransferase,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
AUGMENTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,garcinone E,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
DISRUPTS,GW 4869,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,imipramine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,ARHGAP25 gene|ARHGAP25,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Abnormal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,NLRP12 gene|NLRP12,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
DISRUPTS,FBXW2 gene|FBXW2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"RTN4 protein, human|RTN4",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
CAUSES,interleukin-8,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
CAUSES,TAF8 wt Allele,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
DISRUPTS,PEDS1 gene,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,IL19 gene|IL19,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Lactates,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,DNAJB6 gene|DNAJB6,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,UBE3B gene|UBE3B,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,ZNF703 gene|ZNF703,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Extraction,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,metformin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,Performance,Papillary carcinoma of the breast,0.0,Female Breast Cancer,Other
AFFECTS,Terpenes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
DISRUPTS,OTUB1 gene|OTUB1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,MAF1 gene|MAF1,HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,Gene or Genome
AFFECTS,magnoflorine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Squalene monooxygenase,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,"plY protein, Streptococcus pneumoniae",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,Malignant neoplasm of thyroid,estrogen receptor-negative breast cancer,0.0,Female Breast Cancer,Neoplastic Process
PREDISPOSES,KLF5 gene|KLF5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,directive therapy,Carcinoma breast stage IV,0.0,Female Breast Cancer,Other
PREDISPOSES,interleukin-10,HER2-negative breast cancer,0.0,Female Breast Cancer,Other
DISRUPTS,iridium,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Fresh fruit,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Does ask questions,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,zinc pyrithione,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Element, Ion, or Isotope"
DISRUPTS,Transgenes,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Gene or Genome
DISRUPTS,SFRP2 gene|SFRP2,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,SOCS3 gene|SOCS3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Post-mastectomy radiotherapy,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,Focal Adhesion Kinase 1,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,"Element, Ion, or Isotope"
PREDISPOSES,KDM2A gene|KDM2A,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,oxaliplatin,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,SIAE gene|SIAE,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,secreted frizzled related protein 1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,LINC02086 gene|LINC02086,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,SERPINA5 gene|SERPINA5,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,Dried fruit intake,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Aptamer,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Other
AFFECTS,GRAMD1B gene|GRAMD1B,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,DACH1 gene|DACH1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"PIK3CB protein, human|PIK3CB",Carcinoma breast stage IV,0.0,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,GBP1 gene|GBP1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,MBD4 gene|MBD4,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Vitamin supplementation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
AFFECTS,gene therapy,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AFFECTS,MUTYH Gene Mutation,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Tobacco,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Detected (finding),Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Carcinogens,Basal-Like Breast Carcinoma,0.0039960039960039,Female Breast Cancer,Hazardous or Poisonous Substance
CAUSES,Malignant neoplasm of thyroid,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
DISRUPTS,CHD4 gene|CHD4,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
PREDISPOSES,SLC7A11 gene|SLC7A11,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Liposomes,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,"CREB3L4 protein, human|CREB3L4",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
DISRUPTS,beta catenin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,tomography,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Other
DISRUPTS,NOTCH3 gene,Carcinoma breast stage IV,0.0,Female Breast Cancer,Gene or Genome
CAUSES,ROS1 wt Allele|ROS1,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,EPYC gene|EPYC,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,Neoadjuvant Systemic Therapy,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Nuclear magnetic resonance normal,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,EIF4E gene|EIF4E,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AUGMENTS,Stat3 protein,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,"DICER1 protein, human|DICER1",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,reserpine,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AUGMENTS,MGP gene|MGP,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Cytokeratin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
PREDISPOSES,VAMP7 gene|VAMP7,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,"Discharge, body substance",Noninfiltrating Intraductal Carcinoma,0.0109890109890109,Female Breast Cancer,Substance
AUGMENTS,QSOX2 gene|QSOX2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
AUGMENTS,NUP155 gene|NUP155,Breast Carcinoma,0.0279720279720279,Female Breast Cancer,Gene or Genome
AFFECTS,scopolamine,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,ZNF410 gene|ZNF410,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,"Culture Media, Conditioned",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Element, Ion, or Isotope"
CAUSES,CD8A wt Allele|CD8A,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Luteinizing Hormone-releasing Hormone Agonist,Carcinoma of Male Breast,0.0049950049950049,Male Breast Cancer,Hormone
AFFECTS,Saturated fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
CAUSES,Histone Deacetylase|HDAC9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,Sugars,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Carbohydrate
AFFECTS,Scutellaria barbata extract,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
AFFECTS,Erianin,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Other
CAUSES,"CDK12 protein, human|CDK12",HER2-positive carcinoma of breast,0.0089910089910089,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AUGMENTS,MIR190B gene|MIR190B,estrogen receptor-positive breast cancer,0.0089910089910089,Female Breast Cancer,Gene or Genome
DISRUPTS,Friend Leukemia Integration 1 Transcription Factor,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Neoplastic Process
AUGMENTS,SCARNA4 gene|SCARNA4,Early-Stage Breast Carcinoma,0.0,Female Breast Cancer,Gene or Genome
AUGMENTS,"RAI3 protein, human|GPRC5A",Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
AFFECTS,"PLK1 protein, human|PLK1",Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,"Amino Acid, Peptide, or Protein"
PREDISPOSES,Total body fat,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
PREDISPOSES,JMJD1C gene|JMJD1C,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
PREDISPOSES,PPP1R21 gene|PPP1R21,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
DISRUPTS,BICD1 gene|BICD1,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
CAUSES,Secretome,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AUGMENTS,SLC16A3 gene|SLC16A3,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
AFFECTS,Hypertensive disease,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Disease or Syndrome
DISRUPTS,Triterpenes,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,ANXA9 gene|ANXA9,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Gene or Genome
CAUSES,Mammary Neoplasms,Secondary malignant neoplasm of breast,0.0029970029970029,Female Breast Cancer,Other
PREDISPOSES,Histopathology finding,Malignant neoplasm of breast,0.3386613386613387,Female Breast Cancer,Other
AFFECTS,Gene Mutation,"Breast Cancer, Familial",0.0,Female Breast Cancer,Gene or Genome
PREDISPOSES,EMP2 gene|EMP2,Triple Negative Breast Neoplasms,0.0189810189810189,Female Breast Cancer,Gene or Genome
